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Abstract 
Low bone mineral density (BMD) is established as a primary predictor of osteoporotic 
risk but can also have substantial implications for athlete health and injury risk in the 
elite sporting environment. BMD is a highly multi-factorial phenotype influenced by 
physical activity and genetics. The exact contribution of these factors and the specific 
genetic variants association with BMD, particularly in athletic populations, has yet to 
be determined. Furthermore, few investigations have considered gene-environment 
interactions - in particular, whether specific genes may be sensitive to mechanical 
loading from physical activity and the outcome of such an interaction for BMD and 
potential stress fracture injury risk. Consequently, the overall aim of the current thesis 
was to investigate the genetic associations with BMD, stress fracture incidence and 
marathon performance in high-level endurance runners and compare these to a non-
athlete cohort to explore genotype-physical activity interactions. BMD differences 
between endurance runners and non-athletes as well as between runners who had 
suffered a stress fracture in comparison to those who had not was observed. 
Additionally, WNT16 rs3801387 and BDNF-AS rs6265 genotype-cohort interactions 
with BMD were observed whilst P2RX7 rs3751143, COL1A1 rs1800012 and 
TNFRSF11A rs3018362 genotype associations with BMD were also present. WNT16 
rs3801387, COMT rs4680 and P2RX7 rs3751143 were associated with endurance 
runner status but no variants were associated with performance or stress fracture 
incidence. These results identify novel genetic associations with BMD and athlete 
status in an endurance running population as well as genotype-cohort interactions that 
influence BMD. In conclusion, there appears to be a genotype-dependent influence on 
athlete status as well as BMD, which may be influenced by physical activity level. 
Further research is needed to replicate the associations observed in comparable and 
different populations. Nonetheless, the work presented here has added to our 
understanding of the genetic associations with performance, BMD and stress fracture 
 
 
incidence, which may have implications for exercise programme management and 
improving performance in high-level endurance runners.
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Chapter 1: 
Literature review 
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1.1 Bone 
Bone consists of the fibrous protein collagen, mineralised with calcium 
phosphate/hydroxyapatite (Currey, 2013). The human skeleton consists of 80% 
cortical bone and 20% trabecular bone, although different anatomical sites portray 
different ratios. These two types of bone are formed in a lamellar pattern, in which 
collagen fibrils are placed in alternating orientations (Clarke, 2008). Both cortical and 
trabecular bone are composed of osteons, termed Haversian systems and packets, 
respectively.  
 
Figure 1.1: Structure of bone at cellular level. Taken from (Mitra et al., 2013). 
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1.1.2 Bone mineral density  
Peak bone mass is a function of bone size and volumetric bone mineral density (BMD)  
(Leonard and Bachrach, 2012) and thus, is the amount of bony tissue present following 
skeletal maturation, which can have a substantial influence on osteoporotic risk in later 
life (Bonjour et al., 1994). BMD is defined as the ratio of mass to the area or volume of 
bone, which is known as areal (g/cm2) or volumetric (g/cm3) BMD, depending upon the 
measurement methodology used (Ott et al., 1997). BMD is considered the primary 
predictor of osteoporotic fracture, although it is important to note other factors when 
assessing clinical risk (Cranney et al., 2007). BMD accounts for 60-65% of the variance 
in bone strength so other factors such as bone geometry, collagen properties as well 
as trabecular and cortical microarchitecture are also important determinants of bone 
strength (Schoenau et al., 2002; Fonseca et al., 2014; Cheung et al., 2016).  
Bone mass is regulated by the activity of osteocytes in response to a number of stimuli, 
such as disuse, matrix damage or hormone deficiency (Atkins and Findlay, 2012) and 
the actions of osteoblasts and osteoclasts, which are important for bone formation and 
resorption. Disproportionate activity rates of these bone cells, for instance, greater net 
osteoclastic than osteoblastic activity, can cause bone loss, as observed in ageing 
(Martin and Sims, 2005). Approximately 85-95% of peak bone mass is attained around 
late adolescence (Henry et al., 2004; Walsh et al., 2009). After peak bone mass is 
reached, BMD loss occurs as we age (Figure 1.2) and the rate of loss plays an 
important role in bone health and the development of related conditions, such as 
osteoporosis (Hernandez et al., 2003). BMD deterioration varies between individuals 
as well as anatomical sites, with yearly rates of decline after the age of 25 years at the 
distal radius, distal tibia and lumbar spine reportedly 0.40%, 0.24% and 1.61%, in 
women and 0.38%, 0.40% and 0.84%, in men. Additionally, men and women 
experience 42% and 37% of trabecular bone loss as well as 15% and 6% of cortical 
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bone loss before the age of 50 years (Riggs et al., 2008). Similar to the ability to 
enhance peak BMD with lifestyle choices, it is possible to slow the inevitable decline 
in BMD with ageing using preventative measures via lifestyle modification. Some of 
these factors include not smoking (Law and Hackshaw, 1997), maintaining a healthy 
dietary intake (Darling et al., 2009) and relatively high physical activity level (Pluijm et 
al., 2001; Krall and Dawson‐Hughes, 1993).  
 
Figure 1.2: Schematic representation of typical age and sex-related loss of BMD in 
men and women.  
1.1.3 Bone mineral density and physical activity 
Quantifying the relative contributions of physical activity and other determinants to 
BMD remains difficult. Exercise/physical activity reportedly accounts for up to 30% of 
the variability in total BMD (Table 1.1), emphasising that the contribution of physical 
activity to BMD remains unclear and requires further exploration across various 
population groups.  
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Table 1.1: Contribution of physical activity to BMD. 
Population  BMD determinant Variability in BMD Reference 
Icelandic women 
aged 16-20 
 
Lean mass and 
physical exercise 
30% (Valdimarsson et al., 
1999) 
Men and women 
aged 20-25 
Sports activities 10.4% - Men 
<1% - Women 
(Neville et al., 2002) 
 
 
 
Pre-menopausal 
women 
 
Member of sports club 
Completing persistent 
weight-bearing activity 
in adulthood 
 
5-19% 
 
(Barnekow‐Bergkvist 
et al., 2006) 
 
European 
Caucasian men 
aged 65-80 
 
High-impact unilateral 
training programme 
on one leg (EL) in 
comparison with the 
other leg (CL) 
 
 
1.6% net gain in 
femoral neck 
between EL and CL 
 
(Allison et al., 2015) 
Men and women 
aged 20-54  
Physical activity level Active women and 
men had 2.7-4.6% 
and 1.9-3.0% higher 
BMD respectively  
than sedentary 
counterparts 
 
(Morseth et al., 2010) 
Men aged 17 - 20 Physical activity 
habits 
10.1% (Pettersson et al., 
2010) 
 
Initially proposed by Wolff’s law and further developed by Frost’s mechanostat theory, 
bone adapts or remodels in response to the forces or demands placed upon it (Frost, 
1990). This mechanotransduction is completed through four steps: mechanocoupling, 
biochemical coupling, signal transmission and effector cell response (Duncan and 
Turner, 1995). Bone metabolism is regulated via specific pathways, such as the as 
nuclear factor k-b/nuclear factor k-b ligand/osteoprotegerin (RANK/RANKL/OPG), Wnt 
signalling and purinergic signalling pathways, through initiation of osteoblastic or 
osteoclastic activity (Tyrovola and Odont, 2015). Following physical activity, adenosine 
triphosphate (ATP) is released and osteocytes detect shape and volume changes to 
increase or decrease the liberation of these bone mediators, which consequently 
influences bone formation and resorption (Nakashima et al., 2011) as highlighted 
below (Figure 1.3).  
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Figure 1.3: Osteocytes modulation of bone metabolism through regulation of 
osteoblasts and osteoclasts (Nakashima et al., 2012).  
This notion has been observed in numerous populations including children, adults and 
older adults, with those who complete a large volume of physical activity/exercise 
possessing greater BMD, strength and muscle mass (Chilibeck et al., 1995; Slemenda 
et al., 1991; Beck and Snow, 2003; Warburton et al., 2006). Corresponding with the 
higher BMD possessed by physically active or athletic populations, higher values for 
bone formation markers (e.g. osteocalcin, pyridinoline, deoxypyridinoline) have been 
reported in those undertaking higher training/loading/exercise in comparison with 
control populations (Maïmoun and Sultan, 2011).  
The point in time when this physical activity occurs may also influence bone 
development and bone mass, potentially resulting in lifetime benefits for skeletal health 
(Gunter et al., 2012). Generally, weight-bearing activity in childhood has been shown 
to increase total BMD in adolescents and children (Weeks et al., 2008; Heidemann et 
al., 2013), as well as demonstrate a continued benefit into adulthood at key sites such 
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as the femoral neck and lumbar spine (Strope et al., 2015).Tveit et al. (2013) reported 
exercise-associated high BMD in 46 young male athletes (mean age = 22 years) was 
preserved three decades after retirement and cessation of high volumes of physical 
activity. Similarly, ex-professional baseball players in their ninth decade of life retained 
more than half of the throwing-related benefits in bone size and a third of the throwing-
related benefits in bone strength observed in current professionals (Warden et al., 
2014).  
Some studies have suggested that activity completed in the pre-pubertal stage is the 
most favourable to instigate bone development, due to the elevated levels of growth 
hormone present at this time (Bass et al., 1998). Growing bone has an enhanced 
capability to respond to increased mechanical loading and thus initiate greater 
structural adaptations to this stimulus, compared to adult bone (Bass et al., 1998). This 
notion of an optimal period or “window of opportunity” for exercise-induced bone 
development could be important in improving bone health by maximising peak bone 
mass attainment during this time (Bass et al., 1998), and therefore, delaying the onset 
of age- or menopause-related osteoporosis (Santos et al., 2017). Despite this, 
Behringer et al. (2014) completed a meta-analysis and suggested that weight-bearing 
activities in childhood and adolescence had no significant influence on BMD in 
adulthood. The authors based their conclusion, however, on 27 studies out of a 
possible 109 completed before 2012 and suggests their findings might have been 
skewed as a result. Therefore, the overall consensus, as outlined by the National 
Osteoporosis Foundation’s recent position statement, is that the best evidence 
suggests a positive effect of physical activity during late childhood and pre-pubertal 
years and this is a key period for bone accretion (Weaver et al., 2016). 
The ability to complete studies that are both longitudinal and valid, accounting for 
accurate measurement of activity (i.e. quantifying intensity in relation to the bone-
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loading forces experienced) is extremely problematic. Many investigations have used 
self-report activity questionnaires rather than more direct measurements, such as via 
accelerometers or pedometers (Ondrak and Morgan, 2007). Self-report questionnaires 
rely upon recall and response bias, correlations between self-report and direct 
measurement of physical activity have been reported as low-to-moderate, ranging from 
-0.71 to 0.96 (Prince et al., 2008). Whilst accelerometers are capable of objectively 
quantifying activity level, this is still an estimation limited by validity, reliability and 
calibration concerns (Troiano et al., 2014), as well as being unable to provide direct 
measurement of the stimulus applied to any particular bone or the skeleton as a whole. 
Furthermore, there has been much methodological variance in studies exploring this 
topic, such as participant characteristics and sample size, the differing methods used 
to measure physical activity and types of physical activity/exercise completed in the 
training intervention. These factors make it difficult to draw conclusions on the exact 
influence of physical activity on BMD and may explain the large variability in the extent 
of the skeletal response to loading reported in intervention studies. For reviews on this 
topic see Warburton et al. (2006) and Ondrak and Morgan (2007).  
Quantifying the optimum amount of physical activity for bone health is both difficult and 
complex when considering all of the potential confounding variables. Research has 
suggested the current US Department of Health and Human Services and UK Chief 
Medical Office physical activity guidelines do not allow maximisation of BMD potential 
(Whitfield et al., 2015). Additionally, the type of physical activity may also be important 
for optimising BMD. Habitual levels of high, but not moderate or light, physical activity 
was positively related to BMD in adolescents (Deere et al., 2012) as well as in older 
adults (Hannam et al., 2017). However, high impacts in adolescents were classed as 
>4.0g but only >1.5g in the older adults. Thus, the impact threshold to be bone 
protective is likely to be lower in older adults but higher g-forces may be required to 
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stimulate acquisition during peak attainment in childhood (Tobias, 2014), which adds 
further complexities to understanding the influence of physical activity on bone health. 
Therefore, due to the difficulty of quantifying physical activity and the large number of 
determinants of BMD, investigating the influence or association of physical activity on 
BMD is challenging. Using homogenous cohorts that are known to be undertaking 
similar amounts of physical activity, such as athletic populations, can somewhat 
alleviate this issue.  
1.1.4 Bone mineral density in athletic populations 
Physical activity can be defined as any movement implemented by skeletal muscle 
that results in energy expenditure, whereas exercise refers to physical activity that is 
planned, structured and repetitive with an aim to maintain or improve a physical fitness 
component (Caspersen et al., 1985). Therefore, athletic populations who complete 
large volumes of exercise, also tend to possess higher BMD and bone mass than non-
athletic individuals via the loading adaptation mechanisms mentioned above (Chilibeck 
et al., 1995). However, the loading characteristics of different sports vary, thus the 
BMD of athletes partaking different sports or disciplines also varies, particularly 
between different anatomical sites (Mudd et al., 2007; Bennell et al., 1997). One of the 
earliest applied studies investigating BMD of athletes competing in different sports 
showed significantly higher total and site-specific BMD in volleyball players in 
comparison with gymnasts, swimmers and non-athletic controls, although the BMD of 
the gymnasts was significantly higher than the other two groups (Fehling et al., 1995). 
This emphasises that physical activity/exercise, which expresses higher impacts 
through increased strain rates and high peak-force loading characteristics, as can be 
expected of volleyball players, results in enhanced total or site-specific BMD as shown 
across of number of sports (Table 1.2). 
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Table 1.2: BMD variation across different sports. 
Population Sport BMD variation Reference 
300 Norwegian female 
elite athletes (national 
level at senior or junior)  
300 non-athletic controls 
 
66 Sports 3-20% higher BMD than 
controls. 3-22% higher BMD in 
high impact sports compared to 
medium or low impact sports 
(Torstveit 
and 
Sundgot-
Borgen, 
2005) 
15 elite male athletes 
15 non-athletic controls 
Volleyball 14% and 24% higher BMD at 
the lumbar spine and femoral 
neck respectively in volleyball 
players in comparison with non-
athletic controls 
 
(Calbet et 
al., 1999) 
14 state level female 
athletes 
18 non-athletic controls 
Netball 7.8%, 17.3% and 14% higher 
total body, hip and lumbar spine 
BMD in the netballers in 
comparison with the controls 
 
(Chang et 
al., 2013) 
50 male highly trained 
athletes 
12 non-athletic controls  
12 Judokas 
14 Karate 
athletes 
24 Water 
polo players  
 
Control group total body BMD 
(1.27 g/cm2) was significantly 
lower than the judo (1.40 g/cm2) 
and karate (1.36 g/cm2) group 
but no different to the water polo 
athletes (1.31 g/cm2) 
 
(Andreoli et 
al., 2001)  
59 competitive Finnish 
female athletes 
25 physical active 
individuals  
25 sedentary individuals 
 
 
27 Dancers  
18 Squash 
players       
14 Speed 
skaters  
Squash players had significantly 
higher BMD at the lumbar spine 
(13%), femoral neck (16.8%), 
proximal tibia (12.6%) and 
calcaneus (18.5%) in 
comparison with the sedentary 
group. Aerobic dancers also had 
significantly higher BMD at the 
loaded sites in comparison with 
the sedentary group, ranging 
from 5.3% to 13.5% 
 
(Heinonen et 
al., 1995) 
60 athletes  
15 controls 
15 Runners 
15 Swimmers 
15 Triathletes 
15 Cyclists 
Runners had significantly higher 
total body, femoral neck and leg 
BMD than controls and 
swimmers as well as higher leg 
BMD than cyclists. 
(Duncan et 
al., 2002) 
 
In endurance runners specifically, most studies have shown a higher BMD than control 
populations at the primary loading sites (tibia, femoral neck, calcaneus), although this 
is not always the case at other anatomical sites due to the influence of other variables, 
such as low energy availability. Although higher total-body (8.6%), lumbar spine 
(12.2%), femoral neck (9.7%) and leg (13.2%) BMD has been found in female 
adolescent runners in comparison to controls (Duncan et al., 2002), most studies have 
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reported lower or low (in relation to T- or Z-score) BMD in endurance runners at the 
non-loading sites (Hind et al., 2006; Barrack et al., 2008a; Barrack et al., 2008b; 
Pollock et al., 2010).  
Endurance runners tend to possess lower BMD than athletes from other weight-
bearing sports, such as volleyball or netball players, where forces applied to bone are 
more likely to be varied in magnitude and directions (Scofield and Hecht, 2012). Master 
athletes over the age of 65 years old who are still competing in running events have 
also been reported to possess higher BMD than non-active counterparts (Velez et al., 
2008). Furthermore, former elite runners, soccer players and weightlifters have been 
shown to possess higher BMD than non-active controls as well as suffer osteoporotic 
hip fractures at a significantly older age (Kettunen et al., 2010). This emphasises the 
potential of BMD to be maintained and the importance of weight-bearing exercise in 
contributing to skeletal integrity in later life.  
Studying athletes who experience extreme amounts of loading can somewhat 
compensate for the aforementioned limitations associated with quantifying physical 
activity. High-level athletes in weight-bearing sports are a unique population who 
generally experience extreme amounts of mechanical loading, which, although not a 
perfect solution, presents an attractive model for future research studies hoping to 
investigate the impact of exercise on BMD. Additionally, by selecting homogeneous 
athlete groups, who compete in the same event to a similar standard, it would be 
reasonable to assume these individuals undertake similar training regimes/volumes. 
For instance, Billat et al. (2001) reported high-level male marathon runners with a 
personal best of < 2 h 16 min ran an average weekly distance of 168 km (± 20 km) and 
females with a personal best of < 2h 36 min completed 150 km (± 17 km) on average. 
Although similar weekly running volume may be observed in endurance runners who 
are competing in similar competition distances, differences in loading variability 
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between runners exists. For example, substantial variation in maximum rearfoot 
pronation exists in elite female runners, which in turn may influence risk of Achilles 
tendonitis or shin splints (Williams, 2007), whilst level of ground reaction force may 
also contribute to running injuries (Hreljac, 2005). Consequently, other factors, such 
as those stated above alongside BMD, may influence risk and prevalence of injury in 
this population.   
1.1.5 Bone mineral density and stress fracture injury risk 
Despite the benefits of weight-bearing activity for BMD, at a high sporting level, too 
much activity to the point of overtraining can result in negative outcomes (Kuipers and 
Keizer, 1988). A stress fracture would be one such outcome and is defined as a partial 
or complete fracture of bone from repeated application of force lower than that required 
to fracture a bone in a single loading (Iwamoto and Takeda, 2003). Stress fracture 
injury occurs due to the repetitive mechanical loading that stimulates an incomplete 
remodelling response (Jones et al., 2002) and several factors are known to influence 
an individual’s susceptibility to experiencing a stress fracture (Bennell et al., 1999). 
The exact pathophysiology of stress fracture is unknown but a proposed 
pathophysiological of stress fracture model in regards to altered/incomplete 
remodelling has been elucidated. 
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Figure 1.4: Proposed pathophysiological model of stress fracture. Figure taken from 
(Warden et al., 2006).  
Stress fracture influencing/risk factors include biomechanical gait (Milner et al., 2006), 
bone size and mechanical properties (Tommasini et al., 2005), nutritional factors 
(Nieves et al., 2010), training volume and rapid increments in volume (Snyder et al., 
2006), small musculature and low BMD (Beck et al., 2000).  
Unsurprisingly, higher incidence of lower limb stress fractures is observed in 
endurance runners in comparison with non-athletic controls. Significant amounts of 
site-specific loading combined with other factors typical of this group, such as low 
energy availability, can result in lower BMD and a higher risk of fracture occurrence 
(Loucks, 2007). Stress fractures reportedly account for 50% of all injuries sustained by 
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runners and military recruits, with higher incidence observed in females (Milner et al., 
2006). However, there is a lack of research on stress fractures in running populations 
(Wright et al., 2015). Furthermore, determining accurate prevalence is also difficult due 
to the problematic nature of defining stress fractures. Significant misdiagnosis will 
occur unless limited to radiography because other methods used lack sensitivity and 
specificity (Wright et al., 2015).  
Although lower BMD has been observed at the foot in female athletes with a history of 
stress fracture, compared to those without, this was accompanied by lower lean mass, 
leg-length discrepancy and fewer menstrual cycles per year, which may be influential 
(Bennell et al., 1996). Contradictory findings regarding BMD association and stress 
fracture have been reported in the literature (Kelsey et al., 2007; Bennell et al., 1996; 
Crossley et al., 1999), which may be due to the differences in methodological study 
design. The lack of homogeneity and dissimilarity in both the participants used and the 
methodological design are likely to increase the inter-individual variability within the 
phenotype through differences in training characteristics and mechanical loading. 
Although a number of stress fracture risk factors for endurance runners have been 
proposed as mentioned above, female sex and previous history are the only two to 
have strong support for an association via meta-analysis (Wright et al., 2015). 
Consequently, further research investigating BMD in endurance runners is warranted. 
Investigating BMD, with a particular emphasis on injury, is undoubtedly important 
because stress fractures have substantial implications for athletes. For instance, 
Marathon world record holder, Paula Radcliffe, reportedly suffered a stress fracture 3 
months before the Beijing 2008 Olympics, limiting her preparation for and performance 
at that competition. Furthermore, Ranson et al. (2010) reported 43% of the elite fast 
bowlers they investigated developed symptomatic acute lumbar stress fractures in a 
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two-year follow-up period and subsequently missed 169 days of cricket, per episode, 
on average.   
If athletes are unable to complete their desired or required training volume due to 
injury, this could have substantial negative effects on their performance and success. 
Additionally, if an athlete knows they may be susceptible to injury this could be 
accounted for in their training programmes, by placing a greater emphasis on 
appropriate strengthening exercises and/or allowing longer rest periods between 
sessions. This valuable information for tailored training could then ultimately influence 
progression of athletes from amateur to elite or have implications for selection into 
high-level teams or sporting competitions. It is apparent that a substantial proportion 
of research in this area has been completed in military recruits (Wright et al., 2015). 
This is probably due to the ease of accessing large samples who undertake a 
quantifiable training load, as well as a desire to minimise waste of human and financial 
resources caused by injuries. However, it is difficult to directly extrapolate the findings 
of these military studies to high-level runners due to differences in the level of physical 
fitness, footwear and the loads carried whilst running between these groups. Despite 
the possibility of stress fractures, the positive benefits of physical activity/exercise on 
BMD in a broad population are evident. As discussed, there are a number of 
determinants influencing BMD but relatively little is known about the genetic influence 
on this phenotype and stress fractures, which could be pivotal for future understanding 
in both the sporting and public health domains.  
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1.2 Genetic influence on bone mineral density 
1.2.1 Genetic associations with bone mineral density 
Although BMD is a multi-factorial phenotype, heritability of BMD is suggested to be 50-
85% depending upon anatomical location (Ralston and Uitterlinden, 2010). However, 
it must be emphasised that this proposed large genetic component is in a free-living 
population where most people will not complete extreme volumes of physical activity 
or be severely malnourished and thus, the influence of these other environmental 
factors on BMD will be reduced. Therefore, even a very substantial genetic contribution 
to BMD does not mean physical activity or other factors cannot notably affect an 
individual’s BMD (as shown in section 1.1.3).  
Due to this substantial genetic component, knowing the associated variants could be 
extremely beneficial for both functional research focus as well as application. For 
example, accuracy of fracture risk classification was improved by 7-10% at various 
sites in osteopenic patients by adding a genetic risk score from proposed common or 
rare variants associated with BMD and/or osteoporosis (Lee et al., 2014). In the future, 
this application might be utilised in athletic populations for risk stratification and injury 
prevention. However, implementing a genetic risk score with high-level athletes is 
currently difficult due to a lack of known candidate genes associated with BMD in 
athletic populations, which emphasises the need for replication of potential candidate 
genes and specific studies on particular populations, who may possess high or low 
BMD, or demonstrate specific lifestyle choices/habits that influence BMD.  
Beginning in clinical populations, studies that selected candidate genes for association 
with BMD due to known biological function, such as Vitamin D (1,25- dihydroxyvitamin 
D3) receptor (VDR), insulin like growth factor 1 (IGF1) and oestrogen receptor 1 
(ESR1) (Gong and Haynatzki, 2003), produced inconclusive findings. Candidate gene 
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selection can be based on the premise that the protein plays a role in regulating bone 
cell function or metabolism (Ralston and de Crombrugghe, 2006), and the differing 
variants may affect bone mediators and consequently influence BMD. For example (as 
highlighted in Figure 1.5 below), the human TNF receptor superfamily member 11b 
(TNFRSF11B) gene encodes the protein osteoprotegerin (OPG), which regulates 
bone resorption by inhibiting differentiation and activation of osteoclasts. OPG-
deficient mice have been found to develop early onset osteoporosis, and increased 
tissue mRNA expression has been observed in participants who possess specific 
haplotypes accompanied with reduced BMD, which may be due to increased 
expression resulting in stimulated osteoclast activity (Takács et al., 2010). This 
simplistic model forms the basis of genetic regulation on BMD but, in reality, the 
process is much more complex due to environmental factors and various kinds of 
interactions, which could have a substantial effect on gene expression and phenotype 
outcome. This potential impact of mechanical loading on gene expression can be 
understood by the substantial upregulation and downregulation of numerous genes 
following mechanical loading in rats (Mantila Roosa et al., 2011). Genes including FOS 
like 1, AP-1 transcription factor subunit (FOSL1) and JunB proto-oncogene, AP-1 
transcription factor subunit (JUNB) were both upregulated within 4 hours after loading, 
whilst expression of Wnt/β‐catenin signaling genes sclerostin (SOST) and secreted 
frizzled related protein 4 (SFRP4) was also altered at the synthetic phase of bone 
formation (Mantila Roosa et al., 2011). In the case of OPG, in vitro evidence 
demonstrated that compressive forces increased interleukin-6 (IL6) and prostaglandin 
(PG) E2 production through activation of intracellular calcium/extracellular signal-
regulated kinase 1/2 and nuclear factor -κB translocation (Ca++/ERK1/2/NF-kB) 
signalling pathways. This results in decreased osteoblast OPG expression (and a 
decreased OPG/RANKL ratio) and enhanced matrix metallopeptidases (MMPs) 
production, consequently increasing bone resorption (Sanchez et al., 2009). 
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          Environmental factors/gene-gene interactions/gene-environment interactions 
 
 
TNFRSF11B genotype 1 >>>>>>  OPG protein available  >>>>>> increased bone formation 
TNFRSF11B genotype 2 >>>>>>       OPG deficiency      >>>>>> decreased bone formation 
 
 
Figure 1.5: TNFRSF11B genotype influence on OPG availability and subsequent bone 
formation with the potential of environmental and interaction effects.  
Recent technological advances and large collaborations have seen a number of 
GWAS with BMD completed, which identified many more potential candidate genes 
and SNPs (Richards et al., 2012; Clark and Duncan, 2015). However, the most 
prominent study to date, a meta-analysis conducted by Estrada et al. (2012), identified 
56 loci associated with BMD, osteoporosis and/or fracture that accounted for ~6% of 
the variation in BMD. Overall, more than 66 genetic loci have been associated with 
Dual-energy x-ray absorptiometry (DXA)-derived BMD via GWAS, as well as many 
others through candidate gene association studies, and this number continues to 
increase, emphasising the extremely polygenic nature of BMD (Golchin et al., 2016). 
A further 153 loci have been associated with BMD estimated by quantitative ultrasound 
of the heel (Kemp et al., 2017). A specific recent addition, for instance, is a locus 
harbouring the Patched 1 (PTCH1) gene in an Icelandic population (Styrkarsdottir et 
al., 2016). This rapid discovery rate of new candidate genes and the fact many 
previously discovered candidate genes have had little or no replication through further 
study, means only a very small number can be confidently suggested to have an 
association with BMD. Furthermore, the biological function or involvement with bone 
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metabolism of 30 of these has yet to be elucidated and only seven of the 66 have been 
associated in candidate gene studies previously or positively replicated afterwards 
(Hsu and Kiel, 2012), although some have received no further study as of yet. To have 
only seven candidate genes positively associated through both methods so far is 
surprising, considering almost 100 different loci have been associated with BMD via a 
candidate gene approach (Hsu and Kiel, 2012). Hsu and Kiel (2012) suggested a 
number of reasons why this may have occurred; firstly, false-negative findings due to 
the stringent level of statistical significance typically applied to GWAS data, or 
inadequate statistical power in some studies that were unable to replicate associations 
with modest effect sizes. On the other hand, false-positive findings of candidate gene 
association studies may have prevailed due to small sample sizes or publication bias 
(Munafo et al., 2004).  
Additionally, strong gene-gene or gene-environment interactions could alter the 
number and identity of loci associated with BMD. This could apply to specific 
populations, such as athletes, due to the substantial influence of physical activity on 
BMD. Ultimately, this has resulted in few candidate genes emerging from GWAS 
and/or association studies that also have a known biological function relevant to bone. 
Therefore, further research using well-defined independent cohorts is needed to 
provide further evidence (Agueda et al., 2010). Clark and Duncan (2015) suggest 
greater use of “extreme cohorts” who might possess variants that have stronger 
associations with relevant phenotypes, which could include high-level athletes at one 
end of a continuum (as mentioned in section 1.1.4) and osteoporotic individuals at the 
other. This approach has been applied to BMD successfully in a study of 
postmenopausal women with extremely high or low BMD, where GWAS revealed six 
novel genetic associations (Duncan et al., 2011).  
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Studies so far have only elucidated a small fraction of BMD variance and thus, some 
of the unexplained heritability is likely due to a number of factors, including gene-
environment interactions (Ackert-Bicknell and Karasik, 2013). Despite the substantial 
effect of physical activity/exercise on BMD, there has been little research regarding 
gene-physical activity interactions and its effects on BMD in athletic populations. 
Therefore, due to this limited amount of research, as well as the variance in sample 
size and participant characteristics, means it is difficult to evaluate the extent of the 
gene-physical activity interaction with BMD or propose any definitive candidate genes 
that interact with environmental factors in determining BMD. However, looking at this 
relationship using specific cohorts or populations is gathering momentum - for 
example, investigations exploring interactions with others phenotypes, including 
obesity, are now being conducted (Marti et al., 2008). As mentioned previously (section 
1.1.4), athletes would be an excellent sample group to explore this interaction as they 
present an extreme cohort regarding exercise undertaken and BMD.  
1.2.2 Gene-physical activity interactions on bone mineral density 
Mitchell et al. (2016) were the first to investigate the genetic influence on BMD and the 
relationship with physical activity using SNPs that had been associated with BMD 
using GWAS (Estrada et al., 2012). Analysis revealed physical activity interacted with 
ELKS/Rab6-interacting/CAST family member 1/Wnt family member 5B 
(ERC1/WNT5B) rs2887571 to influence bone mineral content in males and nominal 
interactions with physical activity were also observed with Wnt family member 16 
(WNT16) rs3801387, axin 1 (AXIN1) rs9921222, SOST rs4792909 and stAR related 
lipid transfer domain containing 3 N-terminal like (STARD3NL) rs6959212. Sclerostin 
has a negative effect on bone formation by inhibiting canonical Wnt signalling in 
osteoblasts and also stimulates osteoclastic bone resorption by increasing the 
RANKL/OPG ratio (via enhanced RANKL expression) (Appelman-Dijkstra and 
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Papapoulos, 2016). Despite this strong influence on bone metabolism, conflicting 
results regarding SOST variants and association with BMD have been reported in the 
literature (Sharma et al., 2015). Additionally, serum sclerostin concentration has been 
positively correlated with lumbar spine, femoral neck and total hip BMD but no variants 
were associated with BMD or sclerostin concentration (He et al., 2014). It is important 
to note that children/young adults (age 5-19 yr) were the investigated cohort in the 
Mitchell et al. (2016) study. It is suggested some BMD-associated loci may exert age-
specific effects (Medina-Gomez et al., 2012), and thus the findings cannot be 
generalised to other populations.    
Interesting findings have also been reported in candidate gene association studies. 
Kiel et al. (2007) discovered two SNPs in the LDL receptor-related protein 5 (LRP5) 
gene associated with differences in BMD, which were dependent upon volume of 
physical activity completed. The TT genotype of both the rs3736228 and rs2396862 
SNPs was associated with lower BMD in more physically active men, but with higher 
BMD in less physically active men. Thus, the authors hypothesised that the substitution 
of a C with a T allele in the rs3736228 SNP could alter LRP5-mediated Wnt signalling 
in the case that the catabolic signals induced from the mechanical loading prevail over 
anabolic signalling. This was also the case when expressing alleles as a haplotype in 
vitro, where the T allele was associated with a decreased response to canonical Wnt3a 
signalling in comparison to the C allele. Activation of Wnt/β-catenin (canonical) 
signaling increases the sensitivity of osteoblasts to mechanical loading, which can 
occur via Wnt binding to low-density lipoprotein receptor-related proteins 5 and 6 co-
receptors (Robinson et al., 2006; Krishnan et al., 2006). This mediation of Wnt 
signaling via different LRP5 variants can both enhance and decrease BMD (Ferrari et 
al., 2005). Loss-of-function mutations in LRP5 are also responsible for low bone mass 
disorders, such as osteoporosis pseudoglioma, whereas gain-of-function mutations 
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have been suggested to cause high bone mass syndromes (Levasseur et al., 2005). 
Furthermore, LRP5 variants, such as C135242T, have been associated with BMD 
variability in the general population (Koay et al., 2004) and ds2306862 in osteoporotic 
individuals (Mizuguchi et al., 2004), which highlights the strong influence LRP5 may 
have on bone metabolism, particularly when considering a mechanical loading 
interaction.  
Similarly to some LRP5 variants, the catechol‐O‐methyltransferase (COMT) 
val158met (rs4680) SNP has been reported to influence the association between 
physical activity and BMD, suggesting that certain variants may be particularly 
important for BMD in individuals with low physical activity levels. Higher total BMD was 
observed in individuals completing greater levels of physical activity (> 4 hours) 
compared to those undertaking lower activity (< 4 hours) for GA and AA (lower enzyme 
activity) but not GG (higher enzyme activity) genotypes (Lorentzon et al., 2007). 
Although lower BMD was observed in the lower enzyme activity group, estradiol serum 
levels were not. COMT catalyses the methylation of catechol oestrogens to methoxy 
oestrogens (inactive metabolites) and thus, lower COMT enzyme activity should result 
in less efficient inactivation of catechol oestrogens and higher BMD in these genotypes 
as has been shown in other studies (Eriksson et al., 2005). Therefore, a COMT 
genotype interaction may be present and the potential regulation of the BMD response 
to mechanical loading may be due to the involvement of oestrogen receptors as 
facilitators in a number of key pathways by which mechanical strain stimulates bone 
formation (Galea et al., 2013).  
IL6 is another potential candidate gene with a number of functional polymorphisms, 
suggested as candidates associated with BMD and/or osteoporosis. Meta-analysis 
revealed an association between the GG genotype in the IL6 -174G/C (rs1800795) 
polymorphism and low BMD, as well as increased risk of osteoporosis, in a Caucasian 
23 
 
population (Ni et al., 2014). In the -634C/G (rs1800796) polymorphism, the CC 
genotype was significantly associated with greater BMD in Chinese pre-menarche girls 
who completed higher levels of physical activity (Li et al., 2008). Similarly, total body, 
lumbar spine and femoral neck BMD was lower in the GG genotype compared to the 
CC genotype by 0.03, 0.03 and 0.01 g/cm2 respectively in an Asian population 
(n=3068) following meta-analysis (Yan et al., 2015). IL6 is primarily sourced in 
osteoblastic cells and increases interactions between osteoblasts and osteoclasts, 
thus stimulating bone resorption (Steeve et al., 2004). IL6 is suggested to indirectly 
stimulate osteoclastogenesis by increasing RANKL gene expression in osteoblasts 
(Bakker and Jaspers, 2015) and the G allele has been associated with elevated 
production and secretion of IL-6 in vitro (Kitamura et al., 2002). Therefore, the G allele 
and thus elevated IL6 may be disadvantageous for bone density. Although there are 
limitations regarding control of other BMD-influencing variables and various cohorts 
used in these studies, IL6 remains interesting, particularly when analysing a possible 
relationship with physical activity. In vitro studies have suggested IL6 is produced by 
shear-loaded osteocytes and may influence bone mass by osteocytes reducing 
osteoblast activity via IL6–mediated intercellular signalling (Bakker et al., 2014). 
Elevated IL-6 serum concentrations in have also been observed in trained marathon 
runners immediately post-race, with a positive correlation between IL-6 concentration 
and running intensity (Ostrowski et al., 2000). In longitudinal studies, serum IL6 
concentration has been negatively associated with bone resorption and BMD in older 
adults, although the literature is somewhat conflicting (Ding et al., 2008). IL6 
demonstrates the possibility of strong gene-environment interactions and studies that 
do not control for physical activity risk erroneous findings and/or results that are only 
applicable to limited portions of the population.  
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Overall, completing weight-bearing physical activity has been shown to increase BMD 
as discussed in Section 1.1.3. The effect of potential gene-physical activity interactions 
on BMD across the lifespan, however, has yet to be determined. It could be 
hypothesised (Figure 1.6) that if an individual has a genetic profile/total genotype score 
(TGS) that is disadvantageous and completes low levels of weight-bearing physical 
activity (PA), they may be at risk for low BMD and potentially osteoporosis in later life 
(Disadvantageous TGS and low levels of PA). Those who may have a 
disadvantageous genetic predisposition, however, but complete sufficient weight-
bearing activity to produce a substantial osteogenic response may be able to combat 
their negative genetic predisposition resulting in increased BMD, as evidenced in 
children (Mitchell et al., 2016) (Advantageous TGS or high levels of PA). Similarly, 
those who do not complete suitable levels of activity but possess an advantageous 
genetic profile, may also present with moderate BMD (Advantageous TGS or high 
levels of PA). Those with an advantageous genetic profile who also complete large 
volumes of weight-bearing physical activity are likely to have the highest BMD 
(Advantageous TGS and high levels of PA), which could be induced from a gene-
physical activity interaction.  
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Figure 1.6: Schematic representation of typical age and sex-related loss of BMD in 
men and the effect of physical activity and genetics.   
 
Figure 1.7: Schematic representation of typical age and sex-related loss of BMD in 
women and the effect of physical activity and genetics.   
In the case of a gene-physical activity interaction, a hypothetical relationship between 
genetics, physical activity and the resultant BMD is presented below (Figure 1.7). Each 
bar represents a different individual and a hypothetical scenario for BMD ranging from 
a low BMD to a high BMD (the bar colour indicates BMD at any given level of physical 
activity in Figures 1.6 and 1.7). BMD is dependent on both genetics and physical 
activity level, so as physical activity level increases, BMD is enhanced for every 
individual regardless of their BMD before this increase in physical activity occurred. 
The magnitude of increase in BMD, and maximum BMD level attained, however, is 
under the influence of genetics (Ralston and Uitterlinden, 2010). Consequently, those 
with a more advantageous genetic predisposition, indicated by a higher TGS, 
combined with a higher volume of mechanical loading are more likely to reach a higher 
BMD than those with a disadvantageous genetic predisposition and/or a lower volume 
of mechanical loading, assuming all else is equal.  
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Figure 1.8: Schematic hypothetical representation of the BMD outcome for different 
individuals representing variable genetic profiles (TGS) and levels of physical activity.  
It is possible, however, that a linear relationship between physical activity dose and 
BMD response does not exist at the extremes of physical activity (Figure 1.8). 
NHANES (National Health and Nutrition Examination Survey) data has previously 
demonstrated that BMD did not differ between males who reported completing 4-6 
times more physical activity than the recommended guidelines (Whitfield et al., 2015). 
The physical activity and BMD relationship is still poorly understood and in the case of 
endurance runners, overtraining can negatively affect BMD (Figure 1.9) due to the 
associated influence of energy availability. Other factors such as the type of activity 
and dietary intake, however, are also important in regards to the bone adaptation as 
discussed in Section 2.2 and would consequently affect this relationship.  
B
M
D
Physical activity level
27 
 
  
Figure 1.9: Schematic hypothetical representation of the BMD outcome for different 
individuals (e.g. endurance runners) representing variable genetic profiles (TGS) and 
levels of physical activity.   
1.2.3 Genetic associations with bone mineral density in athletic populations 
In 212 young males, significantly higher total BMD in 84 weight-bearing athletes than 
80 controls was observed in the FF (7.7%) and Ff (6.9%) but not ff (1.8%) genotypes 
of the VDR FokI rs2228570 polymorphism, whilst significantly lower total BMD was 
only observed in the FF (-4.5%) genotype when comparing 48 swimmers with a control 
group (Nakamura et al., 2002a). This suggests that individuals with the FF genotype 
may be more responsive to mechanical loading, resulting in greater BMD when that 
environmental factor is prominent. This notion was further reinforced in 44 Japanese 
track and field athletes, where higher bone volume was expressed in those with the 
FF genotype, but not in those with the Ff genotype (Nakamura et al., 2002b). This 
particular polymorphism, Fokl (rs2228570), exhibits a C to T transition that creates an 
upstream initiation codon, leading to the production of VDR proteins that are three 
more amino acids in length. The F allele codes for the absence of the restriction, whilst 
the f allele codes for the presence of the initiation codon, which leads to the longer 
amino acid length (Gross, 1996; Ames et al., 1999). It is suggested that the F variant 
B
M
D
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shows greater transactivation (protein expression) than the f variant and this increased 
biological activity (and associated increased intestinal absorption of calcium) could 
explain why higher BMD has been reported in those with the FF genotype (Arai et al., 
1997; Colin et al., 2000; Uitterlinden et al., 2004; Ames et al., 1999) as detailed below 
(Figure 1.10). VDR controls the transcription of other genes including bone gamma-
carboxyglutamate protein/osteocalcin (BGLAP) that are instrumental for this calcium 
absorption and bone formation (Moran et al., 2014). A direct effect of 
osteoblastic/osteocytic VDR signalling on bone remodelling has also been proposed, 
although specific understanding of this notion is still lacking and largely depends on 
calcium balance (Lieben and Carmeliet, 2013).  
 
 
 
 
 
 
 
 
Figure 1.10: VDR rs2228570 FF genotype and the associated pathways leading to 
enhanced BMD. 
The potential association of VDR with BMD and/or fracture has also been supported 
across a number of different SNPs (rs1544410, rs7975232 and rs731236) in various 
cohorts, such as pre and postmenopausal women (Riggs et al., 1995; Horst-Sikorska 
et al., 2007; Ji et al., 2010; Marozik et al., 2013). However, contradictory results have 
also been reported across these cohorts (Horst-Sikorska et al., 2013; Moran et al., 
2015; Castelán-Martínez et al., 2015; Dabirnia et al., 2016). The highly conflicting 
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nature of the findings may be due to not adjusting for covariates such as body mass 
index (BMI) as well as the different ethnic groups, sample sizes and study designs 
utilised (Xu et al., 2005).  
A recent study of 99 elite academy footballers found a number of SNPs associated 
with bone phenotypes (trabecular density, cortical thickness and cross sectional area) 
using peripheral quantitative computed tomography (pQCT) analysis. However, these 
associations were only observed before, but not after, a 12-week period of increased 
football training volume and thus, no genotype by time interactions were present. 
These variants included SOST rs1877632, Purinergic receptor P2X 7 (P2RX7) 
rs1718119, P2RX7 rs3751143 as well as TNFRSF11A, TNFSF11 and TNFRSF11B 
SNPs rs9594738, rs1021188 and rs9594759 (Varley et al., 2018). Although no 
genotype by time interactions were observed for the SNPs analysed in this 
investigation, other candidate genes could be sensitive to physical loading (i.e. gene-
environment interaction) and thus modulate athlete health (and, by extension, enhance 
endurance performance). Specifically, if an athlete has a genetic predisposition 
towards low BMD or elevated risk of stress fracture, exercise training and/or diet could 
be modified to accommodate.  
1.2.4 Genetic associations with stress fracture 
There is a lack of conclusive evidence regarding external determinants of stress 
fractures (Wright et al., 2015) as mentioned in Section 1.1.5. In more recent times, the 
idea of a proposed genetic influence has been investigated primarily in military recruits, 
due to the abrupt increase in training, large training volumes and high prevalence of 
stress fractures (Lappe et al., 2008). Examples have included the calcitonin receptor 
(CTR) rs1801197 and LRP5 rs2277268 polymorphisms, which were associated with 
femoral neck stress fractures in 72 Finnish military recruits (Korvala et al., 2010). 
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Participants who possessed the CTR C allele together with a VDR C-A haplotype were 
more protected from stress fractures, which may be due to the role of CTR in osteoclast 
mediated bone resorption (Pondel, 2000).   
Furthermore, larger sized CAG androgen receptor (AR) gene repeats (>16) were more 
common in Israeli military personnel who had suffered stress fractures (23%) than 
those who had not suffered this injury (13%) (Yanovich et al., 2011). A higher number 
of CAG repeats within the AR gene are inversely associated with the transcriptional 
response to testosterone (Zitzmann et al., 2001) and deficiency in such hormones 
could influence bone metabolism and potential bone loss (Mohamad et al., 2016; 
Khosla, 2015).  
Stress fracture susceptibility, in relation to genetics, has also been investigated in 
athletes for the first time recently, with findings suggesting that athletes with specific 
genetic variants may have an increased vulnerability to this injury (Varley et al., 2015; 
Varley et al., 2016; Varley et al., 2017). Interestingly, three of the same SNPs (VDR 
FokI rs2228570, TNFSF11 rs1021188 and the loss of function P2RX7 rs3751143) as 
mentioned above, alongside TNFRSF11A rs3018362, were associated with stress 
fracture incidence in the Stress Fracture in Elite Athlete (SFEA) cohort. However, a 
gain of function P2RX7 SNP (rs1718119) was associated with reduced stress fracture 
occurrence. Functional expression of purinergic receptor P2X 7 primarily regulates 
configuration of osteoclasts (Agrawal et al., 2010), as well as augmenting bone 
formation via a cell-autonomous role that leads to stimulation of mineralisation 
(Panupinthu et al., 2008). This may explain why some P2RX7 polymorphisms have 
also been associated with low baseline and accelerated bone loss in post-menopausal 
women (Gartland et al., 2012). P2RX7 is a particularly interesting candidate gene in 
regards to potential gene-physical activity interactions and outcomes for BMD. Mice 
with a null mutation of P2RX7 have been reported to show >73% reduced sensitivity 
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to mechanical loading (Li et al., 2005). Fluid shear stress increased Prostaglandin E2 
(PGE2) release in wild type osteoblast cells but had no effect was observed on PGE2 
release in knockout osteoblast cells. PGE2 administration activates cortical bone 
modelling resulting in increased bone mass (Jee et al., 1990) and Li et al. (2005) 
suggested these findings indicate ATP signalling through P2RX7 is important for 
mechanically induced release of prostaglandins by bone cells and subsequent bone 
formation. Consequently, variation in P2RX7 SNPs could result in differing responses 
to mechanical loading and alterations to BMD, potentially influencing stress fracture 
susceptibility. 
Although research investigating genetic influence on stress fracture has begun using 
the SFEA cohort, this was a loosely defined group, which comprised athletes of mixed 
abilities and from a range of sports. A more focussed approach, which removes the 
variability (i.e. loading/training patterns) introduced by incorporating athletes from 
different sports into one investigation, would be advantageous. 
1.3 Future directions and conclusions 
There are numerous polymorphisms that need further exploration vis-à-vis BMD. In 
particular, gene-environment (i.e. gene-physical activity) interactions are likely to 
contribute substantially to inter-individual differences in BMD throughout the human 
lifespan. Exciting findings have been observed in regards to gene-physical activity 
interactions and genetic associations with stress fracture, particularly in variants of 
pathways involved in the adaptation of bone to mechanical loading, such as the 
RANK/RANKL/OPG system. 
Therefore, the study of specific cohorts, who experience unusually high mechanical 
loads and who may display unusual bone phenotypes and/or possess genetic 
characteristics that differ from the norm, may provide novel insight into the area. Such 
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individuals include high-level athletes, who are at the extremes of human physiological 
capability, experience much greater environmental (mechanical) stress than most and 
might possess a genotype particularly suitable to tolerate those stresses.  
GWAS or ideally whole genome sequencing (WGS) studies using athletic populations 
with their differentiating extreme phenotypes are, in principle, the next logical steps to 
identify key polymorphisms. Detailed study of gene function can follow. However, most 
GWAS designs cannot account for gene-gene/gene-environment interactions and only 
analyse SNPs with minor allele frequencies of more than 1%, not rare variants that 
may lie between 0.1-1% or even lower. Thus, GWAS is appropriate for the discovery 
of common variants that may confer low/moderate risk but are underpowered for the 
detection of rare variants, which may have a large influence on a complex phenotype 
according to the common disease/rare variant hypothesis (Li and Leal, 2008). 
Conducting GWAS or WGS studies is also extremely challenging due to the associated 
costs and difficulty in recruiting sufficiently large numbers of such a specific population. 
Even a panel of SNPs for investigation that is far lower in number than used in 
contemporary GWAS, for example 500 SNPs, would require a sample size of 1200 to 
detect an effect size of 0.02 in a continuous trait, assuming 80% statistical power, a 
minor allele frequency of 20% and an alpha level of 0.0001. Approximately the same 
size of sample would be needed for each group of a case-control study design, 
assuming the same parameters and an effect size (odds ratio) of up to 1.4 (Bouchard, 
2011). 
While the large cohorts necessary for GWAS and eventually WGS studies of BMD in 
athletes are built, smaller samples (steps towards building the bigger sample) can be 
used to test hypotheses about genetic variants emerging from GWAS in relevant 
clinical populations. Assessing bone and injury phenotype data in those athletes will 
also enhance understanding of any observed genotype-phenotype relationship (Wang 
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et al., 2013). A relatively homogenous group of athletes who experience high 
mechanical loads on some bone structures, such as endurance runners, would be 
suitable for this kind of investigation. Specifically, measuring areal BMD via DXA 
scanning, with a particular emphasis on the primary loading sites in this population, 
would probably provide appropriate data to combat some of the aforementioned 
challenges identified. It would be fascinating to discover whether those athletes have 
a genotype that enhances BMD, protects against the effects of the large volume of 
training required and reduces risk of stress fracture. One preliminary report (using just 
14 participants) even documents an attempt to reduce the risk of tendon, ligament and 
bone injuries by modifying athlete training programmes based upon genetic 
characteristics (Goodlin et al., 2015). This illustrates the kinds of future applications 
possible in this field, after the more fundamental research has been conducted 
successfully.  
1.4 Identifying candidate genes  
Over 66 genetic loci have been associated with DXA-derived BMD/Osteoporosis via 
GWAS and almost 100 have been associated via candidate gene association study 
(Hsu and Kiel, 2012), with some of these variants having also been associated with 
stress fracture (Varley et al., 2015; Varley et al., 2016; Korvala et al., 2010). This vast 
number highlights the likely highly polygenic nature of BMD. Many of the genes 
discovered via GWAS have no known or limited understanding in regards to their 
potential biological function on bone. Only 7 of the >100 variants associated with BMD 
via candidate gene association study have also been associated at GWAS level (Hsu 
and Kiel, 2012). Many of these genes have not had further replication in different 
populations or cohorts via GWAS or in candidate gene association studies. Moreover, 
this means many candidate genes have not had replication in populations where 
environmental stimuli may be prominent, as would be the case of mechanical loading 
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in high-level weight-bearing athletes as highlighted previously in this chapter. 
Candidate gene-selection and the approach utilised to investigate potential 
associations with BMD is consequently, a difficult process.  
GWAS allows identification of genomic loci in a large population of individuals by 
completing an expansive scan of the genome in those who may have a particular 
phenotype/condition of interest in comparison to those who do not have the phenotype 
by typically genotyping two hundred thousand up to two million variants (Estrada et al., 
2012; Visscher et al., 2017). GWAS has been completed in individuals with 
osteoporosis, high bone mass (Gregson et al., 2018) and other bone-related 
conditions, such as Paget’s disease (Albagha et al., 2010) as well as being 
implemented for tissue-specific pathway association analysis (Wang et al., 2017). 
Overall, although GWAS provides strong statistical power, they remain high in costs in 
comparison to candidate gene approach studies. Furthermore, the associated variants 
discovered by GWAS can be missed through excessive statistical power or the 
variants identified within adjacent loci can be correlated and in linkage disequilibrium 
(Wall and Pritchard, 2003). Loci in linkage disequilibrium can both exhibit significant 
genotype-phenotype association but only one may have a functional relevance for the 
phenotype in question. A candidate gene association study is different to GWAS in 
being hypothesis driven and aims to determine association between genetic variations 
and a particular phenotype. Candidate gene association studies can be utilised to 
further study specific variants that may have had strong associations at GWAS level 
(Teare, 2011). Replication of these specific SNPs, via a candidate gene approach may 
provide further evidence that the associations are not false-positive findings as 
discussed in Section 1.2. GWAS was not possible in this thesis and requires large 
sample sizes, which is unfeasible given that high-level endurance athletes who 
complete substantial volumes of mechanical loading are a sparse, homogenous group.  
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Consequently, utilising a candidate gene approach provides the most suitable method 
to investigate the highly evidenced BMD-associated genes, using the current clinical 
standard measurement of BMD (DXA) in a population that has had limited study on to 
date. Moreover, further understanding of the genes associated with BMD in athletic 
populations can add to the understanding of the genetics of athlete status and 
performance. Specifically, in relation to bone, whether certain runners are 
advantageously genetically predisposed to higher BMD and a subsequent reduction in 
stress fracture risk. A number of SNPs associated with health or fitness-related 
phenotypes have been explored in relation to athlete performance, injury and status 
(Guth and Roth, 2013) but investigation using this approach for bone is somewhat 
lacking. Therefore, approximately 20 SNPs were ranked on the basis of the volume 
and strength of evidence in relation to GWAS and/or case-control association and/or 
associated biological function with BMD. Based on available resources, the top 10 
were then selected for investigation.     
Consequently, ten candidate single nucleotide polymorphisms (SNPs) were identified 
for investigation within this thesis, from previous GWAS and/or candidate gene 
association studies, that each have a functional effect on bone physiology/metabolism 
(Table 1.3). Many of these chosen SNPs, for which specific overviews are detailed in 
the subsequent section of this review, have also shown potential gene-physical activity 
interactions or conflicting results in athletic populations. Further investigation of these 
SNPs in athletic cohorts will add to the current body of literature, extend our 
understanding of the genetic associations with BMD and provide new knowledge in 
regards to athlete status and performance.  
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Table 1.3: The candidate gene SNPs and their associated proteins selected for 
analysis for associations with status, performance, BMD and stress fracture incidence 
in high-level endurance athletes.  
Candidate gene Gene abbreviation and 
SNP 
Candidate gene protein 
axin1 AXIN1 rs9921222 axin-1  
 
BDNF antisense RNA 
 
BDNF-AS rs6265 
 
 
Non-protein coding 
Collagen type I alpha 1 
chain 
COL1A1 rs1800012 
 
Collagen alpha-1(I) chain  
Catechol-O-
methyltransferase 
COMT r4680 Catechol O-methyltransferase 
 
LDL receptor related protein 
5 
 
LRP5 rs3736228 
 
Low-density lipoprotein receptor-related protein 5 
 
Purinergic receptor P2X 7 
 
P2RX7 rs3751143 
 
 
P2X purinoceptor 7 
 
TNF receptor superfamily 
member 11a 
TNFRSF11A rs3018362 
 
Tumor necrosis factor receptor superfamily 
member 11A (RANK) 
TNF receptor superfamily 
member 11b 
TNFRSF11B rs4355801 
 
Tumor necrosis factor receptor superfamily 
member 11B (OPG) 
 
vitamin D receptor 
 
VDR rs2228570 
 
Vitamin D3 receptor 
1,25-dihydroxyvitamin D3 receptor 
 
Wnt family member 16 WNT16 rs3801387 Wnt-16 
 
1.4.1 Candidate genes of interest 
AXIN1 rs9921222 
AXIN1 is a Wnt signalling loci, which is known to influence the mechanosensitivity of 
the skeleton (Robinson et al., 2006). AXIN1 is suggested to encode regulators of the 
Wnt signalling pathway, specifically as an element of the beta-catenin destruction 
complex (Baron and Kneissel, 2013; Styrkarsdottir et al., 2016), and therefore, may 
influence bone mass by stimulating differentiation and replication of osteoblasts to 
enhance bone formation. The AXIN1 rs9921222 SNP has been found to have strong 
associations with BMD via GWAS meta-analysis (Estrada et al., 2012). Specifically, 
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the T allele of the AXIN1 rs9921222 was associated with lower femoral neck and 
lumbar spine BMD in a large adult cohort (n > 50,000) but was not associated with 
fracture in 31,016 cases and 102,444 controls (Estrada et al., 2012). The rs9921222 
SNP has also been reported to have nominal associations with BMD via gene-physical 
activity interactions in children and adolescents (Mitchell et al., 2016). Mechanical 
loading leads to an increase in Wnt production by osteocytes, which activates the 
signalling pathway (Klein-Nulend et al., 2012), however, the potential gene-physical 
activity interaction mechanism is unknown. Further functional study of AXIN1 on bone 
is required to confirm potential influence on bone but AXIN1 presents a noteworthy 
candidate to explore gene-physical activity interactions due to the results found from 
investigation so far. Although limited research has been conducted into the potential 
AXIN1-physical activity interactions on BMD, no studies have been conducted utilising 
athletic populations where potential influences on other BMD-related phenotypes such 
as stress fracture, can be explored additionally.  
BDNF-AS rs6265 
Brain-derived neurotrophic factor antisense RNA (BDNF-AS) encodes brain-derived 
neurotrophic factor and has been primarily associated with the repair and plasticity of 
neurons (Lipsky and Marini, 2007). One specific SNP, the C to T missense variation 
at nucleotide 196 resulting in a valine to methionine (Val66Met) substitution at codon 
66 (Egan et al., 2003), has been associated with influencing such phenotypes. At the 
BDNF opposite strand, the BDNF-AS gene is transcribed in a reverse complimentary 
direction that produces alternative RNA transcripts whose fifth exon overlaps with the 
protein coding exon of BDNF, influencing BDNF expression. Inhibition of BDNF-AS 
expression can upregulate BDNF mRNA significantly, resulting in increased protein 
levels. Consequently, alteration of BDNF-AS expression through genetic variation 
could ultimately effect BDNF-associated phenotypes such as neuron plasticity. This 
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alteration could also influence bone phenotypes as proposed in recent mice studies 
that have demonstrated BDNF knockdown can inhibit osteoblast differentiation, 
resulting in increased bone formation (Guo et al., 2016). This strong influence on 
osteoblast differentiation via BDNF through genetic variation in BDNF-AS could have 
a substantial impact for BMD and potential influence on stress fracture via potential 
disturbances in bone remodelling. BDNF influence on BMD has also been observed in 
humans where AA genotype is associated with lower spine and hip BMD in 
Caucasians (Deng et al., 2013). Overall, limited research into BDNF-AS association 
with human phenotypes exists, particularly that which assesses a potential influence 
of BDNF-AS on BMD, and therefore, additional study is still warranted in both 
candidate-gene association and functional studies.  
COL1A1 rs1800012 
COL1A1 encodes Collagen alpha-1(I) chain, which is the most abundant protein in 
bone and presents one of the most extensively studied genes in relation to human 
tissue. COL1A1 SNPs have been associated with both soft-tissue tissue injury and 
bone phenotypes (Posthumus et al., 2009; Ficek et al., 2013). One specific SNP in 
particular, rs1800012, has received extensive research, which has indicated that the 
TT (CC), rather than the CC (AA) genotype is associated with lower hip and lumbar 
spine BMD as well as increased risk of osteoporotic fracture in meta-analysis (Jin et 
al., 2011). Functional studies have also demonstrated that the rs1800012 
polymorphism is associated with alterations in COL1A1 transcription and protein 
production, influencing bone mass (Mann and Ralston, 2003). Specifically, possessing 
the T (C) allele of the COL1A1 rs1800012 SNP increases the amount of transcript for 
α1 chain, which has been suggested to result in the formation of collagen homotrimers 
associated with degenerative bone microarchitecture (Mann et al., 2001; Grant et al., 
1996; Dytfeld et al., 2016). Additionally, COL1A1 gene expression has been to shown 
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to increase following mechanical loading in rats, thus emphasising the potential impact 
of mechanical loading that could be genotype-dependent for COL1A1 variants (Mantila 
Roosa et al., 2011). Research exploring COL1A1 genotype associations has been 
conducted into athletic populations but this has primarily focused on soft tissue injuries 
and not BMD or bone phenotypes (Posthumus et al., 2009). To the author’s 
knowledge, there exists only one study thus far that has investigated a potential 
association of COL1A1 rs1800012 with bone phenotypes in athletes, which observed 
no association with stress fractures (Varley et al., 2018). Consequently, additional 
study on BMD in this population is certainly worthwhile due to the functional influence 
of COL1A1 rs1800012 in bone and previous findings on bone phenotypes in non-
athletic populations. Athletic success is a complex phenotype influenced by a 
substantial number of factors but COL1A1 rs1800012 provides an extremely 
interesting SNP to investigate potential associations with BMD and athlete status due 
to previous associations with soft-tissue injury in this population.   
COMT rs4680 
The COMT gene encodes catechol O-methyltransferase and is important for the 
metabolic degradation of dopamine. The rs4680 SNP has been associated with 
decision making (He et al., 2012), prefrontal cognition (Malhotra et al., 2002) and 
Alzheimer’s disease (Serretti and Olgiati, 2012) but it has also provided interesting 
results in relation to BMD. COMT catalyses the methylation of catechol oestrogens to 
methoxy oestrogens (inactive metabolites) and thus, lower COMT enzyme activity 
results in greater 16-hydroxy-oestradiol, which retains oestrogenic activity and 
enhances BMD (Lorentzon et al., 2007). Consequently, both higher oestradiol serum 
concentration (Eriksson et al., 2004) and higher BMD (Eriksson et al., 2005) have been 
reported in lower enzyme activity AA genotypes. Conflicting results regarding which 
COMT rs4680 genotype is more advantageous for BMD, however, have been 
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observed (Gonçalves et al., 2015), which may be due to interactions of mechanical 
loading. The rs4680 SNP has been shown to influence the association between 
physical activity and BMD, suggesting that certain genotypes may be particularly 
important for BMD in individuals with low physical activity levels as mentioned 
previously in Section 1.2.2 (Lorentzon et al., 2007). A COMT genotype-interaction, 
thus, may be present and the potential regulation of the BMD response to mechanical 
loading may be due to the involvement of oestrogen receptors as facilitators in a 
number of key pathways by which mechanical strain stimulates bone formation (Galea 
et al., 2013). Investigation into COMT and BMD is limited and thus, further study is 
warranted to provide greater evidence of potential associations with BMD and/or a 
gene-physical activity interaction. 
LRP5 rs3736228 
Activation of Wnt/β-catenin (canonical) signaling increases the sensitivity of 
osteoblasts to mechanical loading, which can occur via Wnt binding to low-density 
lipoprotein receptor-related proteins 5 and 6 (LRP5/LRP6) co-receptors (Robinson et 
al., 2006; Krishnan et al., 2006).  
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Figure 1.11: Wnt proteins (1 and 3a) bind with LRP5/LRP6 to form a complex with Frz 
receptors (frizzled receptor family) resulting in increased Wnt signaling and increased 
bone formation. Figure taken from (Rochefort, 2014).  
It has been proposed that the mediation of Wnt signaling via different LRP5 variants 
can both enhance and decrease BMD (Ferrari et al., 2005). Loss-of-function mutations 
in LRP5 are also responsible for low bone mass disorders, such as osteoporosis 
pseudoglioma, whereas gain-of-function mutations have been suggested to cause 
high bone mass syndromes (Levasseur et al., 2005). Furthermore, LRP5 variants, 
such as C135242T, have been associated with BMD variability in the general 
population (Koay et al., 2004) and ds2306862 in osteoporotic individuals (Mizuguchi 
et al., 2004), highlighting the strong influence LRP5 may have on bone metabolism. 
Particularly interesting findings have been reported for the rs3736228 SNP influence 
on BMD, which was dependent upon volume of physical activity completed (Kiel et al., 
2007). Specifically, rs3736228 TT genotypes were associated with lower BMD in men 
with higher physical activity level but higher BMD in those with a lower physical activity 
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level. The authors hypothesised that the C to T allele substitution alters LRP5-
mediated Wnt signalling in the case that the catabolic signals induced from the 
mechanical loading prevails over anabolic signalling (Kiel et al., 2007). This was also 
evidenced when expressing alleles in the context of their haplotype in vitro, where the 
T allele was associated with a decreased response to canonical Wnt3a signalling in 
comparison to the C allele. Overall, LRP5 rs3736228 has reported strong associations 
with BMD and osteoporotic fracture via both GWAS and candidate gene association 
studies in young and older adults (Richards et al., 2008; Saarinen et al., 2007). 
Moreover, similarly to AXIN1 rs9921222, LRP5 rs3736228 has demonstrated initial 
associations with physical activity and exciting outcomes for BMD, but has yet to be 
investigated for associations with these phenotypes in athletic populations and 
therefore represents a candidate variant deserving further investigation in this 
population.  
P2RX7 rs3751143 
Functional expression of purinergic receptor P2X 7 primarily regulates configuration of 
osteoclasts (Agrawal et al., 2010), as well as augmenting bone formation via a cell-
autonomous role that leads to stimulation of mineralisation (Panupinthu et al., 2008) 
and thus may be important for increasing BMD. P2RX7 SNPs have also been 
demonstrated to mediate interleukin-1 beta (IL1B) which has been shown to facilitate 
osteoclast regulation and decrease bone collagen and non-collagen protein synthesis 
(Nemetz et al., 2001). Similarly, P2RX7 mediation on interleukin-18 (IL18) is also 
apparent, IL18 has been shown to increase OPG expression in osteoblastic cells and 
consequently inhibit bone resorption (Makiishi-Shimobayashi et al., 2001). A number 
of P2RX7 polymorphisms have been explored in relation to BMD in osteoporotic 
populations as well as stress fracture incidence in elite athletes and military recruits 
(Varley et al., 2016). One particular P2RX7 variant (rs3751143) has been shown to 
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have effects on receptor functioning, whilst mice with a null mutation of P2RX7 have 
exhibited >73% reduced sensitivity to mechanical loading (Li et al., 2005). Possessing 
the rs3751143 null CC genotype results in a loss of function whereas heterozygotes 
have been proposed to have half the receptor functioning (Gu et al., 2001). This loss 
of function could explain why the C allele has been associated with lower hip and 
lumbar spine BMD in women (Wesselius et al., 2013). C allele associations with stress 
fracture have also been observed both in military recruits and elite athletes (Varley et 
al., 2016) from the elite stress fracture cohort (SFEA). The SFEA comprised a large 
number of athletes that were of mixed abilities across a range of sports and thus, other 
factors such as physical and training characteristics may influence stress fracture 
susceptibility as discussed previously in Chapter 1. P2RX7 rs3751143 alongside a 
number of other candidate genes such as TNFRSF11 rs1021188 and SOST 
rs1877632 have been associated with stress fracture in the SFEA cohort, which is the 
only study so far to investigate genetic associations with stress fracture incidence in 
athletes. Consequently, further research utilising homogenous cohorts representing 
one sport would provide further evidence on these specific variant associations with 
BMD and physical activity phenotypes. P2RX7 rs3751143 therefore, remains a prime 
candidate for further study so that a greater understanding of the potential specific 
contribution P2RX7 may have to BMD and other bone phenotypes such as fracture in 
diverse populations.  
TNFRSF11A rs3018362 
TNFRSF11A is located at 18q22.1 on the chromosome and encodes RANK which 
plays a fundamental role in osteoclast differentiation and function (Albagha et al., 
2010). Binding of RANK to RANKL initiates signalling pathways, such as Mitogen 
activated protein kinase (MAPK), resulting in activation of osteoclasts (Wada et al., 
2006). Genetic regulation of osteoclastogenesis via RANK has been supported in 
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functional studies. For example, nullizygous mice exhibit osteoporosis due to 
osteoclast absence and the associated defect in bone resorption and remodelling (Li 
et al., 2000). This potential strong genetic influence of TNFRSF11A on bone has been 
reported across a number of SNPS, with TNFRSF11A rs3018362 proposed as a prime 
candidate from previous study. The A allele has been associated with Paget’s disease 
and reduced BMD via GWAS (Albagha et al., 2010). Conflicting results, however, have 
reported no TNFRSF11A rs3018362 genotype associations (reaching genome-wide 
significance) with hip BMD in 5861 Icelandic adults. The TNFRSF11A rs3018362 SNP 
has also been associated with stress fracture incidence in athletic populations as 
evidenced within the SFEA cohort (Varley et al., 2015). Overall, strong functional 
evidence has been reported in regards to RANK and initiation of BMD-relevant 
signalling pathways, although contradictory findings regarding the TNFRSF11A 
rs3018362 association with BMD and other bone phenotypes exist. The difference in 
findings could be due to the influence of other factors on RANK expression. For 
example, interleukin-1 (IL1) and IL6 are both mediators of RANK and RANKL 
expression and thus can effect bone resorption by facilitating osteoblast and osteoclast 
interaction (Steeve et al., 2004). Consequently, different determinants, other than 
TNFRSF11A genotype, will regulate RANK expression and ultimately impact BMD, as 
is likely to be the case for a number of other genetic variants involved within bone 
metabolism pathways. Further research is therefore required to provide more evidence 
to the specific contribution of TNFRSF11A variation on BMD across different 
populations. Due to the functional evidence supporting the impact of RANK in bone 
metabolism, it would be particularly interesting to explore if TNFRSF11A rs3018362 
genotype-dependent differences in BMD are present in athletic populations who are 
completing large volumes of mechanical loading.  
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TNFRSF11B rs4355801 
The human TNF receptor superfamily member 11b (TNFRSF11B) gene encodes the 
protein OPG, which is secreted by osteoblasts and aids in regulating bone resorption 
by inhibiting differentiation and activation of osteoclasts. Consequently, alongside 
TNFRSF11A (RANK), OPG forms part of the RANK/RANKL/OPG pathway which 
regulates bone metabolism, through initiation of osteoblastic or osteoclastic activity 
(Tyrovola and Odont, 2015). OPG-deficient mice have been found to develop early 
onset osteoporosis, and increased tissue mRNA expression has been observed in 
participants who possess specific haplotypes, accompanied with reduced BMD, which 
may be due to the increased expression resulting in stimulated osteoclast activity 
(Takács et al., 2010). Alongside these findings, TNFRSF11B rs4355801 genotype 
appears to influence BMD in humans in association studies. Specifically, the 
TNFRSF11B rs4355801 A allele has been associated with lower BMD via GWAS in 
adults (Richards et al., 2008) as well as cortical BMD in adolescents (Paternoster et 
al., 2010). Alongside the association with BMD in GWAS, the “risk” A allele (which 
explained 0.4% of the variance at both the lumbar spine and femoral neck) was also 
associated with reduced TNFRSF11B expression. Although these findings suggest the 
A allele can negatively impact BMD, the proposed “advantageous” G allele has been 
associated with stress fracture in the SFEA cohort (Varley et al., 2015). In the runners 
specifically, those who possessed at least one copy of the G allele had a greater risk 
of stress fracture. Consequently, these findings contradict the majority of other studies 
exploring TNFRSF11B rs4355801 and thus, further study is required to gather a 
greater understanding of which allele may be the more “advantageous” for BMD and 
if this may vary depending upon environmental stimuli such as mechanical loading.  
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VDR rs2228570 
Vitamin D receptor (VDR) controls the transcription of other genes such as osteocalcin 
that are instrumental for calcium absorption and bone formation (Moran et al., 2014). 
Specifically, vitamin D functions as the ligand for VDR, which facilitates calcium and 
phosphate absorption to induce bone mineralisation (Haussler et al., 1998). A direct 
effect of osteoblastic/osteocytic VDR signalling on bone remodelling has also been 
proposed, although specific understanding of this notion is still lacking and largely 
depends on calcium balance (Lieben and Carmeliet, 2013). The potential association 
of VDR with BMD and/or fracture has also been supported across a number of different 
SNPs (Bsml rs1544410, ApaI rs7975232 and TaqI rs731236) in various cohorts, such 
as pre and postmenopausal women (Riggs et al., 1995; Horst-Sikorska et al., 2007; Ji 
et al., 2010; Marozik et al., 2013). One particular SNP (FokI rs2228570) has been 
extensively studied across a number populations with contradictory findings have been 
observed (Gentil et al., 2009). This particular polymorphism, Fokl (rs2228570), exhibits 
a C to T transition that creates an upstream initiation codon, leading to the production 
of VDR proteins that are three more amino acids in length. Consequently, this 
transition influences VDR protein expression and may explain why higher BMD has 
been reported in those with CC genotype (Arai et al., 1997; Colin et al., 2000; 
Uitterlinden et al., 2004; Ames et al., 1999) as described in Section 1.2.3. VDR 
rs2228570 has also been explored in relation to gene-physical activity interactions, 
where the ff genotype was associated with higher BMD (rather than the FF) genotype 
in postmenopausal women (Gentil et al., 2009). However, in athletic populations, 
opposing results have been reported. Significantly higher total BMD in 84 weight-
bearing athletes than 80 controls was observed in the FF (7.7%) and Ff (6.9%) but not 
ff (1.8%) genotypes for the VDR FokI rs2228570 polymorphism, whilst significantly 
lower total BMD was only observed in the FF (-4.5%) genotype when comparing 
47 
 
swimmers with a control group (Nakamura et al., 2002a). Overall, support for both 
alleles with a physical activity interaction exists in the literature and therefore, the 
specific population investigated in regards to age or sex and the type of physical 
activity completed may be accounting for the differences in the findings (Gentil et al., 
2009; Rabon‐Stith et al., 2005). VDR rs2228570 is one of the more extensively studied 
SNPs in relation to BMD, particularly in regard to physical activity. Further study, 
however, is required to determine which allele or genotype may be more beneficial for 
BMD and if this can be explained by differences in genotype sensitivity to the 
mechanical loading completed by athletic populations.  
WNT16 rs3801387  
A number of Wnt ligands exist with some activating through the canonical pathway and 
others through the non-canonical pathway (Garcia-Ibarbia et al., 2013). Wnt16 is 
proposed to signal via the non-canonical pathway (Clements et al., 2011) but has also 
been proposed to signal via the canonical pathway and is a key regulator of osteoblast-
to-osteoclast communication and consequently influence bone mass (Figure 1.12) 
(Gori et al., 2015). Expression of canonical Wnt target genes has also been observed 
to be substantially lower in WNT16 knockout compared to wild type mice (Movérare-
Skrtic et al., 2014).  
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Figure 1.12: Wnt16 is expressed in osteoblasts on the outer surface of cortical bone. 
Wnt16 signals via the canonical Wnt pathway to regulate OPG expression, which 
results in OPG functioning as a decoy receptor for osteoblast and osteoclast RANKL 
expression. The osteoblast-expressed Wnt16 can also impact osteoclasts precursors 
to regulate osteoclastogenesis via the non-canonical pathway. Figure taken from (Gori 
et al., 2015).  
One particular WNT16 SNP (rs3801387) has been reported to influence BMD in a 
number of investigations. The A allele of the rs3801387 was one of the more strongly 
associated SNPs with lower lumbar spine and femoral neck BMD as well as 
osteoporotic fracture in the Estrada et al. (2012) meta-analysis. An A allele association 
with lower LBMD has also been observed in candidate gene association studies 
(Hendrickx et al., 2014), accompanied with reduced WNT16 expression and 
accounting for up to 1.8% of variance in total-body BMD in humans (Medina-Gomez 
et al., 2012). WNT16 remains particularly interesting as age-specific effects of WNT16 
association on BMD have been reported which could suggest specific genetic 
determination of bone accrual in children and a protective effect against osteoporosis 
in later life. Additionally, WNT16 rs3801387 (similarly to AXIN1 rs9921222) has been 
reported to interact with physical activity and demonstrated nominal associations with 
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BMD (Mitchell et al., 2016). Despite the considerable number of studies suggesting 
associations with BMD and evidence from functional investigation, WNT16 rs3801387 
was not associated with stress fracture in the elite athletes of the SFEA cohort (Varley 
et al., 2017). Overall, due to the prior literature proposing WNT16 rs3801387 
association with BMD but not stress fracture occurrence in elite athletes, further study 
is needed in athletic populations to elucidate the exact nature of WNT16 rs3801387 
contribution to BMD and potential associations with physical activity.  
1.5 Aims and objectives 
Consequently, the overall aim of the current thesis was to investigate the genetic 
associations with BMD, stress fracture incidence and performance in high-level 
endurance runners and compare these to a non-athlete cohort to explore genotype-
physical activity interactions. More specifically, the objectives were: 
1) To compare BMD between high-level endurance runners and non-athlete 
controls and identify genetic associations of 10 SNPs (AXIN1 rs9921222, 
BDNF-AS rs6265, COL1A1 rs1800012, COMT rs4680, LRP5 rs3736228, 
P2RX7 rs3751143, TNFRSF11A rs3018362, TNFRSF11B rs4355801, VDR 
s2228570, WNT16 rs3801387), individually and collectively, with BMD in these 
two populations. 
2) To compare BMD in high-level endurance runners who had suffered a stress 
fracture in comparison to those who had not and to determine whether the 10 
aforementioned SNPs, individually and collectively, were associated with stress 
fracture incidence in high-level endurance runners.  
3) To determine whether the 10 aforementioned SNPs were associated with 
marathon personal best time in high-level endurance runners.  
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4) To determine any cohort-dependent differences in BMD-genotype associations 
for the 10 aforementioned SNPs.  
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Chapter 2: 
General methodology 
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2.0 General Methodology  
The full method is listed within this chapter from which subsequent chapters use some 
or all of the participants and/or experimental procedures.  
2.1 Participants and participant recruitment 
All experimental procedures were conducted in accordance with the guidelines in the 
Declaration of Helsinki (World Medical Association, 2013) and approved by the local 
Ethics Committee of Manchester Metropolitan University. The total participant 
population comprised 581 Caucasian middle to long distance (endurance) runners 
(345 males, 236 females) who completed in events ranging from 3000 m to marathon 
and 559 healthy non-athlete controls. A self-report questionnaire (Appendix 1) 
detailing performance history, injury history, sporting activity in childhood and 
menstruation status/history for females was completed by the runners. Non-athletes 
completed a questionnaire designed to assess general health and physical activity 
levels (Appendix 2). Runners were primarily recruited from the London Marathon Expo 
2012–2015 as well as national/regional athletic clubs and organisations, whilst the 
non-athlete control group were recruited through mail-outs, posters and word of mouth.  
Personal best (PB) race time was verified by official race chip timings through 
individual race result websites, the power of 10 (http://www.thepowerof10.info/) and/or 
the International Association of Athletics Federations (IAAF) 
(https://www.iaaf.org/home). Runners were included if they had completed at least one 
official long distance event ≥3000 m in a time faster than a predetermined threshold 
(Table 2.1). The predetermined threshold time for each distance was chosen to ensure 
all athletes placed in at least the top 600 in the UK rankings for a calendar year based 
on the years 2012-2017. Average weekly running distance ranged from 15–110 miles 
and training hours per week ranged from 8-18 hours.  
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Table 2.1: PB selection criteria for both male and female runners. 
Distances Males Females 
3000 m < 8 min 45 s < 10 min 15 s 
5000 m/5 km road < 15 min 45 s < 18 min 45 s 
10000 m/10 km road < 32 min 45 s < 38 min 45 s 
Half marathon < 74 min 00 s < 88 min 00 s 
Marathon < 2 h 45 min 00 s < 3 h 15 min 00 s 
 
2.2 Genetic analysis  
2.2.1. DNA sample collection  
Deoxyribonucleic acid (DNA) for each participant was obtained via one of the three 
methods below: 
A 5 mL blood sample was collected by a trained phlebotomist from a superficial 
forearm vein into EDTA collection tubes and inverted 10–15 times, before being 
aliquoted into 1.5 mL microcentrifuge tubes (Eppendorf AG, Hamburg, Germany) and 
stored at -20°C. Approximately 75% of participant DNA was obtained from whole blood 
samples, whilst the remaining 25% was obtained via saliva sample (23%) or buccal 
swabs (2%). Saliva samples were collected following a minimum 30-minute abstinence 
from food and drink into Oragene DNA OG-500 collection tubes (DNA Genotek Inc., 
Ontario, Canada) in accordance with the manufacturer’s guidelines before being 
stored at room temperature. Although blood sampling is cheaper and potentially 
quicker for collecting large sample sizes of genomic data, saliva or buccal swabs are 
less invasive and were the preferred method for some participants (Feigelson et al., 
2001). Buccal cell samples were also collected after a minimum 30-minute abstinence 
from food and drink. Participants brushed one OmniSwab collection tip (Whatman 
Sterile Omniswab, GE Healthcare, USA) against the inside of one cheek for 30 s before 
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repeating this with a second swab on the opposite cheek to obtain two samples from 
each participant. Each collection tip was ejected into a 2 mL microcentrifuge tube and 
stored at -20°C. All samples were stored anonymously through coding and labelling in 
accordance with the Human Tissue Act (2004) and only members of the research team 
had access to this information and data.  
2.2.2 DNA extraction  
DNA was extracted using the Qiagen QIAcube spin protocol (Qiagen, Crawley, UK) 
and the buffers contained in the Qiagen DNA Blood Mini Kit (Qiagen) for whole blood, 
saliva and buccal samples in accordance with the manufacturer’s guidelines. DNA 
isolation from 200 μL whole blood or saliva required cell lysing with protease and AL 
buffer during incubation at 56°C for 10 min. Following centrifugation and the addition 
of ethanol, the resultant lysate was centrifuged at 8000 rpm for 60 s to allow silica gel 
membrane binding to occur. Removal of proteins, nucleases and other impurities was 
achieved following additional buffer-centrifugation cycles before elution of the 
remaining solution with 200 μL of AE buffer into a 1.5 mL microcentrifuge tube. Buccal 
swab extraction followed the same protocol as above for whole blood, however, an 
additional stage of transferring the lysate into sterile 2 mL microcentrifuge tubes prior 
to the DNA purification phase was required. The automated QIAcube was used to 
standardise these procedures and could complete this process on a maximum of 12 
samples at a time.  
2.2.3 DNA genotyping  
All participants were genotyped for the 10 SNPs on two different machines using the 
fluorophore-based detection technique of TaqMan real-time polymerase chain reaction 
(PCR), which requires amplification of a section of DNA overlapping the specific SNP 
being genotyped. To achieve amplification, forward primers were used to identify the 
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starting point of the DNA segment and reverse primers used to identify the end-point. 
Allele-specific probes, identified by either VIC or FAM (Table 2.2) attached to their 
respective complementary sequences, emitted a different fluorescent dye that could 
be distinguished by the respective PCR machine used. End-point fluorescence 
measurement of VIC and FAM determined the different genotypes (Figures 2.1 and 
2.2) and results were analysed using the software supplied by the respective 
manufacturers of each PCR machine.  
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Table 2.2: SNPs used in genotyping and identification of allele-specific probes.  
SNP VIC FAM Context Sequence(VIC/FAM) 
AXIN1 rs9921222 C-allele T-allele GCTCTGTGTTAGCTCCATCTTCTCT[C/T] 
ATGACGGGGCCTTCGGAAACACCAA 
BDNF-AS rs6265 C-allele T-allele TCCTCATCCAACAGCTCTTCTATCA[C/T] 
GTGTTCGAAAGTGTCAGCCAATGAT 
COL1A1 rs1800012 A-allele C-allele GGGAGGTCCAGCCCTCATCCCGCCC[A/C] 
CATTCCCTGGGCAGGTGGGGTGGCG 
COMT rs4680 A-allele G-allele CCAGCGGATGGTGGATTTCGCTGGC[A/G] 
TGAAGGACAAGGTGTGCATGCCTGA 
LRP5 rs3736228 C-allele T-allele GACTGTCAGGACCGCTCAGACGAGG[C/T] 
GGACTGTGACGGTGAGGCCCTCCCC 
P2RX7 rs3751143 A-allele C-allele CCTGAGAGCCACAGGTGCCTGGAGG[A/C] 
GCTGTGCTGCCGGAAAAAGCCGGGG 
TNFRSF11A rs3018362 A-allele G-allele ATCATCTTACCTACACCAGGTTCAC[A/G] 
TTTTCCATCTTAGAGTTATACAGGA 
TNFRSF11B rs4355801 A-allele G-allele TAAACAGGTGTACAGGTCTCAATAA[A/G] 
TGGGTGGTAGGTGTCAGGGAAAGTC 
VDR rs2228570 A-allele G-allele GGAAGTGCTGGCCGCCATTGCCTCC[A/G] 
TCCCTGTAAGAACAGCAAGCAGGCC 
WNT16 rs3801387 A-allele G-allele TGATTCCCACTTGGTTTCTGACACC[A/G] 
TTCCTAAACTTATGACTCCAAGAAT 
 
Genotyping and subsequent analysis was completed in duplicate using either the (1) 
Fluidigm EP1 (Fluidigm, Cambridge, UK) or the (2) StepOnePlus (Applied Biosystems, 
Paisley, UK) as detailed below: 
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(1) Fluidigm EP1 
The majority of samples (95%) were genotyped for the 10 SNPs by combining 2 μL 
GTXpress Master Mix (X2) (Applied Biosystems), 0.2 μL 20X Fast GT Sample Loading 
Reagent (Fluidigm), 0.2 μL nuclease-free H2O and 1.6 μL of purified DNA into each 
well of a 192x24 microchip plate. Negative controls were also placed into 4 wells on 
each 192x24 microchip, in which nuclease-free H2O replaced the DNA sample. 
Furthermore, 1.78 μL assay (20X) (Applied Biosystems), 1.78 μL 2X Assay Loading 
Reagent (Fluidigm) and 0.18 μL ROX reference dye (Invitrogen, Paisley, UK) were 
combined per assay inlet. An integrated fluid circuit controller RX (Fluidigm) was used 
to mix samples and assays using a Load Mix (166x) script. PCR was performed using 
a real-time FC1 Cycler (Fluidigm) GT 192X24 Fast v1 protocol. Denaturation began at 
95°C for 120 s followed by 45 cycles of incubation at 95°C for 2 s and then annealing 
and extension at 60°C for 20 s. The 192X24 microchip plate was then placed into the 
EP1 Reader for end-point analysis. Genotyping analysis was performed with the 
Fluidigm SNP genotyping analysis software. Duplicates of all samples were in 100% 
agreement.  
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Figure 2.1: Example allelic discrimination plot of a single SNP using the Fluidigm EP1 
system. 
(2) StepOnePlus 
The remaining 5% of the samples were genotyped by combining 5 μL Genotyping 
Master Mix or GTXpress Master Mix (Applied Biosystems), 4.3 μL H2O, 0.5 μL assay 
(Applied Biosystems), and 0.2 μL of purified DNA (~9 ng), for samples derived from 
blood and saliva into wells on a 96-well plate (MicroAmp EnduraPlate Optical 96-Well 
Clear Reaction Plate, Applied Biosystems). For DNA taken from buccal swabs, 5 μL 
Genotyping Master Mix was combined with 3.5 μL H2O, 0.5 μL assay mix, and 1 μL 
DNA solution (∼9 ng DNA). Negative controls were also placed into 2 wells on each 
96-well plate, in which nuclease-free H2O replaced the DNA sample. Each well on a 
96-well plate, therefore, contained a total reaction volume of ~10 μL before being 
covered with an optical seal (MicroAmp Optical Adhesive Film, Applied Biosystems). 
PCR was performed using a StepOnePlus Real-Time PCR system (Applied 
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Biosystems). Denaturation began at 95°C for 10 min, with 40 cycles of incubation at 
92°C for 15 s and then annealing and extension at 60°C for 1 min. Genotyping analysis 
was performed with StepOnePlus software version 2.3. Again, duplicates of all 
samples were in 100% agreement.  
 
Figure 2.2: Example allelic discrimination plot of a single SNP using the StepOnePlus 
Real-Time PCR system.  
Reproducibility between the two PCR systems was evident when 94 samples for the 
LRP5 rs3736228 variant were genotyped on both the StepOnePlus and Fluidigm PCR 
systems and were in 100% agreement.  
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2.3 Measurement of bone mineral density 
Bone mineral density (BMD) was measured using a Dual-energy X-ray absorptiometry 
(DXA) scanner (Hologic Discovery W, Vertec Scientific Ltd, UK) by one trained 
operator, consistent with the manufacturing guidelines. All participants wore a cotton 
examination gown, had no medically inserted metal implants and were instructed to 
remove any metal items prior to the scan. The participants lay supine in the centre of 
the machine table with arms by their sides (in a prone position) and legs internally 
rotated. To aid with internal rotation and comfort in this position, medical tape 
(TransporeTM Medical Tape, 3MTM, USA) was wrapped around the outside of the feet 
(Figure 2.3). This participant placement followed manufacturing guidelines as well as 
ensuring the whole body was within the scanning boundaries and that enough space 
was left between arms, torso and legs to maximise accuracy of subsequent segmental 
analysis. The default whole-body scan mode was selected which emits dual energy 
(140/100 kVp) fan-beams to estimate body composition. The scanning region was 195 
cm x 65 cm x 1.3 cm line spacing and 0.2 cm point resolution. Scan duration was 
approximately 7 minutes and the effective radiation dose to each participant was 8.4 
μsv (Blake et al., 2006). Subsequent segmental analysis for all scans were completed 
by the same trained operator using Physician’s Viewer v6.1 software to obtain leg BMD 
as highlighted below (Figure 2.3). Specifically, leg BMD was obtained by calculating 
the average of the left and right leg BMD that was derived from the segmental analysis.  
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Figure 2.3: Participant positioning for whole-body DXA scanning.  
 
 
Figure 2.4: Example DXA scan whole-body output following segmental analysis 
using Physician’s Viewer v6.1 software. 
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2.4 Statistical analysis 
Microsoft Excel version 2013 and SPSS for Windows version 23 (SPSS, Chicago, IL) 
were used for data analysis and specific statistical analysis for each experimental 
chapter is provided within the respective methods sections.  
In brief, Pearson's Chi-square tests (χ2) were utilised to test for Hardy-Weinberg 
equilibrium (HWE) and compare genotype and allele frequencies between runners, 
runner sub-groups and non-athletes for all 10 SNPs. One-way analysis of variance 
(ANOVA) was used to determine if runner PB differed between genotype groups for 
all 10 SNPs, individually and collectively as a total genotype score, whilst linear 
regression was also completed to identify if a total genotype score (TGS) could predict 
PB. Independent t-test analyses were completed to investigate any differences 
between the TGS of runners, runner sub-groups and non-athletes whilst receiver 
operator curve (ROC) area under the curve (AUC) analyses were conducted to 
determine if TGS was able to classify runners from non-athletes. Multiple analysis of 
variance (MANOVA) was used to compare BMD between the runners and non-athletes 
as well as compare BMD of the runners who had ever suffered a stress fracture with 
those who had no stress fracture injury history. Any genetic association with BMD was 
assessed via MANOVA and any interaction between the 10 investigated SNP 
genotypes and BMD in runners and non-athletes was also investigated via MANOVA 
analysis. BMD of the runners who had ever suffered a stress fracture compared to 
those with no stress fracture injury history was analysed via MANOVA before χ2 tests 
were utilised to compare the genotype and allele frequencies of these two groups.  
Alpha was set at 0.05 and Bonferroni or Benjamini-Hochberg corrections were 
implemented where appropriate (number of corrections were specific to and detailed 
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within each individual experimental chapter) to control false discovery rate.   
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Chapter 3:  
Bone mineral density in high-
level endurance runners and 
non-athletes 
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3.1 Introduction 
Bone mineral density (BMD) is defined as the ratio of mass to the area or volume of 
bone (Ott et al., 1997) and is considered to be the primary predictor of osteoporotic 
fracture (Cranney et al., 2007). BMD is also important in the elite sporting environment, 
where athletes possessing lower BMD are found to be more at risk for stress fracture 
incidence (Myburgh et al., 1990; Bennell et al., 1999). Several factors such as diet, 
hormones, genetics and physical activity are known to influence BMD, contributing to 
the large variability that exists within the phenotype (Pluijm et al., 2001; Krall and 
Dawson‐Hughes, 1993). Following physical activity, osteocytes detect shape and 
volume changes to increase or decrease the liberation of bone mediators, which 
consequently influences bone formation and resorption (Nakashima et al., 2011; 
Nakashima et al., 2012). This response to physical activity occurs across the lifespan, 
with children, adults and older adults, who complete a large volume of physical 
activity/exercise possessing greater BMD than those completing less physical 
activity/exercise (Chilibeck et al., 1995; Slemenda et al., 1991; Beck and Snow, 2003; 
Warburton et al., 2006). Athletic populations who complete large volumes of exercise, 
therefore, tend to possess higher BMD and bone mass than non-athletic individuals 
via the loading adaptation mechanisms mentioned above (Chilibeck et al., 1995). The 
loading characteristics of different sports, however, vary and so the BMD of athletes 
partaking different sports or disciplines also varies, particularly between different 
anatomical sites (Mudd et al., 2007; Bennell et al., 1997). Undertaking sports or 
exercise which express higher impacts through increased strain rates and higher peak-
force loading, such as running, results in enhanced total or site-specific BMD (Fehling 
et al., 1995). 
The influence of mechanical loading on BMD becomes a little more complex, however, 
in endurance athletes, such as long-distance runners. Higher leg BMD (0.14 g/cm2) 
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has been reported in male runners in comparison with non-athletes (Stewart and 
Hannan, 2000) and this enhanced BMD in running populations appears to continue 
into later life, with master athletes over 65 years old possessing higher BMD than non-
active counterparts (Velez et al., 2008). Similarly, measurement of other bone 
parameters, such as cortical thickness at the primary loading sites (e.g. tibia), have 
also demonstrated higher bone mass in runners compared to non-active controls 
(Feldman et al., 2012). Investigation of total-body BMD at other anatomical sites that 
are not directly loaded, however, has produced differing results. Although higher total-
body (8.6%), lumbar spine (12.2%), femoral neck (9.7%) and leg (13.2%) BMD has 
been found in female adolescent runners in comparison to controls (Duncan et al., 
2002), most studies have reported low BMD in endurance runners at the non-loading 
sites. Hind et al. (2006) observed low lumbar spine BMD (<-1.0 T-score) in 37% of the 
male runners aged 19-50 years investigated in comparison with a reference control 
database, whilst lower and low lumbar spine BMD (Z-score of -1.0 to -2.0) has also 
been reported in adolescent and adult female runners compared to control populations 
and reference databases (Pollock et al., 2010; Barrack et al., 2008b). Lower BMD was 
particularly evident in those exhibiting menstrual irregularities or dietary restraint 
(Barrack et al., 2008b; Barrack et al., 2008a). Low or lower BMD, therefore, can be 
observed in endurance runners at any site but particularly at non-loading sites, in those 
who may possess low energy availability and the subsequent suppression of bone 
formation. The influence of relative energy deficiency in sport (RED-S) and/or 
menstruation dysfunction on BMD may explain why runners, particularly females, can 
possess low or lower BMD than other runners or non-athletes (Scofield and Hecht, 
2012; Pollock et al., 2010).  
Overall, the majority of studies have found higher site-specific BMD but similar or lower 
total and non-loading site BMD (e.g. lumbar spine) in runners in comparison to non-
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athletes due to the associated mechanical loading on the lower extremity (Scofield and 
Hecht, 2012). Further investigation is needed to understand the influence of 
mechanical loading on BMD in endurance runners in greater detail as well as to 
uncover the potential prevalence of low BMD and the impact this may have for health 
and performance in this population. Utilising large sample sizes of high competitive 
level (i.e. national and international) endurance runners is fundamental to extending 
our understanding of the importance of BMD in this population to ensure the 
development and implementation of effective injury prevention or management 
strategies to ultimately enhance performance. Although a reasonable number of 
studies have investigated BMD in endurance runners, it is difficult to offer direct 
comparisons or draw conclusions between these studies due to the substantial 
differences in methodological design. For example, many studies report on varied 
sample sizes comprising athletes of differing ability/standard, all of which are likely to 
increase the inter-individual variability within the phenotype. Most studies to date have 
been conducted on non-elite athletes (i.e. defined here as those who have not 
competed at international or national level), with only one study thus far comprising 
wholly of UK elite endurance runners (Pollock et al., 2010). Additionally, some studies 
did not obtain current/previous training hours and running distance to estimate bone 
loading or indicate high site-specific bone loading volume as expected of high-level 
endurance runners. If training volume/load is not accounted for, some studies may 
consist of runners who have completed substantially more training, and consequently 
applied more loading on the bone than another investigated cohort, which, along with 
variance in energy availability, may aid in explaining the conflicting results. Similarly, 
whilst several investigations do appear to use athletes of a similar ability/standard by 
recruiting only ‘national’ or ‘regional’ level athletes, the definitions of what constitutes 
national or regional level athletes are not always clear and consistent, again making 
comparisons between studies difficult (Swann et al., 2015). BMD comparison, 
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therefore, between these populations is difficult due to a probable difference in training 
load characteristics. Summarising the effect of loading on BMD and investigating BMD 
in elite endurance runners in comparison with non-athletes or other sports remains 
difficult due to limited investigation and the aforementioned variances in study design 
or population. In sports where ability/success is based on completion time for a specific 
distance, such as endurance running, criteria based on PB, rather than representative 
level for example, would allow for better assessment of athlete calibre and subsequent 
comparison of BMD between studies.  Utilising a large homogenous cohort of high-
level endurance runners of a similar competitive standard (based on PB), who are also 
likely to be completing similar training volumes and/or intensities, may somewhat 
alleviate the aforementioned issues when investigating BMD in endurance runners 
arising from using loosely defined populations and their potential confounding 
variables.  
The primary aim of this chapter, therefore, was to investigate total body (TBMD), leg 
BMD (LBMD), lumbar spine BMD (LSBMD), total-body T-score and total-body Z-score 
in high-level endurance runners, at UK national standard for their respective PBs, in 
comparison to a non-athlete control group. 
3.2 Method 
The investigated participants and protocols used in Chapter 3 have already been 
described in detail in Chapter 2, thus, only a brief description of these methods is 
detailed below. 
Participant characteristics 
Participants consisted of 103 high-level Caucasian runners (45 males, 58 females) 
and 112 ethnically matched non-athletes (52 males, 60 females) from the cohort as 
described in Table 2.1 of Chapter 2.  
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Protocol 
All runners completed a questionnaire detailing ethnic ancestry, as well as 
performance, injury and sporting history (Appendix 1). Female runners also completed 
a questionnaire detailing menstruation history that allowed potential identification of 
those who demonstrate, or have demonstrated, amenorrheic characteristics. Any 
runner who reported an absence of menses until after age 16 years or had undertaken 
6 months without menstruation were identified as potentially amenorrheic (Gordon and 
Nelson, 2003). This questionnaire was utilised to investigate any potential effect of 
amenorrhea on BMD in the female runners. Non-athletes completed a questionnaire 
detailing ethnicity, general health and physical activity level to establish matched ethnic 
ancestry and ensure no history of high-level sporting competition (Appendix 2). All 
participants completed a whole-body DXA scan to gather BMD (g/cm2) data with 
whole-body and segmental analysis utilised to obtain total-body BMD (TBMD), leg 
BMD (LBMD) and lumbar spine BMD (LSBMD). Total-body T-score (the number of 
standard deviations above or below the mean for a sex- and ethnically-matched 
healthy 30 year-old adult in comparison to the DXA machine manufacturer’s reference 
database, National Health and Nutrition Examination Survey, 2008) and total-body Z-
score (the number of standard deviations above or below the mean for the patient's 
age, sex and ethnicity in comparison to the same database) were also acquired via the 
DXA scan and subsequent analysis.  
Statistical analysis 
Multiple analysis of variance (MANOVA) was used to compare TBMD, LBMD and 
LSBMD between the female runners and non-athletes and as well as between male 
runners and their non-athlete counterparts. To account for any potential influence of 
menstruation, the TBMD, LBMD and LSBMD of female runners who exhibited signs of 
amenorrhea were compared with those who were classed as eumenorrheic via 
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MANOVA analysis. Body mass-adjusted TBMD, LBMD, LSBMD, T-score and Z-score 
values were also reported and analysed via multiple analysis of covariance 
(ANCOVA). Alpha was set at 0.05 and data was reported as mean (SD) unless 
otherwise stated. 
3.3 Results 
LSBMD was <10% lower in male runners than non-athletes controls (P = 0.004; Figure 
3.1) but there were no differences in TBMD (P = 0.176), LBMD (P = 0.963), T-score 
(P = 0.123) or Z-score (P = 0.092) between these two groups (Table 3.1).  
 
Figure 3.1: Difference in LSBMD between male runners and male non-athletes (P = 
0.004). Error bars denote SD. 
 
 
 
 
 
 
 
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
Male runners Male non-athletes
LS
B
M
D
 (
g/
cm
2 )
P = 0.004 
71 
 
Table 3.1: Anthropometric and unadjusted BMD phenotype data in male runners (n = 
48) and non-athletes (n = 52). Data are presented as mean (SD) except for TBMD, 
LBMD, LSBMD, T-score and Z-score ranges which are presented as mean (minimum-
maximum).   
 Runners  Non-athletes  
Age (years) 35 (9) 34 (14) 
Height (m) 1.78 (0.06) 1.79 (0.07) 
Mass (kg) 66.925 (6.606) 78.029 (10.752) 
TBMD (g/cm2) 1.285 (0.094) 1.315 (0.114) 
LBMD (g/cm2) 1.477 (0.108) 1.476 (0.138) 
LSBMD (g/cm2) 1.088 (0.151)* 1.189 (0.181) 
T-score  0.84 (0.88) 1.15 (1.07) 
Z-score 0.82 (0.85) 1.13 (0.95) 
TBMD Range 0.488 (1.034–1.522) 0.564 (1.067–1.631) 
LBMD Range 0.526 (1.193–1.719) 0.749 (1.036–1.785) 
LSBMD Range 0.810 (0.750–1.560) 0.820 (0.830–1.650) 
T-score range 4.60 (-1.70–2.90) 5.10 (-1.40–3.70) 
Z-score range 4.30 (-1.60–2.70) 4.70 (-0.90–3.80) 
* indicates difference from non-athletes.   
Body-mass adjusted TBMD and LBMD were <4% and <6% higher, respectively, in 
male runners than non-athlete controls (P = 0.036; P < 0.001) but there were no 
differences in LSBMD (P = 0.345), T-score (P = 0.111) or Z-score (P = 0.106) between 
the two groups (Table 3.2). 
Table 3.2: Body mass-adjusted bone phenotype data in male runners (n = 48) and 
non-athletes (n = 52). Standard deviation (SD) is presented in brackets.  
* indicates difference from non-athletes.   
 
 
 
 
Group Adj TBMD Adj LBMD Adj LSBMD Adj T-score Adj Z-score 
Runners 
(n=45) 
1.325 
(0.094)* 
1.523 
(0.107)* 
1.123  
(0.174) 
1.18  
(0.94) 
1.14  
(0.80) 
Non-athletes 
(n=52) 
1.281 
(0.094) 
1.436  
(0.108) 
1.159  
(0.173) 
0.86  
(0.94) 
0.85 
(0.79) 
P - value 0.036 <0.001 0.345 0.111 0.106 
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LBMD was ~4% higher in female runners than non-athlete controls (P = 0.015; Figure 
3.2) but there were no differences in TBMD (P = 0.508), LSBMD (P = 0.110), T-score 
(P = 0.475) or Z-score (P = 0.847) between these two groups (Table 3.3).  
 
Figure 3.2: Difference in LBMD between female runners and female non-athletes (P 
= 0.015). Error bar denotes SD. 
Table 3.3: Anthropometric and unadjusted bone phenotype data in female runners (n 
= 58) and non-athletes (n = 60). Data are presented as mean (SD) except for TBMD, 
LBMD, LSBMD, T-score and Z-score ranges which are presented as mean (minimum-
maximum).  
 Runners  Non-athletes  
Age (years) 34 (12) 37 (15) 
Height (m) 1.65 (0.06) 1.64 (0.06) 
Mass (kg) 52.934 (5.180) 64.659 (11.389) 
TBMD (g/cm2) 1.203 (0.088) 1.191 (0.108) 
LBMD (g/cm2) 1.285 (0.099)* 1.235 (0.121) 
LSBMD (g/cm2) 1.127 (0.149) 1.175 (0.178) 
T-score  1.15 (1.04) 1.00 (1.27) 
Z-score 1.05 (0.90) 1.02 (1.15) 
TBMD range 0.350 (1.010–1.360) 0.448 (0.991–1.439) 
LBMD range 0.468 (1.029–1.497)  0.521 (0.993–1.513) 
LS BMD range 0.760 (0.710–1.460) 0.700 (0.870–1.570) 
T-score range 4.10 (-1.20–2.90) 5.30 (-1.50–3.80) 
Z-score range 3.70 (-0.90–2.80) 4.30 (-0.80–3.50) 
* indicates difference from non-athletes.   
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No differences between TBMD (P = 0.293), LBMD (P = 0.528), LSBMD (P = 0.677), 
T-score (P = 0.295) or Z-score (P = 0.740) were observed between amenorrheic and 
eumenorrheic runners (Table 3.4).  
Table 3.4: Anthropometric and unadjusted bone phenotype data in amenorrheic (n = 
18) and eumenorrheic (n = 40) runners. Standard deviation (SD) is presented in 
brackets.  
 Eumenorrheic  Amenorrheic  
Age (years) 37 (11) 27 (12) 
Height (m) 1.64 (0.06) 1.66 (0.06) 
Mass (kg) 52.899 (4.838) 53.011 (6.022) 
TBMD (g/cm2) 1.211 (0.089) 1.185 (0.086) 
LBMD (g/cm2) 1.290 (0.094) 1.272 (0.111) 
LSBMD (g/cm2) 1.132 (0.146) 1.114 (0.158) 
T-score  1.25 (1.04) 0.94 (1.02) 
Z-score 1.08 (0.91) 0.99 (0.89) 
 
Body mass-adjusted TBMD was ~5% and LBMD ~9% higher in the female runners 
compared to the non-athletes (P = 0.005; P <0.001). Body mass-adjusted T-scores (P 
= 0.004) and Z-scores (P = 0.008) were also higher in the runners compared to non-
athletes but no differences in body mass-adjusted LSBMD were observed between the 
two groups (P = 0.893; Table 3.5).  
Table 3.5: Body mass-adjusted bone phenotype data in female runners and non-
athletes. Standard deviation (SD) is presented in brackets.  
* indicates difference from non-athletes.   
 
 
 
 
 
Group Adj TBMD Adj LBMD    Adj LSBMD Adj T-score Adj Z-score 
Runners 
(n=58) 
1.226 
(0.099)* 
1.316 
(0.114)* 
1.154 
(0.175) 
1.43  
(1.22)* 
1.33  
(1.07)* 
Non-athletes 
(n=60) 
1.168  
(0.101) 
1.205  
(0.108) 
1.149 
(0.178) 
0.73  
(1.24) 
0.75  
(1.08) 
P - value 0.005 <0.001 0.893 0.004 0.008 
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3.4 Discussion 
The aim of this chapter was to investigate TBMD, LBMD, LSBMD, T-score and Z-score 
in high-level endurance runners in comparison to a non-athlete control group. This 
study is consistent with previous research suggesting that some endurance runners 
may possess higher site-specific BMD (Duncan et al., 2002) but lower non-loading site 
BMD (Hind et al., 2006) than non-athlete controls as highlighted in Figures 3.1 and 
3.2. Higher LBMD but not TBMD or LSBMD was observed in female runners compared 
to non-athletes whilst lower LSBMD but no differences in TBMD or LBMD were present 
in the male comparison. No differences were present in T-score or Z-score between 
runners and controls in both male and female comparisons. When adjusted for body 
mass, TBMD, LBMD, T-score and Z-score was substantially higher in both the males 
and females in comparison to their non-athlete counterparts. 
LBMD was 0.050 g/cm2 higher in female runners than female non-athletes, highlighting 
the effects of site-specific mechanical loading on the lower extremity in endurance 
runners, which is congruent with some previous research (Duncan et al., 2002; 
Scofield and Hecht, 2012; Nevill et al., 2003; Brahm et al., 1997). Nevill et al. (2003) 
reported higher BMD of the legs in female endurance runners in comparison to upper 
body sites. They concluded that site-specific loading may enhance lower-body BMD 
(via a positive osteogenic effect) at the expense of bone mass of the upper-body sites. 
This may explain why no difference in TBMD or LSBMD between female runners and 
non-athletes was found in this chapter. Opposing findings to this chapter, reporting 
lower LSBMD in female endurance runners in comparison to controls, have primarily 
been observed in those who may have low energy availability and/or menstrual 
dysfunction (Pettersson et al., 1999; Barrack et al., 2008a; Scofield and Hecht, 2012). 
Reduced energy availability has been demonstrated to negatively impact bone 
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metabolism (through examination of bone turnover markers), consequently supressing 
bone formation and potentially reducing BMD (Ihle and Loucks, 2004).  
Reduced energy availability can be particularly harmful for BMD during childhood. 
Adolescent endurance runners have been reported to have lower BMD at sites such 
as the hip or the lumbar spine in both males and females (Barrack et al., 2008a; 
Barrack et al., 2017). Risk factors for low BMD in this population have included running 
over >50 km per week, being <85% of expected body mass and consuming <1 serving 
per day of a calcium-rich food (Barrack et al., 2017). In this chapter, no differences 
were observed in TBMD or LBMD between amenorrheic and eumenorrheic runners, 
suggesting that energy deficiency and menstrual status may not be influencing BMD 
in this investigated cohort, which may explain why no differences in TBMD were 
observed between female runners and non-athletes. It could be speculated that 
runners who experience energy deficiency and/or exercise-induced amenorrhea may 
find it more difficult to reach high-level due to the potential increased injury risk or 
negative effect on health from possessing lower BMD. Experiencing an injury has been 
shown to lead to cessation in sporting activities or reduction in participation, particularly 
in adolescents (Crane and Temple, 2015). It must be noted, however, that energy 
deficiency is difficult to measure and a self-report questionnaire was implemented to 
assess potential amenorrhea. Measurement error has been demonstrated in self-
reported cycle length to assess menstruation status or history (Small et al., 2007) and 
thus, limitation exists when utilising this method. Questionnaire use, however, is 
inexpensive and easy to implement in large cohorts, and hence, has been widely 
accepted and used extensively to determine potential menstruation disturbances in 
athlete studies (Martin et al., 2017; Rosetta et al., 2001; Hoch et al., 2009).   
Another possible explanation for the contradictory findings in this study (higher LBMD 
and no difference in TBMD) compared to previous investigations reporting low or lower 
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BMD may be due to the standard of the runners in the investigated cohort. This chapter 
utilised high-level runners who were all at a UK national standard for their respective 
PBs and completing large training distances between 55–215 km per week on 
average. Of the limited investigation into BMD of elite athletes, most studies have used 
non-elite athletes who are likely to complete lower volumes of training and 
consequently, be less at risk of energy deficiency and the associated negative effect 
on BMD. Although greater running distance per week has been negatively correlated 
with BMD (Hind et al., 2006; Burrows et al., 2003), higher-level runners are more likely 
to undertake resistance/strength based training, which may constitute greater amounts 
of high and multi-directional force to the bone, consequentially benefiting BMD (Nevill 
et al., 2003). Runners who complete higher volumes of resistance-based training have 
been found to possess higher LSBMD (Gordon and Nelson, 2003). The addition of 
high loading force on the bone via more strength-based training in the higher-level 
runners may explain why no difference in LSBMD between the female runners and 
controls was reported in this chapter. Pollock et al. (2010) studied a homogenous 
group of elite UK female endurance runners and is the only other study to date 
(alongside this investigation) that has studied a large cohort of UK endurance runners 
who are all competing at a high-level (i.e. nationally and/or internationally). Low TBMD 
(characterised by a Z-score of -1.0 to -2.0) was observed in 4.9% of the runners and 
a total-body Z-score median of approximately 0.1 was exhibited. In this chapter, a total-
body Z-score of -0.9 was the lowest observed in the female runners and a mean TBMD 
of 1.053 (g/cm2) was found, suggesting a higher TBMD in the runners investigated in 
this chapter. Although the runners utilised in this and the Pollock et al. (2010) study 
were of a similar standard, the practices and undertaking of strength or resistance-
based training by endurance runners, however, varies substantially (Blagrove et al., 
2017), which may explain the different findings between the two investigations.  
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Male runners exhibited lower LSBMD compared to non-athlete counterparts, which is 
congruent with some previous research. Lower vertebral but not tibial or radial BMD 
has been observed in male endurance runners completing 92.2±6.3 km per week 
(Bilanin et al., 1989), whilst Hind et al. (2006) reported low lumbar spine BMD in 
comparison to a reference population in both female and male endurance runners. 
Endurance runners tend to have lower body mass than non-athlete controls, as 
observed in this chapter, and thus less force during loading will be exerted on these 
anatomical sites in comparison to non-athletes. Furthermore, the lumbar spine 
experiences less mechanical loading than the lower extremity when running which may 
also explain why lower BMD at this site in comparison to the non-athletes is present 
(Pollock et al., 2010; Cappozzo, 1983).  
It is surprising to find no difference in LBMD between the male runners and non-
athletes  given that up to 10% higher LBMD in runners compared to non-athletes has 
been reported in a previous investigation (Stewart and Hannan, 2000), although similar 
TBMD and LBMD to non-athletes has also been reported previously (Fredericson et 
al., 2007). Lower LSBMD and no differences in TBMD or LBMD in the runners in 
comparison to the non-athletes found in this chapter may be due to the potential effect 
of RED-S. Previous investigations suggest that male runners may be at risk of RED-S 
(Tenforde et al., 2016; Barrack et al., 2017) as highlighted in the recent IOC consensus 
statement (Mountjoy et al., 2018). The benefits of mechanical loading on BMD, 
therefore, can sometimes be overcome or reduced by the presence of an energy 
deficiency. Essentially, the balance of bone turnover following repeated training in 
male endurance runners does not appear to be affected unless an energy deficiency 
is present, resulting in suppression of bone formation (Zanker and Swaine, 2000). A 
greater magnitude of loading at the lower extremity and the associated mechanical 
impact from running may protect against the potential negative effect of reduced 
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energy availability on BMD and consequently explain why lower LSBMD but similar 
TBMD and LBMD was found in comparison to the control group. Varying levels of 
energy availability and genetic profiles may explain the differences in results in the 
literature and why lower or similar BMD in comparison to non-athletes has been 
observed in endurance running populations.  
Total-body T-scores and Z-scores were generated from the manufacturer’s reference 
system (National Health and Nutrition Examination Survey, 2008). No differences were 
observed in total-body T-score and Z-score between runners in both the male and 
female analysis as would be expected due to non-significant findings in the comparison 
of TBMD. The runners had positive mean total-body T- and Z-scores (males = 0.842, 
0.816; females = 1.153, 1.053), which contradicts some previous literature reporting 
low total-body T- and/or Z-scores in endurance running populations (Pollock et al., 
2010). It must be noted, however, that comparison across studies is difficult due to the 
different DXA machines utilised and different reference databases used to compare 
BMD data. The T-scores and Z-scores for both the runners and non-athletes were 
substantially higher than this reference database, suggesting that the mechanical 
loading completed by the runners has been beneficial for TBMD and that the non-
athlete group may have been completing enough physical activity to initiate an 
osteogenic response although deemed non-athletes. It would be interesting to obtain 
T-scores and Z-scores for the other measured sites (LBMD and LSBMD). Comparing 
the BMD for these sites to a large reference database would help identify if the LSBMD 
of the male runners would be interpreted as low and the LBMD of the female runners 
considered high in comparison to the norm. LSBMD that is classed as low or 
osteoporotic has been observed in endurance runners in comparison to norms 
previously (Pollock et al., 2010; Hind et al., 2006).  
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It is interesting to note the large variance in TBMD, LBMD and LSBMD in both the 
control group and the endurance runners. This substantial range cannot be attributed 
solely to age- or physical activity associated effects on BMD and indicates that other 
determinants, such as genetics, significantly influence BMD. Heritability is suggested 
to be between 50-85% (Ralston and Uitterlinden, 2010) and a large number of genes 
have been hypothesised to influence BMD (Golchin et al., 2016; Hsu and Kiel, 2012). 
The control group possessed a larger range in both TBMD and LBMD in males and 
females than the runners, which suggests that runners could compensate for a 
potential disadvantageous genetic predisposition for BMD via mechanical loading as 
has been proposed in previous investigation (Mitchell et al., 2016).   
This chapter suggests that female runners possess ~4% higher LBMD but not TBMD 
or LSBMD than female non-athletes, whereas male runners possess ~10% lower 
LSBMD but similar TBMD and LBMD compared to controls. Additionally, no 
differences were observed in total-body T- and Z-scores for male or female 
comparisons. This would suggest that female but not male runners benefit from site-
specific mechanical loading on the skeleton, resulting in higher leg BMD. Male runners, 
however, appear to display lower BMD at the lumbar spine in comparison with non-
athletes, which may be due to reduced energy availability. Additionally, a large range 
in BMD was observed in both the male and female runners and controls, suggesting 
that other determinants such as genetics, diet, types of loading and when this loading 
may have occurred also influences BMD across the adult lifespan.  
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Chapter 4: 
Association of bone mineral 
density-related genes with 
athlete status and marathon 
performance in high-level 
endurance runners 
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4.1 Introduction  
Bone mineral density (BMD) is considered the primary predictor of osteoporotic and 
fracture risk, and is heavily influenced by factors such as smoking (Law and Hackshaw, 
1997), dietary intake (Darling et al., 2009) and physical activity (Pluijm et al., 2001; 
Krall and Dawson‐Hughes, 1993). Following bouts of physical activity, osteocytes 
detect shape and volume changes to increase or decrease the liberation of bone 
mediators, which consequently influences bone formation and resorption (Nakashima 
et al., 2011). Thus, completing a larger volume of physical activity/exercise across the 
lifespan increases BMD, reportedly accounting for up to 30% of the variability in total 
BMD (Valdimarsson et al., 1999; Neville et al., 2002; Allison et al., 2015). Athletes who 
compete in weight-bearing sports, therefore, tend to possess higher BMD than non-
athletes, due to the increased strain rates and high peak-force loading characteristics 
experienced by this mechanical loading (Fehling et al., 1995). Despite this, too much 
activity to the point of overtraining can result in negative outcomes (Kuipers and Keizer, 
1988), such as stress fractures (Knapp and Garrett, 1997), which occur due to the 
repetitive mechanical loading that stimulates an incomplete remodelling response 
(Jones et al., 2002). Higher incidence of lower limb stress fractures is observed in 
endurance runners in comparison with non-athletic controls. Significant amounts of 
site-specific loading combined with other factors typical of this group, such as low 
energy availability, can result in lower BMD and a higher risk of fracture occurrence 
(Loucks, 2007).  
Stress fractures have been reported to account for 50% of all injuries sustained by 
runners and military recruits, with higher incidence observed in females, which may be 
due to other influential factors such as lower lean mass, leg-length discrepancy and 
irregular menstruation (Milner et al., 2006). Interestingly, in both female and male 
runners with a history of stress fracture, lower BMD has been observed (Bennell et al., 
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1996; Barrack et al., 2017). Consequently, higher BMD appears important for elite 
endurance running to allow athletes to complete larger volumes of training with less 
potential training interruption from injury, which in turn may increase their likelihood of 
achieving success. 
Although BMD is a multi-factorial phenotype, influenced by diet, hormones and 
physical activity, heritability is suggested to be between 50-85% depending upon 
anatomical location (Ralston and Uitterlinden, 2010). To date, nearly 100 loci have 
been associated with BMD and/or osteoporosis via GWAS (Rocha-Braz and Ferraz-
de-Souza, 2016). Similarly, stress fracture occurrence has been reported to have a 
genetic influence in both military recruits (Korvala et al., 2010; Yanovich et al., 2011) 
and athletic populations (Varley et al., 2015; Varley et al., 2016; Varley et al., 2017). 
Many of the variants associated with BMD and/or stress fracture, however, have not 
been replicated in further study or investigated in different populations where the 
outcome of gene-environment interactions can be explored. The lack of replication is 
particularly evident in those who may exhibit extreme phenotypes or genotypes, or 
undertake a substantial volume of mechanical loading, such as elite marathon runners, 
who have been reported to run an average minimum weekly distance of 150 km (± 17 
km) (Billat et al., 2001).  
Greater understanding of the BMD-associated genetic profile in endurance athletes 
may further our understanding of the complex phenotype of successful endurance 
performance and provide new insight into the genetic association with BMD. The 
primary aim of this study, therefore, was to compare the genotype and allele 
frequencies of 10 genetic variants (detailed in Section 1.5 - AXIN1 rs9921222, BDNF-
AS rs6265, COL1A1 rs1800012, COMT rs4680, LRP5 rs3736228, P2RX7 rs3751143, 
TNFRSF11A rs3018362, TNFRSF11B rs4355801, VDR s2228570, WNT16 
rs3801387) associated with BMD in high-level endurance runners (elite and sub-elite) 
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and a non-athlete control group. Additionally, any association with marathon PB was 
explored for each variant individually, and collectively, as part of a Total Genotype 
Score (TGS) before receiver operator curve (ROC) area under the curve (AUC) 
analysis was implemented to determine if TGS could distinguish runners from non-
athletes. It was hypothesised that the runners, particularly those in the elite category, 
would possess fewer “risk” (lower BMD-associated) genotypes than non-athlete 
controls that would contribute to a potential reduced risk of injury, resulting in less 
training interruption and greater competitive success.  
4.2 Method 
The investigated participants and protocols used in Chapter 4 have already been 
described in detail in Chapter 2, thus, only a brief description of these methods is 
detailed below. 
Participant characteristics 
Participants consisted of 528 European Caucasian marathon runners and 559 
ethnically matched non-athlete controls from the cohort as described in Table 2.1 of 
Chapter 2. The marathon runners were sub-grouped by personal best marathon (PB) 
time into either elite (men < 2 h 30 min, n = 128; women < 3 h 00 min, n = 119) or sub-
elite (men 2 h 30 min – 2 h 45 min, n = 196; women 3 h 00 min – 3 h 15 min, n = 85) 
categories. 
Procedure 
All participants provided a whole-blood, saliva or buccal swab sample, from which DNA 
was subsequently extracted and analysed to obtain genotype data for the 10 
investigated SNPs as described in Chapter 2. 
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Statistical analysis  
Pearson’s Chi-square (χ2) tests were utilised to compare genotype (using three 
analysis models; additive, recessive and dominant) and allele frequencies between all 
runners and non-athletes as well as elite vs non-athletes before completing an elite vs 
sub-elite and then sub-elite vs non-athlete comparison if an initial association was 
observed. Odds ratios were also implemented to estimate effect size. One-way 
analysis of variance (ANOVA) was used to determine if PB differed between genotype 
groups for all 10 variants, individually and collectively as a TGS, whilst linear 
regression was also implemented to evaluate whether TGS could predict marathon 
PB. TGS was calculated using the model reported in Williams and Folland (2008), and 
thus, every SNP was allocated a score according to existing literature. Each SNP 
homozygote associated with higher BMD was given a score of 2, the heterozygotes 
scoring 1 and the other homozygote given 0 (“risk” genotype). The total score was then 
calculated to lie within 0-100 ((e.g. TGS = 100/20 x (2+1+0+1+1+1+0+2+1+2) = 55)). 
Independent t-test analyses were completed to investigate any differences between 
runners and non-athletes, elite and sub-elite athletes (total and according to sex, i.e. 
elite men vs sub-elite men and elite women vs sub-elite women) and the fastest 10% 
compared to the slowest 10% allocated by PB (both collectively and sex-dependent). 
Receiver operator curve (ROC) area under the curve (AUC) analysis was conducted 
to determine if the TGS was able to classify runners from non-athletes. Benjamini-
Hochberg corrections were implemented for genotype and allele frequency 
comparisons when required (each variant submitted to 8 - 9 tests) to account for false 
discovery rate. Corrected probability values are reported (unless stated) and alpha 
was set at 0.05.  
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4.3 Results 
Genotype frequencies 
All genotype data for runners and non-athletes were in Hardy-Weinberg equilibrium (P 
≥ 0.060, χ2 = 3.524) except for the VDR rs2228570 genotype in the control group (P = 
0.035, χ2 = 4.461). For COMT rs4680, the elite group possessed a lower frequency 
(~8%) of the “risk” (lower BMD-associated) GG genotypes than the non-athletes (P = 
0.035, χ2 = 10.123; Figure 4.1) and sub-elite groups (P = 0.049, χ2 = 8.659; Figure 4.1) 
with a trend observed between the runner and non-athlete group (P = 0.083, χ2 = 
6.816). Similarly, in the recessive analysis model, a difference between the genotype 
frequencies of the elite runners compared to non-athletes as well as the sub-elite group 
was observed (P = 0.035, χ2 = 7.366; P = 0.035, χ2 = 8.439). For WNT16 rs3801387, 
genotype frequency differed between the runner and non-athlete groups (P = 0.027, 
χ2 = 10.141) with runners possessing a ~4% lower frequency of the advantageous GG 
genotype. Elite runners possessed an 11% lower frequency of the “risk” AA genotype 
in comparison to sub-elite (P = 0.036, χ2 = 6.816) and a trend for a lower frequency 
(4%) was observed in comparison to non-athletes (P = 0.059, χ2 = 7.313; Figure 4.2). 
In the dominant analysis model, runners exhibited a larger number of “risk” A carriers 
in comparison to non-athletes (P = 0.018, χ2 = 9.865). Genotype frequency differed 
between the runner and non-athlete groups for both the additive and recessive 
analysis models (P = 0.027, χ2 = 9.199; P = 0.012, χ2 = 8.834; Figure 4.3) for the P2RX7 
rs3751143 variant but no differences were observed for the elite vs non-athlete 
comparisons (P ≥ 0.162, χ2 = 3.091). Genotype frequency differed before multiple 
testing correction between the runner and non-athlete group in the VDR rs2228570 
variant for both the additive and dominant analysis model with runners possessing a 
<5% fewer frequency of “risk” T carriers (P = 0.180, χ2 = 7.287; P = 0.180, χ2 = 7.287; 
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Figure 4.3). No differences were observed for any other investigated variant in runner 
vs non-athlete or elite vs non-athlete comparisons (P ≥ 0.330; Table 4.1).   
Figure 4.1: COMT rs4680 genotype frequencies of runners and non-athletes, with 
runners divided into standard subgroups (elite and sub-elite). Differences between elite 
vs non-athlete (*P = 0.035, χ2 = 10.123) and elite vs sub-elite comparisons (**P = 
0.049, χ2 = 8.649). 
Figure 4.2: WNT16 rs3801387 genotype frequencies of runners and non-athletes, with 
runners divided into standard subgroups (elite and sub-elite). Significant differences 
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between runners and non-athletes (*P = 0.027, χ2 = 10.141) and elite vs sub-elite (**P 
= 0.036, χ2 = 11.229) comparisons.  
 
Figure 4.3: P2RX7 rs3751143 and VDR rs2228570 genotype frequencies of runners 
and non-athletes groups. Difference in P2RX7 rs3751143 genotype frequency 
between runners and non-athletes (P = 0.027, χ2 = 9.199).  
Allele frequencies  
Runners possessed a 4% higher frequency of the P2RX7 rs3751143 “risk” C allele 
than non-athletes (P = 0.012, χ2 = 9.130) but no difference was observed in the elite 
vs non-athlete comparison (P = 0.158; Figure 4.4).  Allele frequency also differed 
between runners and non-athletes for the AXIN1 rs9921222 and TNFRSF11A 
rs3018362 variants but not after multiple testing correction (P = 0.112, χ2 = 5.039; P = 
0.116, χ2 = 4.745; Figure 4.4). No differences in allele frequency were observed for 
any other variant in runners vs non-athletes and elite vs non-athletes (P ≥ 0.108; Table 
4.1).  
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Figure 4.4: AXIN1 rs9921222, P2RX7 rs3751143 and TNFRSF11A rs3018362 allele 
frequencies of runners and non-athletes. Difference in P2RX7 rs3751143 allele 
frequency between runners and non-athletes (P = 0.012, χ2 = 9.130).  
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Table 4.1: Genotype and allele frequencies of all investigated variants in runners and 
non-athletes with their respective significant* or non-significant P- and χ2 values.  
SNP 
 
Genotypes 
Alleles 
Groups Group comparison 
 Runners Non-athletes Elite Runner vs 
Non-athlete 
Elite   vs  Non-
athlete 
Genotype 
frequency (%) 
Allele      
frequency (%) 
Genotype   
frequency (%) 
Allele        frequency 
(%) 
Genotype 
frequency (%) 
Allele   
frequency (%) 
P-value 
 
 
Chi-square 
(χ2) 
P-value 
 
 
Chi-square 
(χ2) 
 
AXIN1  
rs9921222 
CC 
CT 
TT 
C 
T 
26.3 
49.1 
24.6 
50.9 
49.1 
29.3 
49.9 
20.8 
54.3 
45.7 
31.2 
45.7 
23.1 
44.7 
55.3 
0.168 
(5.521) 
 
0.112 
(5.039) 
0.546 
(1.785) 
 
0.913 
(0.012) 
BDNF-AS 
rs6265 
GG 
GA 
AA 
G 
A 
66.1 
30.3 
3.6 
81.2 
18.8 
67.8 
28.8 
3.4 
82.2 
17.8 
66.4 
29.6 
4.0 
81.2 
18.8 
0.704 
(0.701) 
 
0.419 
(0.652) 
0.808 
(0.427) 
 
0.551 
(0.356) 
COL1A1 
rs1800012 
AA 
AC 
CC 
A 
C 
65.0 
31.4 
3.6 
80.7 
19.3 
68.0 
28.8 
3.2 
82.4 
17.6 
64.1 
32.4 
3.6 
81.2 
18.8 
0.330 
(2.217) 
 
0.148 
(2.096) 
0.782 
(0.491) 
 
0.482 
(0.944) 
COMT      
rs4680 
GG 
GA 
AA 
G 
A 
20.8 
52.8 
26.4 
47.3 
52.7 
24.0 
47.2 
28.8 
47.6 
52.4 
16.6 
56.3 
27.1 
44.7 
55.3 
0.083 
(6.816) 
 
0.829 
(0.046) 
 0.035* 
(10.123) 
 
0.205 
(1.607) 
LRP5  
rs3736228 
GG 
GA 
AA 
G 
A 
73.7 
24.4 
1.9 
85.9 
14.1 
73.0 
24.5 
2.5 
85.2 
14.8 
64.1 
32.4 
3.6 
86.2 
13.8 
0.663 
(0.821) 
 
0.552 
(0.353) 
0.429 
(1.693) 
 
0.534 
(0.387) 
P2RX7 
rs3751143 
 
AA 
AC 
CC 
A 
C 
65.2 
31.4 
3.4 
80.9 
19.1 
71.0 
26.5 
2.5 
84.3 
15.7 
66.8 
29.1 
4.1 
81.4 
18.6 
 0.027* 
(9.199) 
 
0.012* 
(9.130) 
0.216 
(3.637) 
 
0.158 
(3.091) 
TNFRSF11A 
rs3018362 
GG 
GA 
AA 
G 
A 
42.8 
44.7 
12.5 
65.2 
34.8 
37.9 
50.0 
14.1 
61.9 
38.1 
41.3 
43.7 
15.0 
63.2 
36.8 
0.065 
(5.469) 
 
0.116 
(4.745) 
0.410 
(1.782) 
 
0.564 
(0.373) 
TNFRSF11B 
rs4355801 
AA 
GA 
GG 
A 
G 
30.3 
50.0 
19.7 
55.3 
44.7 
28.1 
52.1 
19.9 
54.1 
45.9 
30.4 
50.2 
19.4 
55.5 
45.5 
0.507 
(1.360) 
 
0.438 
(0.601) 
0.725 
(0.642) 
 
0.547 
(0.363) 
VDR     
rs2228570 
CC 
CT 
TT 
C 
T 
39.6 
45.8 
14.6 
62.5 
37.5 
35.4 
71.7 
12.9 
61.3 
38.7 
40.1 
45.3 
14.6 
62.8 
37.2 
0.180 
(7.287) 
 
0.499 
(0.673) 
0.272 
(3.995) 
 
0.499 
(0.458) 
WNT16 
rs3801387 
AA 
AG 
GG 
A 
G 
50.6 
43.3 
6.1 
72.3 
27.7 
49.4 
40.4 
10.2 
69.6 
30.4 
44.9 
48.2 
6.9 
69.0 
31.0 
0.027* 
(10.141) 
 
0.108 
(3.545) 
0.059      
(7.313) 
 
0.787 
(0.073) 
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Table 4.2: Odds ratio and confidence interval (CI) statistics for runner vs non-athlete 
status of the 10 investigated SNPs. 
 
 
SNP Genetic model Odds ratio 
Runner vs 
NA 
95% CI Odds ratio 
Elite vs NA 
95% CI 
AXIN1  
rs9921222 
T/C 
TT/CC 
TT/C carriers 
T carriers/CC 
 
1.15 
1.26 
1.25 
1.16 
0.970 – 1.359 
0.832 – 1.918 
0.938 – 1.658 
0.891 – 1.516 
1.14 
1.05 
1.15 
0.92 
0.918 – 1.148 
0.690 – 1.588 
0.800 – 1.642 
0.662 – 1.269 
BDNF-AS 
rs6265 
A/G 
AA/GG 
AA/G carriers 
A carriers/GG 
 
1.07 
1.09 
1.06 
1.08 
 
0.857 – 1.325 
0.566 – 2.085 
0.555 – 2.027 
0.839 – 1.391 
1.07 
1.22 
1.20 
0.88 
 
0.815 – 1.407 
0.553 – 2.673 
0.549 – 2.618 
0.390 – 1.967 
COL1A1 
rs1800012 
C/A 
CC/AA 
C/A carriers 
C carriers/AA 
1.12 
1.17 
1.12 
1.15 
0.901 – 1.390 
0.604 – 2.265 
0.582 – 2.162 
0.890 – 1.473  
1.08 
1.17 
1.14 
1.09 
0.825 – 1.425 
0.513 – 2.649 
0.503 – 2.567 
0.796 – 1.503  
COMT 
rs4680 
G/A 
GG/AA 
GG/A carriers 
G carriers/AA 
 
0.99 
0.95 
0.84 
1.13 
0.834 – 1.168 
0.677 – 1.335 
0.627 – 1.111 
0.867 – 1.478 
0.89 
0.74 
0.63 
1.09 
0.721 – 1.103 
0.468 – 1.154 
0.429 – 0.930 
0.777 – 1.519 
LRP5 
rs3736228 
A/G 
AA/GG 
AA/G carriers 
A carriers/GG 
 
0.95 
0.75 
0.75 
0.97 
0.747 – 1.206 
0.329 – 1.707 
0.331 – 1.707 
0.738 – 1.264 
0.92 
0.48 
0.48   
0.97 
0.680 – 1.250 
0.136 – 1.692  
0.136 – 1.681 
0.687 – 1.355 
P2RX7 
rs3751143 
C/A 
CC/AA 
CC/A carriers 
C carriers/AA 
 
1.23 
1.48 
1.37 
1.40 
1.014 – 1.581 
0.727 – 3.028 
0.676 – 2.791 
1.078 – 1.810 
1.23 
1.72 
1.64 
1.30 
0.928 – 1.617 
0.748 – 3.941 
0.719 – 3.751 
0.939 – 1.795 
TNFRSF11A 
rs3018362 
A/G 
AA/GG 
AA/G carriers 
A carriers/GG 
 
0.87 
0.78 
0.87 
0.82 
0.729 – 1.035 
0.538 – 1.142 
0.611 – 1.233 
0.640 – 1.041 
0.95 
0.97 
1.07 
0.87 
0.761 – 1.180 
0.617 – 1.536 
0.701 – 1.634 
0.640 – 1.179 
TNFRSF11B 
rs4355801 
A/G 
AA/GG 
AA/G carriers 
A carriers/GG 
 
1.05 
1.09 
1.11 
1.01 
 
0.886 – 1.242  
0.769 – 1.538  
0.857 – 1.446 
0.749 – 1.362 
1.06 
1.11 
1.12 
1.03 
0.854 – 1.307 
0.714 – 1.709 
0.804 – 1.550  
0.704 – 1.498 
VDR  
rs2228570 
T/C 
TT/CC 
TT/C carriers 
T carriers/CC 
 
0.95 
1.01 
1.16 
0.84 
0.798 – 1.129 
0.696 – 1.475 
0.817 – 1.632 
0.655 – 1.071 
 
0.94 
1.00 
1.15 
0.82 
0.755 – 1.168 
0.627 – 1.596  
0.750 – 1.777 
0.603 – 1.116 
WNT16 
rs3801387 
A/G 
AA/GG 
AA/G carriers 
A carriers/GG 
1.14 
1.72 
1.05 
1.76 
0.945 – 1.370 
1.083 – 2.742 
0.827 – 1.331 
1.122 – 2.761  
0.97 
1.35 
0.83 
1.54 
0.774 – 1.225 
0.751 – 2.420 
0.615 – 1.122 
0.874 – 2.699 
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Total Genotype Score 
No differences were observed in TGS between athletes and controls (P = 0.188) or 
any other comparison (P = 0.067), with all subgroups displaying similar mean TGS 
(Table 4.3). ROC analysis determined that TGS frequency distribution could not 
distinguish a runner from a non-athlete (AUC = 0.477, P = 0.192). Additionally, ROC 
analysis could not differentiate between the top 10% and bottom 10% of male runners 
(P = 0.939, AUC = 0.494) but a tendency for a higher TGS frequency in the 10% 
compared to the bottom 10% in the female runners was observed (P = 0.053 AUC = 
0.675; Figure 4.6d).  
Table 4.3: Mean, mode and median TGS of runners and non-athletes with runners 
divided into standard subgroups (elite and sub-elite) as well as the top 10% according 
to PB (corrected P – value). 
 
Group and 
comparisons 
TGS Mean 
(SD)  
Mode Median P - value 
Runners 63.23 (9.54) 65 65 0.188 (0.372) 
Controls 64.03 (9.65) 65 65 
 
Elite 
 
64.07 (9.70) 
 
65 
 
65 
 
0.067 (0.372) 
Sub-elite 62.54 (9.35)  65 65 
 
Elite men 
 
63.95 (9.45) 
 
65 
 
65 
 
0.188 (0.372) 
Sub-elite men 62.52 (9.70) 65 65 
 
Elite women 
 
64.20 (10.00) 
 
60 
 
65 
 
0.239 (0.372) 
Sub-elite women 62.59 (9.08) 60 60 
 
Top 10% all 
 
63.89 (9.40) 
 
70 
 
65 
 
0.533 (0.622) 
Bottom 10% all 62.78 (9.04) 65 65 
 
Top 10% men 
 
63.79 (9.52) 
 
65 
 
65 
 
0.948 (0.948) 
Bottom 10% men 63.94 (9.41) 65 65 
 
Top 10% women 
 
64.05 (9.43) 
 
70 
 
65 
 
0.266 (0.372) 
Bottom 10% women 60.95 (8.31) 60 60 
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Figure 4.6a: TGS frequency distribution in male runners and non-athletes, with 
runners divided into elite and sub-elite groups.  
 
 
Figure 4.6b: TGS frequency distribution in elite and sub-elite male and female 
runners. 
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Figure 4.6c: TGS frequency distribution in the elite, sub-elite, top 10% and bottom 
10% PB male runners. 
 
Figure 4.6d: TGS frequency distribution in the elite, sub-elite, top 10% and bottom 
10% PB female runners.  
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Marathon Performance 
Personal best times were not associated with any gene variant individually for men (P 
≥ 0.086), women (P ≥ 0.183; Table 4.4) or collectively as a TGS in men (P = 0.835) or 
women (P = 0.257). Additionally, TGS could not predict marathon PB for either males 
(β= -0.006, P = 0.914; Figure 4.7a) or females (β = -0.027, P = 0.705; Figure 4.7b) via 
linear regression.  
Table 4.4: Mean personal best time (h:mm:ss) and associated genotype for all 10 
investigated SNPS in both male and female runners. Uncorrected probability values 
are reported.  
SNP Genotype                      PB (SD) P - value 
Males Females 
AXIN1 
rs9921222 
CC 
CT 
TT 
2:31:33 (0:08:00) 
2:32:04 (0:07:39) 
2:31:24 (0:07:30) 
2:57:19 (0:08:49) 
2:56:09 (0:11:31) 
2:58:01 (0:11:20) 
0.781 
 
0.581 
 
BDNF-AS  
rs6265 
 
GG 
GA 
AA 
 
2:31:35 (0:08:01) 
2:32:08 (0:07:07) 
2:32:09 (0:07:14) 
 
2:57:38 (0:10:30) 
2:55:14 (0:11:24) 
2:55:38 (0:09:09) 
 
0.823 
 
0.877 
 
COL1A1 
rs1800012 
 
AA 
AC 
CC 
 
2:31:58 (0:07:55) 
2:31:25 (0:07:30) 
2:31:39 (0:04:55) 
 
2:56:59 (0:10:30) 
2:57:11 (0:11:43) 
2:54:50 (0:14:00) 
 
0.837 
 
0.877 
 
COMT   
 rs4680 
 
GG 
GA 
AA 
 
2:30:55 (0:06:57) 
2:31:37 (0:07:49) 
2:33:43 (0:07:42) 
 
2:57:31 (0:09:51) 
2:56:35 (0:11:17) 
2:57:18 (0:10:24) 
 
0.086 
 
0.856 
 
LRP5  
rs3736228 
 
CC 
CT 
TT 
 
2:31:56 (0:07:33) 
2:31:17 (0:08:16) 
2:32:54 (0:04:09) 
 
2:57:15 (0:10:13) 
2:56:16 (0:11:44) 
2:53:50 (0:20:24) 
 
0.745 
 
0.755 
 
P2RX7 
rs3751143 
 
AA 
AC 
CC 
 
2:31:55 (0:07:47) 
2:31:55 (0:07:11) 
2:27:49 (0:09:55) 
 
2:56:14 (0:10:51) 
2:58:06 (0:10:18) 
2:59:53 (0:10:48) 
 
0.252 
 
0.378 
 
TNFRSF11A 
rs3018362 
 
GG 
GA 
AA 
 
2:32:28 (0:07:11) 
2:31:31 (0:08:02) 
2:30:35 (0:07:53) 
 
2:57:49 (0:10:22) 
2:56:07 (0:11:26) 
2:56:50 (0:09:11) 
 
0.331 
 
0.568 
 
TNFRSF11B 
rs4355801 
 
AA 
AG 
GG 
 
2:31:18 (0:08:24) 
2:32:04 (0:07:10) 
2:31:50 (0:07:51) 
 
2:57:42 (0:10:13) 
2:57:01 (0:11:07) 
2:55:37 (0:10:21) 
 
0.744 
 
0.639 
 
VDR  
rs2228570 
 
CC 
CT 
TT 
 
2:31:14 (0:07:07) 
2:32:26 (0:08:03) 
2:31:21 (0:07:55) 
 
2:57:30 (0:10:22) 
2:56:30 (0:11:10) 
2:57:15 (0:09:57) 
 
0.396 
 
0.819 
 
WNT16 
rs3801387 
 
AA 
AG 
GG 
 
2:32:12 (0:07:04) 
2:31:23 (0:08:04) 
2:32:16 (0:09:29) 
 
2:58:20 (0:10:54) 
2:55:39 (0:10:34) 
2:54:52 (0:07:29) 
 
0.621 
 
0.183 
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Figure 4.7a: Mean marathon PB for each potential TGS of the male runners.  
 
 
Figure 4.7b: Mean marathon PB for each potential TGS of the female runners. 
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4.4 Discussion 
This is the first time the influence of BMD-associated genetic variants have been 
investigated in a large cohort of high-level endurance runners in comparison to non-
athletes and in relation to marathon personal best time. Elite runners possessed a 
lower frequency of the “risk” (associated with lower BMD) AA and GG genotypes in the 
WNT16 rs3801387 and COMT rs4680 variants, respectively, in comparison to non-
athletes and sub-elites. The “risk” C allele was more frequent in the runners than the 
control group for the P2RX7 rs3751143 SNP.  
Although elite runners possessed a higher frequency of the WNT16 rs3801387 “risk” 
A allele in comparison to non-athletes in the dominant analysis model, they possessed 
a lower frequency of the AA genotype (44.9%) than non-athletes (49.4%) and sub-elite 
runners (55.5%). WNT16 is as an important member of the Wnt signalling pathway 
known to influence BMD, cortical bone thickness and osteoporotic fracture risk (Zheng 
et al., 2012). The WNT16 rs3801387 A allele has consistently exhibited associations 
with lower BMD via GWAS and candidate gene association study in adults and children 
(Koller et al., 2013; Estrada et al., 2012; Warrington et al., 2015). These findings 
therefore, may suggest that not possessing the AA genotype is beneficial for reaching 
elite status through protection against stress fracture injury and potential training 
interruption but does not influence initial capacity to reach high-level marathon 
performance.   
WNT16 and AXIN1 are both Wnt signalling loci, which is known to influence the 
mechanosensitivity of the skeleton (Hens et al., 2005; Johnson and Kamel, 2007) 
Interestingly, both the WNT16 rs3801387 and AXIN1 rs9921222 variants have been 
reported to have nominal associations with higher BMD via gene-physical activity 
interactions previously (Mitchell et al., 2016), although no differences in allele 
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frequency for the AXIN1 rs9921222 variant were observed after multiple testing 
correction. Mechanical loading leads to an increase in Wnt production by osteocytes, 
which activates the signalling pathway (Klein-Nulend et al., 2012). The concept of a 
gene-physical activity interaction has had limited investigation thus far, although 
previous results have suggested certain genotypes may be more sensitive than others 
to mechanical loading. For example, the LRP5 rs2306862 and rs3736228 TT 
genotypes were associated with lower BMD in men with higher physical activity level 
but higher BMD in those with a lower physical activity level. However, the LRP5 
rs3736228 SNP did not present any significant findings in this chapter. This may be 
due to the effects of other proteins within the Wnt signalling pathway that may be more 
sensitive to mechanical loading in general or particular types of mechanical loading. 
SOST and Dickkopf (DKK) bind to LRP5/LRP6 which inhibits the Wnt signalling 
pathway by preventing Wnt ligand binding, reducing bone formation (Kawano and 
Kypta, 2003; Williams and Insogna, 2009). Deletion of SOST has been associated with 
insensitivity in unloading whilst SOST expression is also varied depending upon the 
nature of the loading conditions (Lin et al., 2009). Therefore, the influence of loading 
may mediate other components of the Wnt signalling pathway (such as SOST) and 
consequently differences in LRP5 genotype may not be as important for bone 
phenotypes within this mechanism. Additionally, young adults were the investigated 
cohort in the Mitchell et al. (2016) study and childhood appears to be a key point in 
time for bone accrual and age-specific effects for particular loci on BMD has been 
reported (Medina-Gomez et al., 2012). This age-associated influence and potential 
gene-physical activity interaction emphasises the difficulty in making appropriate or 
direct comparisons/conclusions and may explain why contradictory results, such as 
finding no association with the LRP5 rs3736228 variant in this investigation, are 
present. 
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Elite runners possessed a much lower frequency of the “risk” GG COMT rs4680 
genotype in comparison to non-athletes (16.6% vs 24.0%) and the sub-elite athletes 
possessed the highest frequency of the GG genotype (24.6%). These findings are 
similar to the WNT16 rs3801387 variant, suggesting that elite athletes may be 
genetically predisposed to be at less risk of lower BMD by possessing at least one 
“protective” A allele, although no differences in allele frequency were observed. GA 
genotypes were more prominent in the runner group in comparison to non-athletes 
(52.8% vs 47.2%) and an even larger representation was present in the elite runners 
(56.3%) when divided into subgroups. COMT catalyses the methylation of catechol 
oestrogens to methoxy oestrogens (inactive metabolites) and thus, lower COMT 
enzyme activity results in greater 16-hydroxy-oestradiol, which retains oestrogenic 
activity and enhances BMD (Lorentzon et al., 2007). Consequently, both higher 
oestradiol serum levels (Eriksson et al., 2004) and higher BMD (Eriksson et al., 2005) 
have been reported in lower enzyme activity AA genotypes. Conflicting results 
regarding the more beneficial COMT rs4680 genotype for BMD, however, have been 
observed (Gonçalves et al., 2015) which, may be due to the effect of mechanical 
loading.  
The COMT rs4680 SNP has been shown to influence the association between physical 
activity and BMD, suggesting that certain genotypes may be particularly important for 
BMD in individuals with low physical activity levels. Higher total BMD has been 
observed in individuals completing greater levels of physical activity compared to those 
undertaking lower activity for GA and AA (lower enzyme activity) but not GG (higher 
enzyme activity) genotypes (Lorentzon et al., 2007). A COMT genotype interaction, 
thus, may be present and the potential regulation of the BMD response to mechanical 
loading may be due to the involvement of oestrogen receptors as facilitators in a 
number of key pathways by which mechanical strain stimulates bone formation (Galea 
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et al., 2013). This notion, due to the substantial amount of mechanical loading 
marathon runners undertake, may explain why the GA genotype was overrepresented 
in the elite group. Therefore, possessing the GA genotype may be advantageous for 
BMD via a mechanical loading interaction, allowing runners to complete the necessary 
training volumes with a smaller chance of stress fracture occurrence to reach elite 
status.   
Surprisingly, the “risk” C allele of the loss of function P2RX7 rs3751143 was more 
frequent in the runners than non-athletes, with non-athletes possessing a higher 
frequency (>6%) of the advantageous AA genotype. Functional expression of 
purinergic receptor P2X 7 primarily regulates configuration of osteoclasts (Agrawal et 
al., 2010), as well as augmenting bone formation via a cell-autonomous role that leads 
to stimulation of mineralisation (Panupinthu et al., 2008) and thus, may be important 
for increasing BMD. Previous studies in military recruits and elite athletes have also 
found the C allele to be associated with stress fracture incidence (Varley et al., 2016). 
A lower frequency of the C allele in the runners than non-athletes and the subsequent 
protection from large volumes of mechanical loading, would therefore, be expected. 
The P2RX7 gene codes for a trimeric ligand-gated cation channel, which, when 
activated by ATP, results in the release of pro-inflammatory mediators and cell 
proliferation. Consequently, some P2RX7 variants have been implicated in a number 
of human health or related conditions, such as Tuberculosis and Rheumatoid arthritis 
as well as osteoporosis (Sluyter and Stokes, 2011). The P2RX7 rs3751143 CC loss of 
function genotype has been associated with reduced risk of ischemic stroke and P2X7 
deficient mice have been reported to be protected from thrombosis in vivo (Gidlöf et 
al., 2012). Therefore, although the elite runners may possess the genotype associated 
with lower BMD, it could be protective or advantageous in other important determinants 
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for endurance success, such as cardiovascular factors, albeit speculative at this 
moment in time.  
A higher prevalence of the VDR rs2228570 CC genotype in runners than the non-
athlete group (39.6 vs 35.4%) was observed before multiple testing correction, which 
presents an interesting finding given previous studies on this variant. The CC genotype 
has been reported to be more frequent in track and field athletes than controls and 
associated with higher BMD (Nakamura et al., 2002b). This notion was further 
reinforced in a similar investigation in 44 Japanese track and field athletes, where 
higher bone volume was expressed in those with the CC genotype, but not in those 
with the CT genotype (Nakamura et al., 2002a). Interestingly, within the control group 
only, the CC genotype was not associated with the highest BMD, thus, suggesting that 
individuals with the CC genotype may be more responsive to mechanical loading, 
resulting in greater BMD, when physical activity is prominent. Together, these 
aforementioned findings, known biological function of the associated protein and the 
tendency observed in this chapter could suggest a potential benefit for enhancing BMD 
and reducing injury risk for high-level endurance runners possessing the CC genotype. 
Future research capturing the athlete-associated BMD data could provide evidence 
that the CC genotype aids in achieving high-level endurance runner status through 
enhanced BMD (via a potential gene-physical activity interaction) and subsequent 
protection against stress fracture injury. No association was observed when comparing 
elite runners against non-athletes or when analysing an association with PB in this 
investigation, which may suggest the CC genotype provides protection to reach high-
level status but does not influence performance once this level has been achieved.  
A difference in TNFRSF11A rs3018362 allele frequency between runners and non-
athletes was only observed before multiple testing correction and no differences in 
genotype or allele frequencies were discovered for the other four investigated variants 
101 
 
(BDNF-AS rs6265, COL1A1 rs1800012, LRP5 rs3736228 and TNFRSF11B 
rs43558010). Personal best times were also not associated with any individual 
genotype in both males and females (Table 4.4) or collectively as part of TGS. 
Additionally, TGS could not predict PB via regression analysis. These findings suggest 
that the investigated genetic variants do not influence marathon PB singularly or 
collectively as part of a TGS. Successful endurance performance is multi-factorial and 
genes influencing other important phenotypes, such as VO2 max or lactate threshold 
(Sleivert and Rowlands, 1996; Jones and Carter, 2000), are also likely to be influential 
in determining performance.   
Mean TGS was investigated between the runners and non-athletes as well as between 
sub-groups as a whole and by sex (Table 4.3). No differences were observed in any 
comparison although a tendency (before multiple testing correction) highlighting that 
the elite group possessed a higher mean TGS than the sub-elite runners was 
observed. It was also interesting to note that a tendency for a higher TGS frequency 
distribution in the top 10% compared to the bottom 10% (according to PB) in the female 
runners via ROC analysis was observed but no such tendency was apparent in the 
equivalent male comparison. Grealy et al. (2015) found comparable findings in the top 
10% vs the bottom 10% performers in Ironman Championship male and female 
triathletes when investigating variants associated with endurance performance. A shift 
towards a higher TGS distribution was apparent alongside a higher TGS mean (+7) in 
the fastest 10% in comparison with the bottom 10% finishers. Similarly, TGS was not 
significantly different between the groups and not associated with performance time. 
It is acknowledged that the 10% vs 10% analysis consists of a small sample size but 
the top 10% female group comprises runners who all have a PB of < 2 h 41 min for the 
marathon, which is notably faster than the current 2 h 45 min Olympic qualifying time. 
This could suggest having an advantageous genetic profile in relation to BMD could 
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provide a small contribution for female endurance runners to achieve elite status on 
top of possessing other advantageous genotypes for VO2 max, lactate threshold or 
running economy. Female athletes are more prone to stress fractures (Milner et al., 
2006) due to lower BMD through potential complications of RED-S via irregular 
menses and/or energy deprivation (Loucks, 2007). Possessing a more advantageous 
genetic profile and consequently higher BMD, therefore, may provide greater 
protection from bone injury in female runners completing rigorous training 
volume/intensity. TGS provides an interesting model to analyse potential associations 
with athletic status or performance in a polygenic rather than singular nature, 
particularly due to the difficulty of calculating the effect size of single or multiple 
polymorphisms. However, this is also the primary limitation of the model. The 
assumption of an additive effect between genotypes and that all variants are given the 
same weight in the total score, suggests each variant explains the same proportion of 
variance within the phenotype (Eynon et al., 2011) which is extremely unlikely. Further 
understanding of the genetic influence of specific SNPs will allow more accurate 
allocation of variance in the future to enhance the model.  
The findings regarding genotype/allele frequency differences and influence on PB 
emphasise the complex and multifaceted nature of successful marathon performance, 
which is comprised of many more components including volume of training, VO2 max 
and economy of movement. Similarly, BMD is also a multifactorial phenotype 
influenced by hormones and diet as well as physical activity. These complex traits and 
their individual components are undoubtedly polygenic, influenced by a large number 
of genes and subsequent gene-gene and gene-environment interactions and thus, 
require further investigation to better our understanding of the genetic contribution. 
Over 66 loci have been associated with BMD via GWAS and many variants have not 
been investigated further or explored in other populations (Hsu and Kiel, 2012) whilst 
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no common variant profile has been attributed to world-class endurance athletes 
(Rankinen et al., 2016). Although there is a reasonable volume of evidence highlighting 
the association between particular SNPs and BMD (Hsu and Kiel, 2012) as well as 
BMD and stress fracture injury (Bennell et al., 1996), this approach linking SNP to BMD 
to stress fracture injury and subsequently performance is somewhat speculative due 
to the complex and multi-factorial nature of BMD, stress fracture injury and 
performance as individual concepts. This hypothetical approach also aligns with the 
findings from the thesis as this complex hypothesis is not portrayed or followed through 
as a finding in the data. Consequently, additional research to establish the initial 
genetic associations with BMD as well as low BMD and stress fracture injury risk is 
needed so this approach can be further developed.  
This study is the first to investigate any potential association of bone mineral density-
related genes and marathon performance in high-level endurance runners. The COMT 
rs4680 and WNT16 rs3801387 variants may aid in achieving elite marathon runner 
status but do not influence performance once high-level status has been attained. 
Surprisingly, the risk C allele of the P2RX7 rs3751143 variant is more frequent in high-
level endurance runners than non-athletes, although the mechanisms underlying why 
this may be the case are not yet understood. Additionally, the other investigated 
variants singularly, or collectively as part of a TGS, did not influence athlete status or 
marathon PB, although an advantageous polygenic predisposition may be of a slight 
benefit for female elite marathon runners at Olympic qualifying level. Therefore, these 
results suggest that elite runners may benefit from genetic resistance to bone injury in 
the COMT rs4680 and WNT16 rs3801387 variants, and a resulting ability to sustain 
large training volumes and achieve successful marathon performance. Further 
research incorporating BMD data and injury history alongside the associated genotype 
information is required to provide more conclusive evidence.    
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Chapter 5: 
Genetic associations with bone 
mineral density in high-level 
endurance runners and non-
athletes 
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5.1 Introduction 
Bone mineral density (BMD) is considered to be the primary predictor of osteoporotic 
fracture (Cranney et al., 2007) and is also important in the elite sporting environment, 
where athletes possessing lower BMD are proposed to be at greater risk of stress 
fracture injury (Myburgh et al., 1990; Bennell et al., 1999). Several factors such as diet, 
hormones, and physical activity are known to influence BMD, contributing to the large 
variability that exists within the phenotype (Pluijm et al., 2001; Krall and Dawson‐
Hughes, 1993). 
A genetic influence on BMD also exists, with heritability reported as approximately 50-
80% (Ralston and Uitterlinden, 2010). Genome-wide association studies (GWAS) and 
case-control designs have revealed many loci associated with variation in BMD. A 
number of the candidate genes identified at these loci, however, have no known 
associated biological function or have yet to be replicated in subsequent investigations 
to confirm associations with BMD (Hsu and Kiel, 2012). Furthermore, few 
investigations have considered gene-environment interactions - in particular, whether 
specific genes may be sensitive to mechanical loading from physical activity and the 
outcome of such an interaction for BMD and potential injury risk.  
Mitchell et al. (2016) investigated the genomic influence on BMD and the relationship 
with physical activity using SNPs that had been associated with BMD via GWAS 
(Estrada et al., 2012). Analysis revealed nominal interactions with physical activity at 
the lumbar spine with variants such as WNT16 rs3801387, AXIN1 rs9921222, SOST 
rs4792909 and STARD3NL rs6959212 in children. Other variants such as VDR FokI 
rs2228570 have also been suggested to exhibit gene-physical activity interactions, 
with the TT (ff) genotype associated with higher BMD in active postmenopausal 
women (Gentil et al., 2009). When investigating the same SNP (VDR FokI rs2228570) 
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in athletes, however, significantly higher total BMD was observed in the CC and CT 
but not TT genotypes compared to 80 non-athlete controls. Interestingly, in a sub-
group of swimmers from within this athlete population, a lower total BMD was observed 
in the CC genotype when compared to non-athlete controls (Nakamura et al., 2002a). 
Together, these findings suggest that individuals with the CC genotype may be more 
responsive to mechanical loading, resulting in greater BMD when that mechanical 
loading is prominent and therefore, contradicting the findings reported in 
postmenopausal women (Gentil et al., 2009). Physical activity levels and other factors, 
such as the effect of cessation of menopause, however, may be influencing the 
findings from the study investigating postmenopausal women so a direct comparison 
between the two populations cannot be completed. Only one other study to date has 
investigated gene-physical activity interactions and the outcome for bone phenotypes 
in athletic populations according to the authors’ knowledge. Variants such as SOST 
rs1877632, TNFRSF11A rs9594738, TNFSF11 rs1021188 and TNFRSF11B 
rs9594759 were associated with bone phenotypes before completion of a 12-week 
training programme in academy football players but no genotype by time interactions 
were observed (Varley et al., 2018). Consequently, proposed genetic associations with 
bone phenotypes were observed but no genetic interactions with mechanical loading 
were apparent and therefore, conflict previous investigations (Nakamura et al., 2002b; 
Nakamura et al., 2002a).  
Overall, only a small number of BMD-associated variants have been explored in 
athletic populations or in relation to gene-physical activity interactions and thus, the 
potential influence on BMD in athletic populations is not yet fully understood. 
Individuals who complete higher levels of weight-bearing physical activity tend to 
possess higher BMD but it is not yet known which specific genetic variants may 
contribute to this increased BMD and whether this is via a potential gene-physical 
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interaction, or if those individuals predisposed to having a higher BMD self-select 
weight-bearing physical activities and sports in which to partake. Understanding of the 
genetic association with BMD could have substantial future implications for athlete 
health, status and performance. For athletes specifically, a manipulation of training 
load or practices would certainly be useful for athletes who possess a disadvantageous 
genetic disposition.  
Athletic populations present the most logical participants to investigate potential gene-
physical activity interactions due to the difficulty in assessing physical activity volume 
as discussed in Chapter 1 of this thesis. Endurance runners, in particular, represent a 
homogenous group that experience high volumes of mechanical loading at certain 
sites (e.g. tibia) as well as areas of less loading such as the lumbar spine. Thus, this 
group presents an ideal population in which to investigate the potential gene-physical 
activity interactions for BMD. 
The purpose of this study, therefore, (1) was to investigate any association of the ten 
BMD-associated variants described in Chapter 1 with total-body BMD (TBMD), leg 
BMD (LBMD), lumbar spine BMD (LSBMD), total-body T-score and total-body Z-score 
in high-level endurance runners and non-athletes and (2) explore whether a genotype-
dependent influence on the adaptations of bone phenotypes to long-term mechanical 
loading was present in the runners.  
5.2 Method 
The participants and protocols used in Chapter 5 have already been described in detail 
in Chapter 2, thus, only a brief description of these methods is detailed below. 
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Participant characteristics 
Participants consisted of 103 high-level Caucasian runners (45 males, 58 females) 
and 112 ethnically matched non-athletes (52 males, 60 females) from the cohort as 
described in Table 2.1 of Chapter 2.  
Protocol 
All runners completed a questionnaire detailing ethnic ancestry, as well as 
performance, injury, and sporting history (Appendix 1). Non-athletes completed a 
questionnaire detailing ethnicity, to establish matched ethnic ancestry, general health 
and physical activity level to ensure no history of high-level sporting competition 
(Appendix 2). All participants completed a whole-body DXA scan to gather BMD 
(g/cm2) data with whole-body and segmental analysis utilised to obtain TBMD, LBMD, 
LSBMD, T-score and Z-score. All participants provided a whole-blood, saliva or buccal 
swab sample, which was subsequently extracted and analysed to obtain genotype 
data for the ten investigated SNPs (AXIN1 9921222, BDNF-AS rs6265, COL1A1 
ra1800012, COMT rs4680, LRP5 rs3736228, P2RX7 rs3751143, TNFRSF11A 
rs3018362, TNFRSF11B rs4355801, VDR rs2228570, WNT16 rs3801387) as 
described in Chapter 2. 
Statistical analysis 
Using both an additive and dominant analysis model, multiple analysis of variance 
(MANOVA) was implemented to determine associations between any of the ten 
variants (individually and then collectively as a TGS) with TBMD, LBMD, LSBMD, T-
score or Z-score in the total cohort (runners plus non-athletes) as well as within runners 
and non-athletes independently. The MANOVA model was also used to assess 
potential differences in any bone parameter between the runners and non-athletes with 
the same genotype (i.e. a genotype-cohort interaction). Significant associations from 
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any MANOVA model (i.e. main effect of genotype on any bone phenotype or a 
genotype-cohort interaction effect on any bone phenotype) were then subjected to sex-
dependent pairwise statistical analyses among each of the two or three genotype 
groups. Consequently, independent t-tests (corrected for multiple testing via 
Benjamini-Hochberg) were conducted to analyse genotype-dependent differences in 
any bone parameter following a significant main effect of genotype on the total cohort, 
runners or non-athletes from the initial MANOVA model. Similarly, following a 
significant genotype-cohort interaction on a bone phenotype, independent t-tests were 
used to analyse cohort-dependent differences in these bone phenotypes across the 
same genotypes. Alpha was set at 0.05 for the main effect of genotype and significant 
genotype-cohort interaction but tendencies such that P > 0.05 but < 0.15 (Danilovic et 
al., 2007; Fischer et al., 2004) were reported for the subsequent pairwise analyses as 
and data are reported as mean (SD).  
5.3 Results 
Genotype-cohort interaction 
Genotype-cohort interaction analyses (Tables 5.1 and 5.2) are provided within the 
appendices (Appendix 3 and 4, respectively). A genotype-cohort interaction was 
observed for the WNT16 rs3801387 variant in males and BDNF-AS r6265 variant in 
females. Specifically, a genotype-cohort interaction was present for the LBMD, LSBMD 
and Z-score but not TBMD or T-score for the WNT16 rs3801387 variant in the additive 
model analysis (P = 0.032; P = 0.042; P = 0.045; P = 0.057; P = 0.051; Table 5.1). In 
the BDNF-AS rs6265 variant, the genotype-cohort interaction was observed for 
LSBMD in the dominant analysis model only (P = 0.037).  
Within the WNT16 rs3801387 interaction, runners with AA genotype possessed lower 
(~17%) LSBMD and Z-score (P = 0.004; Figure 5.1; 0.62 vs 1.35; P = 0.036; Table 
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5.1) and a tendency to possess lower LBMD than non-athletes with AA genotype (P ≥ 
0.120; Figure 5.2). Additionally, a tendency for runners with AG genotype to possess 
higher LBMD than non-athletes with AG genotype was observed (P = 0.120; Figure 
5.2).  
In the BDNF-AS rs6265 interaction, runners with the GG genotype possessed ~9% 
lower LSBMD than non-athletes with the GG genotype (P = 0.022; Figure 5.3). No 
differences in LSBMD were observed between runners who carried the A allele in 
comparison to non-athletes who were A allele carriers (P = 0.416; Figure 5.3). No other 
genotype-cohort interactions with any bone phenotypes were observed for either 
males or females for any other variant (P ≥ 0.057; Table 5.1; Table 5.2). 
 
 
Figure 5.1: LSBMD in WNT16 rs3801387 AA, AG and GG genotypes in male runners, 
male non-athletes and the male total cohort (runners + non-athletes). Higher LSBMD 
in AA genotype non-athletes than AA genotype runners (P = 0.004). Error bars denote 
standard deviation.  
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Figure 5.2: LBMD in WNT16 rs3801387 AA, AG and GG genotypes in male runners, 
male non-athletes and the male total cohort (runners + non-athletes). Tendency for 
lower LBMD in AA genotype runners than AA genotype non-athletes (*P = 0.120). 
Tendency for higher LBMD in AG genotype runners than AG genotype non-athletes 
(**P = 0.120). Error bars denote standard deviation. 
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Figure 5.3: LSBMD in BDNF-AS rs6265 GG and A allele carriers genotypes in male 
runners and male non-athletes. Lower LSBMD in GG genotype runners than GG 
genotype non-athletes (P = 0.022). Error bars denote standard deviation.  
Genetic association 
Males 
A main effect of TNFRSF11A rs3018362 genotype on TBMD was observed in the 
males for both the additive and dominant analysis models (P ≤ 0.043; Table 5.1). 
Specifically in the total cohort, those with the TNFRSF11A rs3018362 GG genotype 
possessed ~4% higher TBMD than GA genotypes (P = 0.032; Figure 5.4). In non-
athletes, GG genotypes possessed higher TBMD than GA genotypes (P = 0.032; 
Figure 5.3). No further genotype-dependent differences in TBMD were observed within 
non-athletes (P ≥ 0.160) and no main effect of TNFRSF11A rs3018362 genotype on 
TBMD was present in the runners (P = 0.619; Figure 5.4).  
In the dominant analysis model, those who were GG genotypes possessed higher 
TBMD (~4%) than the “risk” A allele carriers in the male total cohort (P = 0.032; Figure 
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5.4). In the non-athlete analysis, similarly, those who were GG genotypes possessed 
higher TBMD than those who carried the A allele (P = 0.032). No main effect of 
TNFRSF11A rs3018362 genotype on TBMD was apparent within the runners in the 
dominant analysis model (P = 0.362).  
Figure 5.4: TBMD in G allele carriers, GG, GA and AA genotypes of the TNFRSF11A 
rs3018362 variant in the male runners, male non-athletes and total male cohort 
(runners + non-athletes). Higher TBMD in GG genotypes than A allele carriers in the 
total cohort (*P = 0.032). Higher TBMD in GG than GA genotypes in the total cohort 
analysis (**P = 0.032). Higher TBMD in GG than GA genotype non-athletes (***P = 
0.032). Higher TBMD in GG genotypes than A allele carriers in the non-athletes (****P 
= 0.032). Error bars denote standard deviation. 
A main effect of COL1A1 rs1800012 genotype on LBMD and T-score was also 
observed in males (P = 0.021; P = 0.033; Table 5.1). Specifically in the total cohort, 
individuals with COL1A1 rs1800012 AA genotype possessed ~5.5% higher LBMD than 
AC genotype counterparts (P = 0.018; Figure 5.5). There was a tendency for COL1A1 
rs1800012 AA genotypes to possess a higher T-score than AC genotypes in both the 
male total cohort and non-athletes (both P = 0.051). No other COL1A1 rs1800012 
genotype-dependent differences in LBMD or T-score were observed for the total cohort 
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or non-athletes and no main effect of genotype was apparent in runners (P ≥ 0.190; 
Figure 5.5).  
In the dominant analysis model, a main effect of COL1A1 rs1800012 genotype in the 
total cohort was observed, with AA genotypes possessing higher TBMD, LBMD, T-
score and Z-score than C allele carriers (P = 0.043; P = 0.018; P = 0.022; P = 0.039; 
Figure 5.6). No main effect of genotype was apparent in runners or non-athletes (P ≥ 
0.070). 
No other SNPS, individually or collectively as part of a TGS, were associated with any 
of the bone phenotypes in men (P ≥ 0.168). 
 
Figure 5.5: LBMD in AA, AC and CC COL1A1 rs1800012 genotypes in the male 
runners, male non-athletes and total male cohort. Higher LBMD in AA than AC 
genotypes in the total cohort (P = 0.018). Error bars denote standard deviation. 
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Figure 5.6: TBMD and LBMD in COL1A1 rs1800012 AA genotypes and C allele 
carriers in the male runners, male non-athletes and total male cohort. Higher TBMD 
and LBMD in AA genotypes than C allele carriers in the total cohort (*P = 0.043; **P = 
0.018).  
Females 
A main effect of P2RX7 rs3751143 genotype on TBMD, LBMD, T-score and Z-score 
for the total cohort was observed in the female additive model (P = 0.030; P = 0.048; 
P = 0.030; P = 0.022; Table 5.2). AA genotypes possessed higher TBMD and LBMD 
than AC genotypes (P = 0.045, Figure 5.7; P = 0.036, Figure 5.8) and AA genotypes 
also exhibited a higher T-score and Z-score than AC genotypes (P = 0.042; P = 0.028).  
A main effect of P2RX7 rs3751143 genotype on TBMD, T-score and Z-score also 
existed within the runners (P ≤ 0.043). Specifically, a tendency for AA genotypes to 
possess higher TBMD and T-score than AC genotypes was observed (P = 0.063; P = 
0.061), whilst a tendency for AC genotypes to possess lower TBMD and T-score than 
CC genotypes was also apparent (P = 0.113; P = 0.130; Figure 5.7). Runners with AA 
genotype possessed a higher Z-score than AC genotypes (P = 0.037). No further 
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genotype-dependent differences for TBMD, T-score or Z-score were present within 
runners (P ≥ 0.122) and no main effect of P2RX7 rs3751143 genotype on any bone 
phenotype was apparent in the non-athletes (P ≥ 0.248).  
A main effect of P2RX7 rs3751143 genotype on the total cohort TBMD in the dominant 
analysis model was also observed (P ≤ 0.040). Specifically, AA genotypes possessed 
4% higher TBMD and LBMD, as well as a higher T-score and Z-score than those who 
were C allele carriers (P = 0.045; P = 0.036; P = 0.042; P = 0.028; Figure 5.7 and 
Figure 5.8). No main effect of P2RX7 rs3751143 genotype on any bone phenotype 
was present in the runners or non-athletes (P ≥ 0.061).  
No other SNPS, individually or collectively as part of a TGS, were associated with any 
of the bone phenotypes in women (P ≥ 0.124; Table 5.2).  
 
 
Figure 5.7: TBMD in C allele carriers, AA, AC and CC genotypes of the P2RX7 
rs3751143 genotype in the female runners, female non-athletes and total female 
cohort (runners + non-athletes). Higher TBMD in AA than AC genotypes in the total 
cohort (*P = 0.045). Tendency for higher TBMD in AA than AC genotype runners (**P 
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= 0.063). Higher TBMD in AA genotypes than C allele carriers in the whole cohort (***P 
= 0.013). Tendency for higher TBMD in CC than AC genotype runners (****P = 0.113). 
Error bars denote standard deviation. 
 
Figure 5.8: LBMD in C allele carriers, AA, AC and CC genotypes of the P2RX7 
rs3751143 variant in the female runners, female non-athletes and total female cohort 
(runners + non-athletes). Higher LBMD in AA than AC genotypes in the total cohort 
(*P = 0.036). Higher LBMD in AA genotypes than C allele carriers in the total female 
cohort (**P = 0.045). Error bars denote standard deviation.  
5.4 Discussion 
The aim of this chapter was to investigate BMD-associated SNPs on TBMD, LBMD, 
LSBMD, T-score and Z-score in endurance runners and non-athletes as well as 
explore potential gene-mechanical loading interactions in these investigated SNPs by 
analysing gene-cohort interactions.   
Genotype-cohort interactions 
Runners with WNT16 rs3801387 AA genotype possessed lower LSBMD and Z-score 
and a tendency to possess lower LBMD than non-athletes with AA genotype, whilst a 
tendency for runners with AG genotype to possess higher LBMD than non-athletes 
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with AG genotype was also observed, highlighting an interaction between genotype 
and the two cohorts for the two anatomical sites. These findings could suggest that the 
G allele is important for BMD in male endurance runners via an adaptation to chronic 
high mechanical loading. The “risk” A allele has been associated with lower lumbar 
spine and femoral neck BMD via GWAS (Estrada et al., 2012) and candidate gene 
association studies (Hendrickx et al., 2014) in osteoporotic and non-athlete 
populations. In this chapter, no differences in BMD between WNT16 rs3801387 
genotypes in the non-athletes was observed and thus, contradicts these previous 
investigations. The difference in the findings could be due to the influence of 
mechanical loading completed by the running cohort, with the majority of studies 
having been conducted in non-athletic populations. Although a main effect of WNT16 
rs3801387 genotype was not present, and thus these differences were not significant, 
it is interesting to note that non-athletes with AA genotype possessed the highest 
LBMD and LSBMD in their group whereas AA genotype runners possessed the greater 
LBMD and LSBMD in their group. Additionally, a greater difference in BMD between 
GG and AA genotypes in both the runners and non-athletes was observed at the LBMD 
(where the site-specific bone adaptation to mechanical loading will occur in the 
endurance runners) than LSBMD, which may indicate the potential impact of a greater 
mechanically induced strain on bone adaption by possessing a G allele.  
Wnt16 is predominantly expressed in osteoblasts and is an important member of the 
Wnt signalling pathway, activating both both canonical and non-canonical pathways 
and consequently, having substantial implications for cortical bone mass (Gori et al., 
2015). Wnt16 is a key regulator of osteoblast-to-osteoclast communication and 
targeted disruption of Wnt16 in mice results in a 27% loss in bone size and 43-61% 
loss in bone strength (Zheng et al., 2012). WNT16 knockout mice have exhibited 
substantial reductions (20-70%) in expression levels of canonical Wnt signalling 
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markers in the periosteum at 5 weeks of age in comparison to wild-type mice, 
suggesting that Wnt16, via Wnt signalling, moderates mechanical loading-induced 
periosteal bone formation and size (Wergedal et al., 2015). Additionally, the WNT16 
rs3801387 SNP has also been reported to interact with physical activity to demonstrate 
nominal associations with BMD in children and adolescents (Mitchell et al., 2016), 
providing further support for a gene-mechanical loading interaction on BMD. The 
findings from this chapter could therefore suggest that possessing a WNT16 
rs3801387 G allele is associated with higher LBMD in endurance runners compared 
to non-athletes due to the effect of mechanical loading on Wnt production via 
osteocytes, leading to activation of the Wnt signalling pathway, which subsequently 
impacts bone tissue via the canonical or non-canonical pathway. This interpretation, 
however, has to be taken with caution as no differences in the dominant model analysis 
or in the GG genotype between the runners and non-athletes were observed. 
Additionally, mechanically loaded mice have demonstrated no upregulation of Wnt16 
expression (Todd et al., 2015). Further functional and phenotype studies in human 
populations are therefore required to confirm this potential mechanism on BMD.  
BDNF-AS rs6265 also exhibited a genotype-cohort interaction for LSBMD in the 
female analysis. Runners with the advantageous (higher BMD-associated) GG 
genotype possessed lower LSBMD than non-athletes who were GG genotype. 
Additionally, (although no main effect of genotype was present in the runners or non-
athletes) runners with the A allele possessed higher LSBMD than the GG genotypes, 
whilst non-athletes with the GG genotype possessed higher LSBMD than the A allele 
carriers. BDNF-AS rs6265 association with BMD has not been explored in athletic 
cohorts so these findings could suggest that the GG genotype may be 
disadvantageous for BMD in this population and contribute towards the low LSBMD 
reported in some endurance runners (Pollock et al., 2010). It is difficult to suggest a 
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potential mechanism for this finding as osteoblastic cells transfected with the A allele 
have shown decreased BDNF protein phosphorylation, expression of osteoblastic 
genes and osteoblastic activity, whilst lower BMD has also been reported in those 
possessing the A allele in humans (Deng et al., 2013). It therefore could also be 
postulated that runners are able to combat a potential disadvantageous genetic 
predisposition via high volumes of mechanical loading and still reach high-level athlete 
status. This hypothesis, however, needs to be interpreted with caution as it would be 
expected to occur at the sites of greatest loading and no genotype-cohort interaction 
was observed for LBMD in this chapter. Moreover, limited study exists in regards to 
potential BDNF-AS associations with BMD and further investigation in both functional 
and association studies is required to provide greater evidence regarding mechanism 
and outcome for BMD.   
No further genotype-cohort interactions for any bone phenotypes were observed in 
either the male or female analysis. The findings in regard to the P2RX7 rs3751143 and 
TNFRSF11A rs3018362 SNPs are therefore, in agreement with previous study, which 
found no genotype by time interactions on bone phenotypes following completion of a 
12-week training programme in academy football players (Varley et al., 2018). All the 
participants in the Varley et al. (2018) study were over the age of 16 years and it could 
be suggested that the majority of age-associated bone accrual may have been attained 
by the footballers by this age, or that the 12-week training period may not be long 
enough to observe changes in the bone phenotypes measured in some participants. 
Interestingly, the SNPs investigated in the Varley et al. (2018) study exhibited varying 
associations on the different bone phenotypes. For example, P2RX7 rs1718119 was 
associated with cortical thickness, whereas SOST rs1877632 was associated with 
trabecular density. Cortical bone adapts to loading at a slower rate than trabecular 
bone, which may be due to genotype-dependent differences. Certain SNPs may be 
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sensitive to particular types of mechanotransduction, which could consequently effect 
the associated molecular pathway resulting in these differences in bone phenotypes 
as described in Chapter 4 in relation to LRP5. Potential genotype-dependent 
differences in responses to various types of mechanical loading may explain why 
inconsistency in the literature in regards to gene-mechanical loading and outcomes for 
bone phenotypes exists.  
Of the other investigated variants in this chapter, AXIN1 rs9921222, LRP5 rs3736228 
and VDR rs2228570 have been reported to have potential gene-physical 
activity/mechanical loading interactions with BMD previously (Mitchell et al., 2016; 
Nakamura et al., 2002b). Observing no gene-cohort (physical activity) interaction for 
AXIN1 rs9921222, LRP5 rs3736228 or VDR rs2228570 in this chapter may be due to 
differences in the investigated populations and/or measurement of physical activity. 
Participants in this investigation were high-level endurance runners who had 
experiences large amounts of mechanical loading during training to achieve the 
personal best criteria as highlighted in Chapter 2. Mitchell et al. (2016), however, 
utilised questionnaires to measure physical activity level in children, which can present 
issues with accuracy and reliability (Prince et al., 2008), particularly in non-adult 
populations, whilst Nakamura et al. (2002b) investigated track and field as well as 
handball and volleyball athletes. The track and field athletes comprised high and long 
jumpers, which alongside handball and volleyball constitute movements of high-impact 
loads and forces that are multi-directional in nature and thus are very different to the 
lower impact and cyclical movements completed in endurance running. These 
differences in movements may affect the signalling pathways differentially and the 
outcomes of potential gene-mechanical loading interactions for bone may be varied as 
a result as discussed above. Furthermore, most studies have been completed in adult 
populations and it is suggested some BMD-associated loci may exert age-specific 
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effects (Medina-Gomez et al., 2012), and thus, the findings from the Mitchell et al. 
(2016) study cannot be generalised across different population groups.  
Genotype associations 
Genotype associations with BMD were present for the COL1A1 rs1800012, P2RX7 
rs3751143 and TNFRSF11A rs3018362 variants in this chapter. COL1A1 rs1800012 
genotype explained >8.1% of the variance in LBMD and T-score in the total male 
cohort, with individuals who were AA genotype possessing higher LBMD and T-score 
than those who were AC genotype. Possessing the A allele of the COL1A1 rs1800012 
SNP is associated with reduced amount of transcript for α1 chain, resulting in the 
formation of collagen homotrimers, which are associated with degenerative bone 
microarchitecture (Mann et al., 2001; Grant et al., 1996; Dytfeld et al., 2016). This 
mechanism may explain why males with the AA genotype possessed higher BMD in 
the current chapter, however, it does not account for why this was not observed in 
females. Moreover, meta-analysis in untrained adult populations has reported that AA 
genotype is associated with higher BMD at a number of anatomical sites and reduced 
risk of fracture in females only (Jin et al., 2011; Ralston et al., 2006). No apparent 
COL1A1 rs1800012 association with BMD/fracture in males via meta-analysis may be 
due to the research focus on osteoporosis, consequently resulting in fewer studies on 
males and therefore, further study is required to confirm whether the COL1A1 
rs1800012 influence is sex-dependent. Sex-variant interactions have been reported in 
some BMD-associated genetic loci in children, which highlights this could also be the 
case for COL1A1 rs1800012 (Mitchell et al., 2015).  
TNFRSF11A rs3018362 was associated with TBMD, but similar to COL1A1 
rs1800012, in males only. Those of GG genotype possessed ~4% higher TBMD than 
those of GA genotype in the total cohort. Similarly in the non-athletes, GG genotypes 
possessed higher TBMD than those of GA genotype. In the dominant analysis model, 
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GG genotypes possessed higher TBMD than A allele carriers in both the non-athletes 
and total cohort analysis. Binding of RANK (TNFRSF11A) to RANKL on the surface of 
osteoclast precursors initiates a large number of signalling pathways, such as Mitogen 
activated protein kinase (MAPK), resulting in activation of osteoclasts (Wada et al., 
2006). The specific nature of how TNFRSF11A genotype differences may influence 
bone metabolism in not well understood due to the number of signalling cascades that 
induce the activation of bone metabolism transcription factors during RANK to RANKL 
ligation (Atkins et al., 2006). However, it could be proposed that RANK expression 
could be increased by possessing the GG genotype, which results in facilitation of 
RANK-RANKL binding and consequently, greater initiation of the signalling cascades 
as well as increased osteoclastogenesis. 
The findings from this chapter suggest that possessing the TNFRSF11A rs3018362 
GG genotype may be important for BMD in non-athlete populations as suggested by 
previous GWAS and candidate gene association study, where the A allele has been 
associated with lower BMD (Paternoster et al., 2010; Styrkarsdottir et al., 2009). No 
TNFRSF11A rs3018362 association with TBMD in the runners was exhibited, which 
could indicate that high-level runners may be able to compensate for a potential 
disadvantageous genetic predisposition for TNFRSF11A rs3018362. Large volumes 
of mechanical loading could result in increased BMD and provide greater security 
against stress fracture incidence despite a potential disadvantageous predisposition. 
This potential protective mechanism for BMD has been observed in children, where 
the benefit of weight-bearing physical activity on BMD was still observed in those with 
a disadvantageous genetic predisposition (Mitchell et al., 2016).  
P2RX7 rs3751143 was associated with differences in bone phenotypes in females but 
not males. Specifically in the total cohort, those of AA genotype possessed higher 
TBMD, LBMD, T-score and Z-score than those of AC genotype. AA genotypes also 
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possessed 4% higher TBMD and LBMD than C allele carriers in the dominant analysis 
model. These findings suggest that the AA genotype is associated with higher BMD 
as congruent with previous investigation (Wesselius et al., 2013). Wesselius et al. 
(2013) observed decreased hip BMD values in CC genotype women over the age of 
50 years, whilst another investigation reported the CC genotype to be associated with 
increased fracture risk (Ohlendorff et al., 2007). Lower LSBMD in CC genotypes has 
been observed in osteoporotic females (Husted et al., 2013) although no association 
was observed in this chapter, which could again be due to the differences in the 
populations investigated, the influence of mechanical loading or the confounding 
effects of age. The P2RX7 rs3751143 variant has been shown to have effects on 
purinergic receptor P2X 7 functioning and mice with a null mutation of P2RX7 have 
>73% reduced sensitivity to mechanical loading (Li et al., 2005). Consequently, genetic 
variation in P2RX7 SNPs such as rs3751143 could produce differing responses of 
BMD to mechanical loading.  
Although no genotype-cohort interaction on any bone phenotypes was observed for 
the P2RX7 rs3751143 to highlight this potential mechanism, genotype-dependent 
differences in bone phenotypes were apparent within the runners. Z-score was higher 
in the AA than AC genotypes, with a tendency for AA genotypes to possess higher 
TBMD and T-score than AC genotypes. Moreover, AA genotypes possessed higher 
LBMD than C allele carriers, albeit not statistically significant, in the dominant model 
analysis. These findings indicate that possessing the AA genotype might aid in 
increasing BMD (particularly at the running site-specific loading sites) and 
consequently protect from stress fracture. Although BMD was not measured, Varley et 
al. (2016) observed associations between the P2RX7 rs3751143 C allele and stress 
fracture incidence in elite athletes. P2RX7 rs3751143 has been proposed to work in a 
dose-response manner, with possession of the null CC genotype resulting in a loss of 
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receptor function, whereas heterozygotes are observed to have half the receptor 
functioning (Gu et al., 2001). The P2RX7 rs3751143 C allele has been associated with 
osteoclast apoptosis (Ohlendorff et al., 2007) and reduced bone strength (Varley et 
al., 2018) which indicates that the loss-of-function C allele may reduce BMD and 
increase risk of stress fracture. It would therefore be expected that CC genotypes 
would possess the lowest BMD in the runners in the current study. However, a 
tendency for AC genotypes to possess lower TBMD and T-score than CC genotypes 
was observed, whilst CC genotypes possessed the highest TBMD in the runners. 
Despite this observation, only a small number of female runners possessed the CC 
genotype (n = 3) and runners with the AA genotype did possess the highest BMD at 
the site of higher stress fracture incidence in runners (LBMD). Moreover, AA genotypes 
possessed higher LBMD than C allele carriers in the dominant model analysis as 
mentioned above. Consequently, when taking all of the above findings into 
consideration, the results indicate a potential genotype-mediated protective 
mechanism against stress fracture incidence for runners via AA genotype and 
enhanced BMD.  
The findings for P2RX7 rs3751143 and the other significant variant associations in this 
chapter, however, have to be interpreted with caution. Bone phenotype data for each 
variant genotype, particularly rare homozygotes, is based on a small sample of high-
level endurance runners. This population, however, represent one of the most 
appropriate to investigate BMD and potential gene-physical activity interactions and 
thus, further study to explore these associations is certainly warranted.   
This study is the first to investigate BMD-associated variants in a homogenous group 
of high-level endurance runners in comparison with a non-athlete control group. 
Runners who possessed the BDNF-AS rs6265 GG genotype possessed a lower 
LSBMD than non-athletes who possessed GG genotype, which suggests the 
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advantageous (higher BMD-associated) G allele may in fact contribute to lower 
LSBMD in endurance runners. Runners with the WNT16 rs3801387 (lower BMD-
associated) AA genotype possessed lower LSBMD and Z-score, and a tendency to 
possess lower LBMD, than non-athletes who were AA genotype. Additionally, a 
tendency for runners with AG genotype to possess higher LBMD than non-athletes 
with AG genotype was also observed, highlighting an interaction between genotype 
and the two cohorts for the two anatomical sites. These findings could suggest that the 
G allele is important for BMD in male endurance runners via a mechanical loading 
interaction. TNFRSF11A rs3018362 GG and COL1A1 rs1800012 GG genotypes are 
associated with higher TBMD and LBMD in males, respectively, whilst P2RX7 
rs3751143 AA genotype may be important for BMD in female endurance runners, 
regardless of mechanical loading. Further study in large sample sizes of homogenous 
athletic populations such as endurance runners is required to investigate the genetic 
association with BMD and provide greater evidence for these findings. Limited study 
into the genetics of BMD in athletes exists and utilising homogenous athletic 
populations will aid in exploring potential gene-mechanical loading interactions, which 
could have substantial implications for skeletal health and injury.  
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Chapter 6: 
Bone mineral density and 
stress fracture occurrence in 
high-level endurance runners 
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6.1 Introduction 
Stress fractures are defined as a partial or complete fracture of bone from repeated 
application of force lower than that required to fracture a bone in a single loading 
(Iwamoto and Takeda, 2003). Stress fracture injury occurs due to the repetitive 
mechanical loading that stimulates an incomplete or dysfunctional remodelling 
response and exceeds intrinsic repair mechanisms (Bennell et al., 1999). Specifically, 
under continued extreme volumes of mechanical loading without an ample rest period, 
a micro-crack may be induced. Subsequently, increased intra-cortical remodelling via 
enhanced osteoblastic activity resulting in bone expansion and reduced volume may 
occur (O’Brien et al., 2003; Burr et al., 1997; Doblaré et al., 2004). Several factors are 
known to influence an individual’s susceptibility to experiencing a stress fracture and 
include biomechanical gait (Milner et al., 2006), bone size and mechanical properties 
(Tommasini et al., 2005), nutritional factors (Nieves et al., 2010), genetics (Korvala et 
al., 2010), training volume and rapid increments in volume (Snyder et al., 2006), small 
musculature and low bone mineral density (BMD) (Beck et al., 2000).  
A substantial proportion of the research investigating stress fracture determinants, 
such as BMD, has been conducted in military recruits. It is difficult to extrapolate the 
findings of these military studies to other populations, such as athletes, due to 
differences in the level of physical fitness, footwear and the loads carried whilst running 
between these groups (Wright et al., 2015). Many of these studies have also used 
inappropriately matched control groups that may differ in other risk factors, such as 
body mass, which means it is difficult to analyse the extent of the association of the 
investigated risk factor. For example, although lower BMD was present in male recruits 
who developed a stress fracture, these recruits were also 11% lighter than those who 
had not suffered a stress fracture (Beck et al., 1996; Bennell et al., 1999).  
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Stress fracture prevalence can be significant in athletic populations due to the 
repetitive mechanical loading undertaken and this can have negative consequences 
for health and performance. If athletes are unable to complete their desired or required 
training volume due to injury, this could have substantial negative effects on their 
performance and subsequent success. In endurance runners, higher incidence of 
lower limb stress fractures is observed in comparison with non-athletic controls, 
reportedly accounting for 15-20% of all musculoskeletal injuries sustained by runners, 
with higher incidence observed in females (Milner et al., 2006; Wright et al., 2015). 
Significant amounts of site-specific loading combined with other factors typical of this 
group, such as low energy availability and low body mass, can result in lower BMD 
and a higher risk of fracture occurrence (Loucks, 2007). Despite this, meta-analysis 
demonstrated there is only data to suggest previous history of stress fracture and 
female sex as the two key risk factors for stress fractures in endurance populations 
(Wright et al., 2015). There is, however, a lack of robust research into the other, 
aforementioned, potential risk factors for stress fractures. In particular, the possible 
influence of BMD on stress fracture risk in endurance runners requires further 
investigation. Both male and female endurance runners have been shown to possess 
low BMD or lower BMD than that of non-athletes, particularly at non-loading sites (Hind 
et al., 2006; Pollock et al., 2010). Similarly, research so far has suggested this low or 
lower BMD in endurance runners is associated with stress fracture but this conclusion 
is based on a limited number of conflicting studies.  
Low total bone mass has been associated with stress fracture risk in 
collegiate/postcollegiate female cross-country runners aged 18–26 years old (Kelsey 
et al., 2007) and female track and field athletes, in addition to lower lean mass, leg-
length discrepancy and fewer menstrual cycles per year over a 12-month period, but 
not males (Bennell et al., 1996). Crossley et al. (1999) also reported no association 
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with tibial BMD and stress fracture in male endurance runners, whereas Nattiv et al. 
(2000) observed lower total-body, spine and hip BMD in both male and female 
collegiate runners who developed stress fractures in comparison to their uninjured 
counterparts. Low BMD, therefore, is suggested to be a risk factor for stress fracture 
in runners, at least in females, although contrasting findings have been reported. 
Korpelainen et al. (2001) reported no difference in BMD between six female long-
distance runners who had suffered at least one stress fracture and a control group, 
whilst Duckham et al. (2012) and Duckham et al. (2015) also observed no association 
between BMD and stress fracture injury in UK high-level female endurance runners 
and triathletes.  
Alongside the lack of research investigating BMD and stress fracture incidence in 
endurance runners, the few studies on this topic have not always measured the 
specific site of the stress fracture, thus, the BMD data reported may not be reflective 
of the fracture site BMD (Bennell et al., 1999). Additionally, studies in the field 
investigating BMD and stress fracture association have used small sample sizes and 
comprise athletes of differing training volumes and ability. Duckham et al. (2012) and 
(2015) utilised triathletes and runners across a range of abilities from county to 
international level and observed only two runners who suffered a stress fracture across 
the 12-month prospective study. This lack of homogeneity and dissimilarity in both the 
participants used and the methodological design are likely to increase the inter-
individual variability within the phenotype through differences in training characteristics 
and mechanical loading as outlined in Chapter 3 of this thesis. Overall, little research 
exists to determine the association of BMD on stress fracture, particularly in 
homogenous cohorts of high-level endurance runners. 
Further research is needed to explore stress fracture injury in running populations. 
Stress fracture injury can have a substantial negative impact on training, performance 
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and health, ultimately influencing the likelihood of achieving elite status. Utilising large 
sample sizes of high competitive level (i.e. national and international) endurance 
runners is fundamental to extending our understanding of the importance of BMD on 
stress fracture incidence in this population. Effective prevention strategies can then be 
developed and implemented to reduce risk and ultimately enhance performance. The 
aim of this study, therefore, was to assess total BMD (TBMD), leg BMD (LBMD), 
lumbar spine BMD (LSBMD), total-body T-score and Z-score of high-level endurance 
runners who had suffered a stress fracture in comparison to those who had not.   
6.2 Method 
The investigated participants and protocols used in Chapter 6 have already been 
described in detail in Chapter 2, thus, only a brief description of these methods is 
detailed below. 
Participant characteristics 
Participants consisted of 103 high-level endurance runners (45 males, 58 females) as 
described in Table 2.1 of Chapter 2. To ensure subsequent analyses occurred 
between clearly defined participant groups and explored BMD in runners with other 
potential bone-overloading conditions: Participants who had a stress fracture 
diagnosed by a scan were placed in the stress fracture (SF) group and those who 
reported no history of stress fracture were placed in the no stress fracture (NSF) group. 
Those participants who reported a stress response/stress reaction via scan or reported 
having a potential stress fracture diagnosed by a medical professional were classified 
in the symptoms of stress fracture (SSF) group. The SSF group contained runners 
who had scan diagnoses confirming a stress response/reaction and not a fracture as 
well as those who were hypothesised to have a potential fracture based on symptoms 
by a medical professional and therefore, fracture occurrence had no scan confirmation. 
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Dividing participants in this manner removed runners that lacked stress fracture clarity, 
thus, allowing for analysis between clearly defined groups. Of the 103 runners, 7 males 
and 15 females had suffered at least one stress fracture injury (SF), 36 males and 32 
females had no history of stress fracture injury (NSF) and 2 males and 11 females 
reported a stress response/stress reaction via scan or stress fracture diagnosis by a 
medical professional (SSF).  
Protocol 
All runners completed a questionnaire detailing ethnic ancestry, as well as 
performance, injury and sporting history (Appendix 1). Stress fracture injury was self-
reported and runners were asked to confirm whether their stress fracture had been 
diagnosed by computed tomography (CT) or magnetic resonance imaging (MRI) scan 
on the questionnaire, and/or if the stress fracture had been diagnosed by a medical 
professional. All participants completed one whole-body DXA scan to obtain BMD data 
with whole-body and segmental analysis utilised to gather total-body BMD (TBMD), 
leg BMD (LBMD), lumbar spine BMD (LSBMD), total-body T-score and Z-score. 
Statistical analysis 
Multiple analysis of variance (MANOVA) was used to compare TBMD, LBMD, LSBMD, 
T-score and Z-score between the SF and the NSF groups of the female runners and 
male runners independently. MANOVA on the same phenotypes was then completed 
on the SF group, SSF group and NSF group in the female runners only before 
Bonferroni correction were implemented to account for multiple-testing. In the male 
analysis, only two runners were placed into the SSF group so no further sub-group 
analyses were completed. Alpha was set at 0.05 and data were reported as mean (SD) 
unless otherwise stated. 
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6.3 Results 
TBMD (P = 0.026), and LSBMD (P = 0.005) were ~7%, and ~16% higher, respectively, 
in SF than NSF male runners but no difference in LBMD (P = 0.052) between the two 
groups was observed (Figure 6.1; Table 6.1). Total-body T-score (P = 0.028) and Z-
score (P = 0.034) were also higher in the SF than NSF group (Table 6.1).  
  
Figure 6.1: Differences in TBMD (*P = 0.026) and LSBMD (**P = 0.005) but not LBMD 
(P = 0.052) between SF and NSF male runners. Error bars denote standard deviation. 
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Table 6.1: Anthropometric and BMD phenotype data in SF (n = 7) and NSF male 
runners (n = 36). Data are presented as mean (SD) except for TBMD, LBMD, LSBMD, 
T-score and Z-score which are presented as mean (minimum-maximum). 
 SF  NSF  
Age (years) 38 (11) 36 (9) 
Height (m) 1.80 (0.06) 1.78 (0.06) 
Mass (kg) 70.609 (5.041) 66.401 (6.835) 
TBMD (g/cm2) 1.360 (0.108)* 1.273 (0.088) 
LBMD (g/cm2) 1.552 (0.104) 1.464 (0.106) 
LSBMD (g/cm2) 1.224 (0.075)* 1.058 (0.143) 
T-score  1.53 (0.93)* 0.73 (0.84) 
Z-score 1.46 (0.88)* 0.71 (0.82) 
TBMD Range 0.296 (1.226–1.522) 0.434 (1.034–1.468) 
LBMD Range 0.257 (1.438–1.695) 0.526 (1.193–1.719) 
LSBMD Range 0.230 (1.150–1.380) 0.810 (0.750–1.560) 
T-score range 2.60 (0.30–2.90) 4.20 (-1.70–2.50) 
Z-score range 2.50 (0.20–2.70) 4.00 (-1.60–2.40) 
*Indicates differences from NSF group  
 
No differences in TBMD (P = 0.154), LBMD (P = 0.236), LSBMD (P = 0.870), T-score 
(P = 0.152) or Z-score (P = 0.143) were observed between the female SF and NSF 
groups in the initial comparison (Figure 6.2; Table 6.2).  
When analysed as three groups (SF, SSF and NSF), differences were only observed 
for TBMD, T-score and Z-score between the SF and SSF group. Higher TBMD (P = 
0.030), T-score (P = 0.033) and Z-score (P = 0.015) were possessed by the SSF 
female runners in comparison to the SF group (Figure 6.2; Table 6.2). No further 
differences were found for any BMD parameter between any group comparison (P ≥ 
0.057; Figure 6.2; Table 6.2).   
135 
 
 
Figure 6.2: Differences in TBMD (*P = 0.030) but not LBMD (P = 0.063) or LSBMD (P 
= 0.167) between the female SF and SSF runners. Error bars denote standard 
deviation. 
Table 6.2: Participant anthropometric, BMD phenotype data, T-score and Z-score in 
SF (n = 15), SSF (n = 11) and NSF (n = 32) female runners. Data are presented as 
mean (SD) except for TBMD, LBMD, T-score and Z-score which are presented as 
mean (minimum-maximum).   
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 SF  NSF  SSF  
Age (years) 32 (11) 36 (13) 34 (12) 
Height (m) 1.64 (0.05) 1.65 (0.06) 1.67 (0.06) 
Mass (kg) 51.764 (4.478) 52.766 (5.642) 55.017 (4.389) 
TBMD (g/cm2) 1.164 (0.082) 1.204 (0.091) 1.253 (0.066)* 
LBMD (g/cm2) 1.247 (0.088) 1.284 (0.104) 1.338 (0.079) 
LSBMD (g/cm2) 1.115 (0.133) 1.108 (0.152) 1.197 (0.149) 
T-score 0.69 (0.99) 1.17 (1.07) 1.74 (0.74)* 
Z-score 0.64 (0.85) 1.05 (0.89) 1.63 (0.69)* 
TBMD Range 0.282 (1.036–1.318) 0.338 (1.010–1.348) 0.189 (1.171-1.360) 
LBMD Range 0.354 (1.046–1.400) 0.415 (1.029–1.444) 0.282 (1.215-1.497) 
LSBMD Range 0.420 (0.880–1.290) 0.760 (0.710–1.460) 0.370 (1.020-1.390) 
T-score range 3.40 (-0.90–2.50) 4.00 (-1.20–2.80) 2.10 (0.80-2.90) 
Z-score range 3.00 (-0.90–2.10) 3.10 (-0.80–2.30) 2.20 (0.60-2.80) 
*P = 0.030 
P = 0.063 
P = 0.167 
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6.4 Discussion 
The aim of this chapter was to investigate TBMD, LBMD, LSBMD, total-body T-score 
and Z-score in high-level endurance runners who had suffered at least one stress 
fracture in comparison to runners who had never suffered a stress fracture. No 
difference in BMD was observed in female runners who had suffered a stress fracture 
(SF) in comparison to those who had no stress fracture injury history (NSF). Lower 
BMD, however, was observed in SF female runners in comparison to those who had 
reported stress fracture symptoms but had no scan diagnosis (SSF). In male runners, 
the SF group possessed higher BMD than the NSF group. Consequently, this chapter 
is consistent with previous research suggesting that female endurance runners who 
have suffered at least one stress fracture may possess lower BMD than those who 
have no stress fracture injury history confirmed via scan but this is only apparent in 
those who have suffered stress fracture symptoms (SSF).  
Low BMD can contribute to stress fracture incidence through reducing bone strength, 
resulting in increased accumulation of microdamage via repetitive loading over a 
prolonged time period (Bennell et al., 1999). It is interesting to note that when the 
runners were split into the three subgroups (SF, SSF and NSF), the SSF group 
possessed higher TBMD, LBMD, LSBMD, T-score and Z-score than the other two 
cohorts (albeit only significant for TBMD, T-score and Z-score between SF and SSF 
groups). The SSF group comprised runners who self-reported a medical professional 
diagnosed stress fracture/stress response/stress reaction or stress response/reaction 
via scan. It could be hypothesised that some of these SSF runners may not have 
suffered a true stress fracture (visible cortical fracture) due to possessing higher BMD. 
Possessing higher BMD may have provided greater protection to extensive loading 
and thus, explain why some only experienced stress responses/reactions and not a 
true stress fracture diagnosed via scan. Determining accurate prevalence of stress 
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fractures, however, is difficult due to the problematic nature of defining stress fractures 
and, therefore, some of the SSF may have suffered a stress fracture occurrence. 
Significant misdiagnosis of stress fractures can occur through medical professional 
assessment unless supported by radiography, although radiography can still lack 
sensitivity and specificity (Wright et al., 2016).  
The notion that BMD was not higher in the NSF than SF group suggests that other 
factors, such as training characteristics, energy availability and/or menstrual 
dysfunction may also be influencing stress fracture susceptibility in female runners. No 
difference in BMD was observed between potential amenorrheic and eumenorrheic 
runners in Chapter 3 of this thesis, with previous studies having reported an 
association between menstrual irregularity and low BMD (Tenforde et al., 2015). The 
influence of energy availability and/or menstrual dysfunction, therefore may explain 
why some previous studies have reported BMD associations with stress fracture 
(Kelsey et al., 2007; Bennell et al., 1996) but this chapter did in the SF vs SSF but not 
SF vs NSF comparisons. It is interesting to note that the difference in BMD found 
between the female SF and SSF groups was total-body and not site-specific (i.e. leg). 
Although LBMD provides better analysis than TBMD to assess the influence of BMD 
when the fracture sites are present in the lower extremity (Bennell et al., 1999), each 
standard deviation decrease in TBMD (293.2 g) in female endurance runners, has 
been reported to increase stress fracture rate two-fold (Kelsey et al., 2007). It is also 
important to emphasise that LBMD was still lower in the SF group than the NSF group, 
albeit non-significant. Possessing low BMD increases the potential risk of stress 
fracture but leg geometry, hormonal and nutritional factors are also contributory risk 
factors (Moreira and Bilezikian, 2016) and thus, possessing low BMD does not confirm 
a runner will suffer a stress fracture. The same principle applies with osteoporosis, 
where individuals with low BMD and consequently, diagnosed with the condition, may 
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never suffer an osteoporotic fracture, as other factors such as bone geometry, collagen 
properties and microarchitecture also influence clinical risk (Schoenau et al., 2002; 
Fonseca et al., 2014; Cheung et al., 2016).  
In the male analysis, higher TBMD, LSBMD, T-score and Z-score were possessed by 
the SF group in comparison to the NSF group, whilst no differences in LBMD were 
observed between the two groups. Bennell et al. (1996) and Crossley et al. (1999) both 
reported no association with BMD and stress fracture risk in male runners, although 
BMD was not higher in their respective stress fracture groups. In male runners, it would 
therefore appear that other risk factors, such as anthropometrics, gait, genetics and 
rapid changes in training are potentially more important than BMD for stress fracture 
susceptibility. Body mass has been proposed as a significant determinant for stress 
fracture risk in military recruits (Knapik et al., 2012) but no differences in body mass or 
height were present between the SF and NSF group in this chapter. Kinematic and 
kinetic variables such as peak hip adduction, peak rear foot eversion and absolute free 
movement have also been reported to predict tibial stress fracture history (Pohl et al., 
2008). More recently, genetic associations with stress fracture have also been reported 
in athletes (Varley et al., 2015; Varley et al., 2016; Varley et al., 2017). Genetics and 
running gait are likely to have substantial variance in endurance running populations, 
and although not investigated in this chapter, may have provided greater aetiology, 
rather than BMD, to stress fracture occurrence in the male runners in this chapter. The 
potential finding that BMD is not influencing stress fracture incidence in males, 
however, must be taken with caution. Only seven male runners had suffered a stress 
fracture in this investigation and a very small number of studies investigating stress 
fractures and BMD in male endurance runners exist with some reporting conflicting 
findings to this chapter, suggesting a potential association with low BMD and stress 
fracture occurrence (Bennell et al., 1996; Crossley et al., 1999; Nattiv et al., 2000). 
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Further investigation of BMD in male runners with stress fractures is required before 
confident interpretation regarding the influence of BMD on stress fractures can be 
concluded. In Chapter 3 of this thesis, lower LSBMD was observed in the male 
endurance runners in comparison to controls, as also reported in previous studies 
(Hind et al., 2006). Lower BMD has been reported in female runners with stress 
fractures alongside reduced energy availability, which can also occur in males 
(Mountjoy et al., 2018). Stress fracture occurrence is multi-factorial and it is likely that 
a combination of potential factors discussed throughout this chapter will contribute to 
stress fracture risk. 
Runners were included as part of the SF group as long as they had suffered at least 
one stress fracture incidence and thus, some may have had stress fractures that 
occurred a substantial amount of time ago. Variation between participants in the time 
between undergoing the DXA scan, when the stress fracture occurred and at which 
anatomical site, as well as in the severity of the stress fracture may influence the 
findings due to the likely disparity in the treatment programmes. It is possible some 
may have undergone extensive immobilisation or experienced a large reduction in 
mechanical loading volume, which may have had a modest effect on BMD (Bennell et 
al., 1999). Although this can be considered a limitation of the study, the vast majority 
of stress fractures in runners heal within 8 weeks through conservative treatment 
(Kahanov et al., 2015) and the mean age of the runners was 34 in the females and 36 
in the males. BMD remains relatively stable (unless severe and/or prolonged unloading 
occurs) after peak bone mass is reached up until aged 50 approximately (Bonjour et 
al., 1994).  
This chapter suggests that BMD does not appear to influence stress fracture incidence 
in male endurance runners and thus, other determinants such as gait, training 
characteristics or genetics may contribute to stress fracture occurrence. Female 
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runners, however, who had symptoms but did not suffer a stress fracture confirmed 
via scan appear to possess higher TBMD, T-score and Z-score than those who have 
suffered a stress fracture diagnosed via scan. Such higher BMD might protect against 
development of a confirmed stress fracture despite continued extensive loading during 
training.    
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Chapter 7: 
Genetic associations with 
stress fracture occurrence in 
high-level endurance runners 
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7.1 Introduction 
Stress fractures are defined as a partial or complete fracture of bone from repeated 
application of force lower than that required to fracture a bone in a single loading 
(Iwamoto and Takeda, 2003). Stress fracture injury occurs due to the repetitive 
mechanical loading that stimulates an incomplete remodelling response, exceeding 
intrinsic repair mechanisms (Bennell et al., 1999). Several factors are known to 
influence an individual’s susceptibility to experiencing a stress fracture and include 
biomechanical gait (Milner et al., 2006), bone size and mechanical properties 
(Tommasini et al., 2005), nutritional factors (Nieves et al., 2010), training volume and 
rapid increments in training volume (Snyder et al., 2006), small musculature and low 
bone mineral density (BMD) (Beck et al., 2000).  
The notion of a potential genetic influence on stress fracture susceptibility has also 
been proposed, with the majority of research having been completed in military recruits 
(Lappe et al., 2008). Indeed, the calcitonin receptor (CTR) rs1801197 and LRP5 
rs2277268 polymorphisms have been associated with femoral neck stress fractures in 
72 Finnish military recruits and those recruits who possessed the CTR C allele together 
with a VDR rs10735810 C-A haplotype were more protected from stress fractures 
(Korvala et al., 2010). Furthermore, larger sized CAG androgen receptor gene repeats 
(>16) were more common in Israeli military personnel who had suffered stress 
fractures (23%) than those who had not suffered this injury (13%) (Yanovich et al., 
2011). These findings, therefore, demonstrate there appears to be a genetic influence 
on stress fracture incidence in populations of increased training/loading.  
Athletes and in particular, endurance runners, are another cohort where high incidence 
of stress fractures are reported, accounting for 15-50% of all injuries (Milner et al., 
2006). Stress fractures can have substantial negative implications for health and 
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performance in endurance runners, potentially affecting training load/volume and 
consequently providing a barrier to success or reaching high performance levels. 
Although meta-analysis has suggested that only previous history of stress fracture and 
female sex are the two key risk factors for stress fracture incidence in endurance 
runners (Wright et al., 2015), low BMD still remains a logical and supported risk factor 
for stress fracture susceptibility in this population (Kelsey et al., 2007; Nattiv et al., 
2000; Bennell et al., 1996). 
It could also be speculated that a lack of research on genetics associations with BMD 
is why only previous stress fracture history and female sex were the key two risk factors 
associated with stress fracture incidence. Heritability of BMD is suggested to be 50-
85% (Ralston and Uitterlinden, 2010), depending upon anatomical location, whilst 
potential gene-mechanical loading interactions influencing BMD in athletes have also 
been reported (Nakamura et al., 2002a; Nakamura et al., 2002b). Studying potential 
genetic associations with stress fracture in athletes due to the substantial heritable 
nature of BMD, therefore, provides an interesting and noteworthy route to further 
explore the aetiology of stress fracture susceptibility.  
A limited number of studies have investigated a potential genetic association with 
stress fracture injury so far, all having been conducted in the Stress Fracture Elite 
Athlete (SFEA) cohort (Varley et al., 2015; Varley et al., 2016; Varley et al., 2017). 
VDR FokI rs2228570, TNFSF11 (RANKL) rs1021188, P2RX7 rs3751143 and 
TNFRSF11A (RANK) rs30218362 were some of the SNPs associated with stress 
fracture in the 125 athletes that had suffered a radiographically confirmed stress 
fracture in comparison to 376 athletes who had no stress fracture history. Investigation 
of the genetic association on stress fracture using the SFEA cohort, represents the 
largest study in athletes to date, consisting of 501 athletes in total. These athletes, 
however, were of mixed abilities from a range of sports, which varied in loading/training 
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patterns/physical characteristics, which have been shown to influence stress fracture 
susceptibility (Bennell et al., 1996; Cosman et al., 2013; Bennell et al., 1999). Utilising 
a homogenous group of athletes from one sport would therefore, somewhat alleviate 
differences in these aforementioned factors that influence stress fracture susceptibility 
and allow better assessment of genetic association of stress fracture injury. Greater 
understanding of the aetiology of stress fracture injury will ultimately allow better 
development and implementation of training, prevention and management strategies 
to aid in performance and recovery.   
The aim of this study, therefore, was to compare the genotype and allele frequencies 
of the 10 genetic variants associated with BMD described in Chapter 1, in high-level 
runners who had suffered a stress fracture in comparison with those who had never 
suffered a stress fracture. It was hypothesised that the runners who had suffered a 
stress fracture would possess more “risk” (lower BMD associated) genotypes in 
comparison to the runners who had never suffered a stress fracture suggesting a 
potential genetic contribution to stress fracture injury in endurance runners.  
7.2 Method 
The participants and protocols used in Chapter 7 have already been described in detail 
in Chapter 2, thus, only a brief description of these methods is detailed below. 
Participants 
Participants consisted of 195 high-level Caucasian runners (102 males, 93 females) 
from the cohort as described in Table 2.1 of Chapter 2. To ensure subsequent analyses 
occurred between clearly defined participant groups, participants who had a stress 
fracture diagnosed by a scan were placed in the stress fracture (SF) group and those 
who reported no history of stress fracture were placed in the no stress fracture (NSF) 
group. Those participants who reported a stress response/stress reaction via scan or 
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reported having a stress fracture diagnosed by a medical professional but not 
confirmed via scan were classified into the symptoms of stress fracture group stress 
fracture (SSF) group. Dividing participants in this manner removed potential 
misdiagnoses of stress fractures and thus allowed for analysis between clearly defined 
groups. Consequently, a total no stress fracture group consisting of SSF + NSF (TNSF) 
were compared to the SF group before the SSF runners were removed and a 
comparison between the clearly defined groups was completed (SF vs NSF). Of the 
195 runners, 12 males and 21 females had suffered at least one stress fracture injury 
(SF), 86 males and 56 females had no history of stress fracture injury (NSF) and 4 
males and 16 females reported a stress response/stress reaction via scan or having a 
stress fracture diagnosed by a medical professional (SSF). 
Protocol 
All runners completed a questionnaire detailing ethnic ancestry, as well as 
performance, injury and sporting history (Appendix 1). Stress fracture injury was self-
reported and runners were asked to confirm whether their stress fracture had been 
diagnosed by computed tomography (CT) or magnetic resonance imaging (MRI) scan 
on the questionnaire, and/or if the stress fracture had been diagnosed by a medical 
professional. All participants provided a whole-blood, saliva or buccal swab sample, 
from which DNA was subsequently extracted and analysed to obtain genotype data 
for the 10 investigated SNPs (AXIN1 9921222, BDNF-AS rs6265, COL1A1 ra1800012, 
COMT rs4680, LRP5 rs3736228, P2X7R rs3751143, TNFRSF11A rs3018362, 
TNFRSF11B rs4355801, VDR rs2228570, WNT16 rs3801387) as described in 
Chapter 2.  
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Statistical analysis 
Pearson’s Chi-square (χ2) tests were utilised to compare genotype (using three 
analysis models; additive, recessive and dominant) and allele frequencies between the 
SF and the combined NSF and SSF groups (TNSF) before being implemented 
between the SF and NSF groups. Fisher’s exact test was used for genotype analysis 
when a genotype group had a sample size <5 and χ2 could not be completed, which 
occurred on 18 occasions. Odds ratios were also calculated to estimate effect size. 
Independent t-tests were completed to compare total genotype score (TGS) between 
SF and NSF as well as SF and TNSF groups. TGS was calculated and implemented 
in the same manner as outlined in chapter 4, where each SNP homozygote associated 
with higher BMD given a score of 2, the heterozygotes scoring 1 and the other 
homozygote given 0 (“risk” genotype). The total score was then calculated to lie within 
0-100 ((e.g. TGS = 100/20 x (2+1+0+1+1+1+0+2+1+2) = 55)). Receiver operator curve 
(ROC) area under the curve (AUC) analyses was conducted to determine if TGS was 
able to classify SF from NSF or TNSF runners. Benjamini-Hochberg corrections were 
implemented for genotype and allele frequency comparisons when required (each 
SNP submitted to 8 tests) to account for false discovery rate. Corrected probability 
values are reported and alpha was set at 0.05.  
7.3 Results 
No differences in genotype or allele frequency were observed for any SNP between 
SF vs NSF or SF vs TNSF comparisons after multiple testing correction (P ≥ 0.120; 
Table 7.1). Before multiple testing correction, the TNFRSF11A rs3018362 “risk” 
(lower BMD-associated) AA genotype was more frequent in the SF than NSF group 
and in the SF vs TNSF group comparison (Figure 7.1), whilst in the recessive 
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analysis model, the TNFRSF11B rs4355801 “risk” (lower BMD-associated) AA 
genotype was more frequent in the SF than NSF group (Figure 7.2).  
 
Figure 7.1: TNFRSF11A rs3018362 AA genotype in SF, NSF and TNSF runners.  
 
 
Figure 7.2: TNFRSF11B rs4355801 AA and AG + GG genotypes in SF and NSF 
runners 
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Table 7.1: Genotype and allele frequencies of all investigated SNPs in SF, NSF, SSF 
and TNSF groups with their respective P- and χ2 values from the additive analysis 
model. N/A indicates that no individual possessed the specific genotype for that SNP.   
SNP Genotype 
Allele 
SF NSF SSF TNSF SF vs NSF SF vs TNSF 
Genotype 
frequency (%) 
Allele       frequency 
(%) 
Genotype 
frequency (%) 
Allele       
frequency (%) 
Genotype 
frequency (%) 
Allele 
frequency (%) 
Genotype 
frequency (%) 
Allele 
frequency (%) 
P-value 
 
 
Chi-square 
(χ2) 
 
P-value 
 
 
Chi-square 
(χ2) 
 
AXIN1  
rs9921222 
CC 
CT 
TT 
C 
T 
30.3% 
42.4% 
27.3% 
51.5% 
48.5% 
23.2% 
54.2% 
22.5% 
50.4% 
49.6% 
50.0% 
35.0% 
15.0% 
67.5% 
32.5% 
26.5% 
51.9% 
21.6% 
52.5% 
47.5% 
0.390 
1.885 
 
0.850 
0.036 
 
0.540 
1.232 
 
0.977 
0.024 
BDNF-AS  
rs6265 
GG 
GA 
AA 
G 
A 
63.6% 
36.4% 
0% 
81.8% 
18.2% 
66.9% 
29.6% 
3.5% 
81.6% 
18.3% 
65.0% 
30.0% 
5.0% 
80.0% 
20.0% 
66.7% 
29.6% 
3.7% 
81.5% 
18.5% 
0.546 
N/A 
 
0.979 
0.001 
 
0.565 
N/A 
 
0.944 
0.005 
COL1A1 
rs1800012 
AA 
AC 
CC 
A 
C 
78.8% 
18.2% 
3.0% 
87.9% 
12.1% 
62.7% 
33.1% 
4.2% 
79.2% 
20.8% 
70.0% 
30.0% 
0.0% 
85.0% 
15.0% 
63.6% 
32.7% 
3.7% 
80.0% 
20.0% 
0.250 
3.697 
 
0.214 
3.003 
0.250 
3.372 
 
0.214 
2.595 
 
COMT        
rs4680 
GG 
GA 
AA 
G 
A 
18.2% 
54.5% 
27.3% 
45.5% 
54.5% 
22.5% 
48.6% 
28.9% 
46.8% 
53.2% 
15.0% 
40.0% 
45.0% 
35.0% 
65.0% 
21.6% 
47.5% 
30.9% 
45.4% 
54.6% 
0.761 
0.548 
 
0.663 
0.190 
 
0.719 
0.659 
 
0.989 
<0.001 
LRP5   
rs3736228 
GG 
GA 
AA 
G 
A 
69.7% 
27.3% 
3.0% 
83.3% 
16.7% 
69.7% 
26.8% 
3.5% 
83.1% 
16.9% 
85.0% 
15.0% 
0.0% 
92.5% 
7.5% 
71.6% 
25.3% 
3.1% 
84.3% 
15.7% 
0.987 
0.026 
 
0.959 
0.003 
 
0.967 
0.067 
 
0.836 
0.043 
P2X7R 
rs3751143 
 
AA 
AC 
CC 
A 
C 
63.6% 
30.3% 
6.1% 
78.8% 
21.2% 
62.7% 
33.1% 
4.2% 
79.2% 
20.8% 
80.0% 
20.0% 
0.0% 
90.0% 
10.0% 
64.8% 
31.5% 
3.7% 
80.6% 
19.4% 
0.841 
0.346 
 
0.930 
0.008 
0.772 
0.517 
 
0.717 
0.132 
TNFRSF11A 
rs3018362 
GG 
GA 
AA 
G 
A 
54.5% 
24.2% 
21.2% 
66.7% 
33.3% 
45.8% 
43.0% 
11.3% 
67.3% 
32.7% 
55.0% 
40.0% 
5.0% 
75.0% 
25.0% 
46.9% 
42.6% 
10.5% 
68.2% 
31.8% 
0.123 
6.142 
 
0.919 
0.010 
 
0.123 
6.631 
 
0.901 
0.072 
TNFRSF11B 
rs4355801 
AA 
GA 
GG 
A 
G 
45.5% 
33.3% 
21.2% 
62.1% 
37.9% 
28.9% 
52.8% 
18.3% 
55.3% 
44.7% 
40.0% 
50.0% 
10.0% 
65.0% 
35.0% 
30.2% 
52.5% 
17.3% 
56.5% 
43.5% 
0.154 
5.666 
 
0.422 
1.249 
 
0.154 
5.121 
 
0.473 
0.854 
VDR    rs2228570 CC 
CT 
TT 
C 
T 
30.3% 
42.4% 
27.3% 
51.5% 
48.5% 
36.6% 
47.9% 
15.5% 
59.6% 
39.4% 
55.0% 
40.0% 
5.0% 
75% 
25% 
38.9% 
46.9% 
14.2% 
62.3% 
37.7% 
0.229 
3.521 
 
0.213 
2.262 
 
0.190 
4.741 
 
0.190 
3.298 
WNT16 
rs3801387 
AA 
AG 
GG 
A 
G 
45.5% 
45.5% 
9.1% 
68.3% 
31.8% 
52.2% 
40.1% 
7.7% 
72.2% 
27.8% 
65.0% 
35.0% 
0.0% 
82.5% 
17.5% 
53.7% 
39.5% 
6.8% 
73.5% 
26.5% 
0.745 
0.590 
 
0.468 
0.526 
0.615 
0.971 
 
0.332 
0.942 
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The SF group had over 1.7 times the odds of possessing the VDR rs2228570 “risk” TT 
genotype in comparison to the NSF and TNSF groups (Table 7.2; Table 7.3). Similarly, 
the SF group had over 1.5 times the odds of possessing the TNFRSF11A rs3018362 
“risk” AA genotype in comparison to the NSF and TNSF groups and over twice the 
odds of possessing the TNFRSF11B “risk” AA genotype (Table 7.2; Table 7.3).  
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Table 7.2: Odds ratio and confidence interval (CI) statistics for stress fracture injury in 
SF vs NSF of the 10 investigated SNPs.  
SNP Genetic model Odds ratio 95% CI 
AXIN1  rs9921222 T/C 
TT/CC 
TT/C carriers 
T carriers/CC 
 
0.96 
0.93 
1.29 
0.70  
0.56 – 1.63 
0.33 – 2.58 
0.55 – 3.05 
0.30 – 1.61 
 
BDNF-AS rs6265 A/G 
AA/AG 
AA/G carriers 
A carriers/GG 
 
0.99 
N/A 
N/A 
1.16 
0.50 – 1.99 
N/A 
N/A 
0.52 – 2.55 
COL1A1 rs1800012 C/A 
CC/AA 
CC/A carriers 
C carriers/AA 
0.53 
0.57 
0.71 
0.45 
 
0.24 – 1.16 
0.07 – 4.96 
0.08 – 6.09 
0.18 – 1.11 
COMT rs4680 G/A 
GG/AA 
GG/A carriers 
G carriers/AA 
 
0.95 
0.85 
0.76 
1.08 
 
0.55 – 1.62 
0.28 – 2.65 
0.29 – 2.01 
0.46 – 2.53 
LRP5 rs3736228 A/G 
AA/GG 
AA/G carriers 
A carriers/GG 
 
0.98 
0.86 
0.86 
1.50 
 
0.48 – 2.02 
0.10 – 7.73 
0.09 – 7.58 
0.72 – 3.16 
P2X7R rs3751143 C/A 
CC/AA 
CC/A carriers 
C carriers/AA 
 
1.03 
1.14 
1.46 
0.78 
 
0.53 – 1.98 
0.22 – 5.99 
0.28 – 7.59 
0.36 – 1.66 
TNFRSF11A rs3018362 A/G 
AA/GG 
AA/G carriers 
A carriers/GG 
 
1.03 
1.58 
2.12 
0.70 
 
0.58 – 1.81 
0.56 – 4.43 
0.79 – 5.67 
0.33 – 1.51 
TNFRSF11B rs4355801 A/G 
AA/GG 
AA/G carriers 
A carriers/GG 
 
1.33 
1.36 
2.05 
0.83   
 
0.77 – 2.30 
0.49 – 3.78 
0.95 – 4.46 
0.33 – 2.12 
 
VDR  rs2228570 T/C 
TT/CC 
TT/C carriers 
T carriers/CC 
 
1.45 
1.77 
1.89 
1.11 
0.84 – 2.48 
0.65 – 4.81 
0.78 – 4.57 
0.51 – 2.41 
WNT16 rs3801387 A/G 
AA/GG 
AA/G carriers 
A carriers/GG 
0.83 
0.74 
0.77 
0.84  
0.46 – 1.47 
0.19 – 2.99 
0.36 – 1.64 
0.22 – 3.20 
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Table 7.3: Odds ratio and confidence interval (CI) statistics for stress fracture injury in 
SF vs TNSF of the 10 investigated SNPs. 
SNP Genetic model Odds ratio 95% CI 
AXIN1 rs9921222 T/C 
TT/CC 
TT/C carriers 
T carriers/CC 
 
1.04 
1.11 
1.36 
0.83 
0.61 – 1.77 
0.41 – 3.02 
0.58 – 3.19 
0.37 – 1.89 
 
BDNF-AS rs6265 A/G 
AA/GG 
AA/G carriers 
A carriers/GG 
 
0.98 
N/A 
N/A 
1.14 
 
0.49 – 1.94 
 
 
0.52 – 2.50 
COL1A1 rs1800012 C/A 
CC/AA 
CC/A carriers 
C carriers/AA  
0.55 
0.66 
0.81 
0.47 
0.25 – 1.21 
0.08 – 5.73 
0.10 – 6.98 
0.19 – 1.15 
COMT rs4680 G/A 
GG/AA 
GG/A carriers 
G carriers/AA 
 
1.00 
0.95 
0.81 
1.19 
0.59 – 1.71 
0.31 – 2.92 
0.31 – 2.11 
0.52 – 2.75 
LRP5 rs3736228 A/G 
AA/GG 
AA/G carriers 
A carriers/GG 
 
1.07 
1.01 
0.98 
1.65 
0.53 – 2.18 
0.11 – 9.04 
0.11 – 8.68 
0.79 – 3.43 
P2X7R rs3751143 C/A 
CC/AA 
CC/A carriers 
C carriers/AA 
 
1.07 
1.35 
1.68 
0.85 
0.56 – 2.04 
0.26 – 7.06 
0.32 – 8.70 
0.40 – 1.81 
TNFRSF11A rs3018362 A/G 
AA/GG 
AA/G carriers 
A carriers/GG 
 
1.07 
1.74 
2.30 
0.74 
 
0.61 – 1.88 
0.63 – 4.82 
0.87 – 6.08 
0.35 – 1.56 
TNFRSF11B rs4355801 A/G 
AA/GG 
AA/G carriers 
A carriers/GG 
 
1.26 
1.22 
1.92 
0.78 
0.73 – 2.18 
0.45 – 3.36 
0.90 – 4.12 
0.31 – 1.96 
VDR  rs2228570 T/C 
TT/CC 
TT/C carriers 
T carriers/CC 
 
1.56 
2.05 
2.09 
1.22 
0.92 – 2.65 
0.77 – 5.51 
0.87 – 5.03 
0.57 – 2.62 
WNT16 rs3801387 A/G 
AA/GG 
AA/G carriers 
A carriers/GG 
0.77 
0.63 
0.72 
0.73 
0.44 – 1.37 
0.16 – 2.54 
0.34 – 1.52 
0.19 – 2.77 
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No differences were observed in TGS between SF vs NSF and SF vs TNSF 
comparisons (P = 0.978; P = 0.715) with similar means, modes and medians for TGS 
observed in all three cohorts (Table 7.4). ROC analysis determined that TGS 
frequency distribution could not distinguish SF from NSF (AUC = 0.498, P = 0.977; 
Figure 7.3) or SF from TNSF runners (AUC = 0.479, P = 0.703; Figure 7.3).  
Table 7.4: Mean (SD), mode and median TGS of SF, NSF and TNSF groups. 
Group TGS Mean 
(SD) 
Mode Median Comparisons and P- 
value 
SF (n = 33) 62.73 (8.01) 65.00 65.00 SF vs NSF 0.978 
NSF (n = 142) 62.78 (10.51) 60.00 60.00  
TNSF (n = 162) 63.43 (10.37) 60.00 65.00 SF vs TNSF 0.715 
 
 
 
Figure 7.3: TGS frequency distribution in SF, NSF and TNSF groups.  
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7.4 Discussion 
The aim of this chapter was to investigate the influence of BMD-associated genetic 
variants on stress fracture occurrence in high-level endurance runners. No differences 
in genotype or allele frequency were observed for any SNP between SF vs NSF and 
SF vs TNSF comparisons but the “risk” (lower BMD-associated) TNFRSF11A 
rs3018362 and TNFRSF11B rs4355801 AA genotypes were more frequent in the SF 
group before multiple testing correction. Additionally, the SF group had over 1.5 times 
and almost twice the odds of possessing the TNFRSF11A rs3018362 and 
TNFRSF11B rs4355801 AA genotype, respectively, in comparison to the NSF and 
TNSF groups.  
Although no associations were present after multiple testing correction, runners who 
had suffered a stress fracture (SF) possessed >9% higher frequency of the “risk” lower 
BMD-associated TNFRSF11A rs3018362 AA genotype than runners who had no 
history of stress fracture injury confirmed via scan (NSF and TNSF). There was also a 
~17% higher frequency of the “risk” lower BMD-associated TNFRSF11B rs4355801 
AA genotypes in the SF than NSF runners in the recessive analysis model. 
TNFRSF11A and TNFRSF11B encode RANK and OPG respectively, forming part of 
the RANK/RANKL/OPG signalling pathway, which plays an essential role in regulating 
osteoclast differentiation and activity following mechanical loading (Boyle et al., 2003) 
and is therefore, important for bone turnover.  
Although not directly causing the disease, the AA genotype of the TNFRSF11A 
rs3018362 SNP has been associated with Paget’s disease of bone and reduced BMD 
(Styrkarsdottir et al., 2009; Albagha et al., 2010) as well as stress fracture in elite 
athletes before multiple testing correction (Varley et al., 2015). Paget’s disease is 
characterised by abnormal bone architecture via irregular bone remodelling (extensive 
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osteoclast-mediated bone resorption before defective osteoblast-mediated bone 
repair), causing bone expansion and softening, resulting in overproduction of poor 
quality bone (Delmas and Meunier, 1997; Whyte, 2006). Although the direct 
mechanism underpinning how the AA genotype may affect the protein product and 
subsequently influence BMD, it could be hypothesised that possessing the AA 
genotype aids in increasing bone turnover, raising the amount of poor quality bone and 
consequently increasing risk of stress fracture in athletes.  
Previous study has suggested the A allele to be associated with reduced BMD and 
TNFRSF11B expression, as well as increased risk of osteoporotic fracture via GWAS 
(Richards et al., 2008). Consequently, this reduced expression and associated lower 
BMD via possession of the A allele may explain why runners with stress fracture injury 
history had increased odds of possessing the A allele. Despite these findings, Varley 
et al. (2015) observed the G allele, rather than the A allele, to be associated with 
multiple stress fracture injury history in the Stress Fracture Elite Athlete (SFEA) cohort. 
BMD was not measured in the Varley et al. (2015) investigation and thus other stress 
fracture risk factors such as training load, body composition and type of mechanical 
loading (as discussed throughout the thesis) may have provided a greater contribution 
to stress fracture incidence than genetics in that investigation. The underpinning 
mechanisms of how genetic variation in SNPs in the RANK/RANKL/OPG pathway 
such as the ones investigated in this chapter may be influencing BMD (and 
subsequently stress fracture) is not well understood as discussed in Chapter 5. 
Alongside influencing osteoclastogenesis, a TNFSF11 (RANKL) SNP (rs9594738) 
was found to be associated with BMD and the region where harboured appeared to be 
stimulated by the presence of vitamin D, indicating a potential role in the 
RANK/RANKL/OPG equilibrium (Yoskovitz et al., 2013).   
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Runners with previous stress fracture history had over 1.7 and 2.0 times the odds of 
possessing the VDR rs2228570 “risk” TT genotype in comparison to those who had 
no history of stress fracture confirmed via scan (NSF and TNSF). This observation is 
in agreement with a previous study in athletic populations, where the VDR rs2228570 
T allele was associated with stress fracture in the Stress Fracture Elite Athlete Cohort 
(SFEA) (Varley et al., 2017) as well as in military recruits (Chatzipapas et al., 2009). A 
number of VDR SNPs have been proposed to influence BMD and it has proposed that 
genotype variation can regulate VDR concentration, which could potentially impact 
parathyroid hormone or vitamin D binding and as a consequence, calcium absorption 
(McClung and Karl, 2010). The VDR rs2228570 C allele appears to increase 
transactivation (protein expression) compared to the T allele - this increased biological 
activity (and associated increased intestinal absorption of calcium) could explain why 
higher BMD has been reported in those with the CC genotype (Arai et al., 1997; Colin 
et al., 2000; Uitterlinden et al., 2004; Ames et al., 1999). Consequently, this enhanced 
BMD through C allele possession and the associated reduced risk of stress fracture 
may explain why runners with no history of stress fracture were 1.5 times less likely to 
carry the T allele in this chapter and why the T allele has been associated with stress 
fracture in previous investigation.   
A number of risk factors (alongside the aforementioned ones above) such as dietary 
intake, hormonal levels and biomechanical gait have been proposed as determinants 
of stress fracture in endurance runners, which may explain why no genetic 
associations with stress fracture were observed after multiple testing correction in this 
chapter. It could also be hypothesised that BMD may not be involved in the direct 
pathophysiology of stress fracture injury whilst pathophysiological differences between 
osteoporotic and stress fracture exist. Ultimately, other bone phenotypes may have a 
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greater impact on risk, such as lower cortical area and bone size, ultimately influencing 
bone strength (Popp et al., 2009; Evans et al., 2008).  
Further research, however, is needed to support the evidence of these risk factors as 
meta-analysis has indicated that previous stress fracture history and female sex are 
the only two factors that have strong evidence to support an association with stress 
fracture in endurance runners (Wright et al., 2015). Although no association for any 
SNP with stress fracture was observed in this chapter, this could suggest that these 
other factors are contributing to stress fracture incidence more so than genetics in 
athletic populations. However, previous investigations reported genetic associations 
with stress fractures in athletic populations (Varley et al., 2015; Varley et al., 2016; 
Varley et al., 2017) and, although it was not significant after multiple testing correction, 
TNFRSF11A rs3018362 was associated with stress fracture injury in both this chapter 
as well as the runners of the SFEA cohort (Varley et al., 2015).  
Differences in the findings between this chapter and the only other studies to date 
investigating genetic associations of stress fracture in athletes via the SFEA, however, 
do exist (Varley et al., 2015; Varley et al., 2016; Varley et al., 2017). LRP5 rs3736228, 
COL1A1 rs1800012 and WNT16 rs3801387 observed no association with stress 
fracture in the SFEA cohort as in agreement with this chapter (Varley et al., 2017). 
TNFRSF11A rs3018362 was associated with stress fracture in this chapter and with 
the SFEA cohort before multiple testing correction (Varley et al., 2015), whilst P2X7R 
3751143 was associated with stress fracture injury only in the SFEA cohort (Varley et 
al., 2016; Varley et al., 2017). These differences between studies may relate to 
differences in sample size and participant characteristics. Whilst the SFEA cohort 
(Varley et al., 2015; Varley et al., 2016; Varley et al., 2017) comprised a larger sample 
size of 125 athletes who had suffered stress fractures in comparison to the current 
chapter, these comprised athletes of mixed abilities across of a number of sports 
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including football, rowing and boxing, where substantial variation in athlete physical 
characteristics exist. The athlete sample in this chapter, however, consisted wholly 
endurance runners of similar standards who have congruent physical characteristics. 
Specifically, the SF male runners from this chapter were 1.80 ± 0.06 m and 70.6 ± 5.0 
kg in height and body mass whilst the NSF runners were 1.78 ± 0.06 m and 66.4 ± 6.8 
kg. In the SFEA, male athletes who had suffered stress fractures were 1.85 ± 0.07 m 
and 82.9 ± 10.6 kg and those who had no stress fracture history were 1.82 ± 0.07 m 
and 79.6 + 9.4 kg in height and body mass, respectively. Alongside these differences 
in physical characteristics, variability in stress fracture location for different sports is 
also likely and thus, these different locations may be comprised of varying amounts of 
trabecular and cortical bone. It has been proposed that different genes and phenotypes 
may have specific roles in cortical or trabecular bone adaptation as outlined in Chapter 
5.  Utilising a more homogenous cohort can somewhat strengthen the statistical power 
and better assess the genetic influence on stress fracture by reducing the variability in 
these factors. 
The collective genetic association, as part of a TGS, found no association with stress 
fracture in this chapter. A large number of genes have been proposed to be associated 
with BMD and osteoporotic fracture in non-athlete populations (Hsu and Kiel, 2012). It 
is possible that certain variants may have a greater influence in athletes than non-
athlete populations, which may explain why genes associated with non-athlete and 
untrained populations have not been replicated in this chapter or other studies in 
athletes (Varley et al., 2018; Varley et al., 2015; Varley et al., 2016; Varley et al., 2017). 
This variation association may be dependent upon the particular biological function of 
that variant. Specifically in relation to endurance runners, certain genes/SNPs may be 
important in the adaptation of bone to large volumes of mechanical loading and thus 
may demonstrate a greater influence on BMD and/or stress fracture risk than in non-
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endurance or non-athletic participants. For example, VDR and TNFRSF11A have been 
suggested to influence bone through a mechanically induced interaction and 
consequently associated with bone phenotypes in athletic populations, although the 
specific mechanisms are not yet understood. COL1A1 rs1800012 was not associated 
with stress fracture in this chapter or in the elite athlete cohort (Varley et al., 2017), 
although it has been associated with degenerative bone microarchitecture (Mann et 
al., 2001; Grant et al., 1996; Dytfeld et al., 2016) and associated with BMD (Jin et al., 
2011). It could therefore be hypothesised that COL1A1 rs1800012 may have greater 
influence on other conditions or populations, such as osteoporosis imperfecta (Marini 
et al., 2007), where the mechanical loading influence will be less prominent. These 
potential function-specific differences may explain why some variants and not others 
are associated with stress fracture in athletic populations. Moreover, this becomes 
more complex when considering that pleiotropic effects between BMD and lean mass 
(a shared genetic component of 43%) have been recently reported (Medina-Gomez et 
al., 2017). Thus, variability in the muscle capacity to absorb bone could impact the 
bone tissue and subsequent fracture risk (Brotto and Bonewald, 2015; Varley et al., 
2018). It is also underdetermined how gene-gene interactions or SNPs that are 
involved within the same signalling pathway may interact to impact BMD. Overall, 
stress fracture injury is likely to be polygenic in nature but is also influenced by 
environmental determinants such as dietary intake and training characteristics (Wentz 
et al., 2012).  
This chapter suggests that AXIN1 9921222, BDNF-AS rs6265, COL1A1 ra1800012, 
COMT rs4680, LRP5 rs3736228, P2X7R rs3751143, TNFRSF11A rs3018362, 
TNFRSF11B rs4355801, VDR rs2228570 and WNT16 rs3801387 are not associated 
with stress fracture incidence in high-level endurance runners. However, associations 
with the TNFRSF11A rs3018362 and TNFRSF11B rs4355801 (lower BMD-
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associated) AA genotypes to be more frequent in runners who had suffered a stress 
fracture in comparison to those who had no stress fracture injury history before multiple 
testing correction were observed. Additionally, runners who had previous stress 
fracture history had over 1.5 times the odds of possessing the TNFRSF11A rs3018362 
or TNFRSF11B rs4355801 “risk” AA genotypes or the VDR rs2228570 “risk” TT 
genotype in comparison to runners with no stress fracture injury history. This data, 
alongside previously reported functional studies and associations with stress fracture 
as well as BMD, could suggest that variation in the TNFRSF11A rs3018362, 
TNFRSF11B rs4355801 and VDR rs2228570 SNPs may influence stress fracture 
occurrence. Further study, utilising larger sample sizes of homogenous cohorts to 
increase statistical power is needed to provide greater evidence of these potential 
genetic associations with stress fractures in athletes.  
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Chapter 8:  
Discussion 
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8.1 Overview: 
The overall aim of the current thesis was to investigate the genetic associations with 
BMD, stress fracture incidence and performance in high-level endurance runners and 
compare these to a non-athlete cohort to explore genotype-physical activity 
interactions. 
8.1 Bone mineral density 
8.1.1 Bone mineral density in high-level endurance runners and non-athletes  
Female runners possessed ~4% higher LBMD but similar TBMD and LSBMD than 
their non-athlete counterparts, whilst no differences in total-body T-score or Z-score 
were present between the two cohorts. Higher site-specific BMD (i.e. LBMD) in 
endurance runners has also been observed in previous investigation (Duncan et al., 
2002; Scofield and Hecht, 2012; Nevill et al., 2003; Brahm et al., 1997) and these 
findings highlight the site-specific nature of bone adaption following mechanical 
loading. Contradictory findings, reporting lower or low in female endurance runners, 
specifically at sites of smaller magnitudes of loading, however, have been reported 
(Pollock et al., 2010; Barrack et al., 2008b). This may be due to reduced energy 
availability or the specific training programme completed by the individual runner as 
discussed in Chapter 3. It must be noted that the only other study investigating BMD 
in a homogenous group of UK high-level female endurance runners observed low BMD 
(Z-score of -1.0 to -2.0) in some of the runners investigated (Pollock et al., 2010). The 
findings from this investigation, therefore, have to be interpreted with caution and 
further research is needed to confirm the nature of BMD in female high-level 
endurance runners.  
162 
 
Male endurance runners possessed lower (~10%) LSBMD but similar TBMD and 
LBMD in comparison to the male non-athletes. Total-body T-score and Z-score 
comparisons between the two groups also revealed no differences. Lower LSBMD in 
male endurance runners has been reported previously (Hind et al., 2006), which 
suggests some male runners may be at risk of reduced energy availability, which has 
been highlighted in the recent IOC consensus statement (Mountjoy et al., 2018). 
Consequently, the combination/relationship of energy availability, low body mass and 
large training volumes, as well as the difference in BMD in comparison to the non-
athletes occurring at a site that is subjected to less loading, may explain why lower 
LSBMD was observed in the male runners in comparison to non-athletes.  
These findings from Chapter 3 suggest that male runners have lower BMD at sites of 
less loading in comparison to non-athletes, and could therefore be at risk for 
complications associated with low BMD such as fracture or osteoporosis. Large 
variance in BMD was present in both the runners and non-athletes for both males and 
females, which highlights the substantial genetic contribution to BMD, even when 
physical activity/mechanical loading level is relatively homogenous as is the case for 
the endurance runners.  
8.1.2 Bone mineral density and stress fracture occurrence in high-level endurance 
runners 
Chapter 6 revealed no differences in any bone phenotype between the female runners 
who had suffered a stress fracture (SF) in comparison to those who had no stress 
fracture injury history (NSF). However, lower TBMD, T-score and Z-score were 
observed in SF female runners in comparison to those who had reported stress 
fracture symptoms but had a negatives scan result or no scan diagnosis (SSF). The 
higher BMD observed in the SSF than SF female runners could indicate that the SSF 
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runners did not suffer a true stress fracture (visible cortical fracture) due to possessing 
higher BMD as discussed in Chapter 6. Previous studies have produced inconsistent 
findings in regards to BMD association with stress fracture (Crossley et al., 1999; 
Duckham et al., 2012; Bennell et al., 1996; Kelsey et al., 2007). Possessing lower BMD 
can contribute to stress fracture incidence through reducing bone strength, resulting in 
increased accumulation of microdamage via repetitive loading over a prolonged period 
(Bennell et al., 1999). Stress fracture occurrence, however, is a multi-factorial 
phenotype, and other factors such as biomechanical gait, other bone characteristics 
and genetics have all been associated with stress fracture injury, which may explain 
the inconsistent literature.  
In contrast to females, male runners who had suffered at least one stress fracture 
possessed higher TBMD, LBMD, T-score and Z-score than non-stress fracture 
runners. Analysing Chapters 3 and 6 collectively alongside the functional mechanism 
behind stress fracture and lower BMD, it would be expected that BMD would be lower 
in those who had suffered a stress fracture. However, previous study investigating 
BMD and stress fracture occurrence in male endurance runners has primarily 
suggested that BMD is not associated with stress fracture incidence (Crossley et al., 
1999). Consequently, other risk factors, rather than BMD, as mentioned previously, 
may provide a more pivotal role in stress fracture occurrence in male endurance 
runners. These findings, however, have to be interpreted with caution as only seven 
male endurance runners formed the stress fracture group and therefore, further study 
is still required to provide confidence to this conclusion.   
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8.2 Genetic associations 
8.2.1 WNT16 rs3801387 
In Chapter 3, elite runners possessed a lower frequency of AA genotype than the non-
athletes and sub-elite runners. This suggests that possessing the AA genotype is 
beneficial for reaching elite status through protection against stress fracture injury and 
potential training interruption but does not influence initial capacity to reach high-level 
marathon performance. When WNT16 rs3801387 was explored in relation to BMD in 
the endurance runners in Chapter 5, runners who were AA genotype possessed lower 
LSBMD and Z-score, and a tendency to possess LBMD than non-athletes with AA 
genotype. Additionally, a tendency for runners who were AG genotype to possess 
higher LBMD than non-athletes with AG genotype was observed, suggesting a 
differing association between genotype and BMD for the two cohorts. The findings from 
Chapters 3 and 5 (combined with previous research reporting the A allele association 
with lower BMD) could therefore indicate that a lower frequency of WNT16 rs3801387 
AA genotypes exists in elite endurance runners due to associated lower BMD that 
could ultimately influence ability to train and thus performance. Higher BMD in the AG 
genotype runners than non-athletes could also indicate that the G allele is important 
for BMD in male endurance runners via a mechanical loading interaction and a 
subsequent influence on the Wnt signalling pathway. WNT16-mechanical loading 
interaction effects for bone phenotypes have been reported in both mice and humans 
(Wergedal et al., 2015; Mitchell et al., 2016) providing support for this notion. These 
interesting findings regarding WNT16 rs3801387, however, need to be taken with 
caution, as no WNT16 rs3801387 association with stress fracture occurrence was 
observed in a previous study (Varley et al., 2018) or Chapter 7.  
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8.2.2 P2RX7 rs3751143 
The P2RX7 rs3751143 was associated with both high-level endurance runner status 
in Chapter 3 and with BMD in females in Chapter 5 but no association with stress 
fracture was observed in Chapter 7. In Chapter 3, surprisingly, the “risk” (lower BMD- 
associated) C allele was more frequent in the runners than controls. It could be 
proposed that the C allele serves another beneficial purpose via the cardiovascular 
system (through the release of pro-inflammatory mediators and cell proliferation) to aid 
in reaching high-level marathon performance, as discussed in Chapter 3. 
In chapter 5, P2RX7 rs3751143 AA genotypes possessed higher TBMD, LBMD, T-
score and Z-score than AC genotypes (as well as C allele carriers when investigated 
in the dominant analysis model) in the total female cohort, which is agreement with 
previous studies (Wesselius et al., 2013). Tendencies for AA genotype runners to 
possess higher than AC genotypes but CC to possess higher than AC genotypes was 
also observed in the female runners. It therefore could be that a potential CC genotype-
mechanical loading interaction exists but this was not apparent in Chapter 5 and no 
effect of P2RX7 rs3751143 on bone phenotypes was reported following a 12-week 
training programme in academy football players (Varley et al., 2018). The findings 
could also indicate that runners may be able to combat a potential disadvantageous 
genetic predisposition and enhance BMD through mechanical loading as has been 
reported previously in children (Mitchell et al., 2016), which may explain why no 
association with stress fracture was present in Chapter 7. Additionally, P2RX7 SNPs 
have been associated with cortical thickness and CSA (Varley et al., 2018) and thus 
may influence stress fracture incidence through other bone phenotypes, rather than 
BMD. Overall, the AA genotype appears to be associated with BMD females but does 
not seem to affect athlete status or influence stress fracture in high-level endurance 
runners.  
166 
 
8.2.3 COL1A1 rs1800012 
In males, COL1A1 rs1800012 AA genotypes possessed higher LBMD than AC 
genotypes whilst AA genotypes also possessed higher TBMD and LBMD than C allele 
carriers (in the dominant analysis model). This association has been primarily reported 
in females (Jin et al., 2011; Ralston et al., 2006), which may be due to a lack of 
research in male populations. No further significant associations were present in 
Chapter 5 or within any other chapter, which would suggest that COL1A1 rs1800012 
does not appear to be associated with BMD or stress fracture in endurance runners 
as has also been observed previously (Varley et al., 2017) and is not influenced by 
physical activity. Consequently, further research regarding COL1A1 rs1800012 is still 
warranted to explore potential mechanisms and determine if COL1A1 rs1800012 
genotype differences in BMD are population-specific.   
8.2.4 COMT rs4680 
In this thesis, COMT rs4680 was not associated with any particular bone phenotype 
or stress fracture but appeared to influence endurance runner status in Chapter 3. 
Specifically, the elite runners possessed a much lower frequency of the “risk” (lower 
BMD-associated) GG genotype in comparison to the non-athletes. This could suggest 
that elite endurance runners are genetically predisposed to be at less risk of lower 
BMD by possessing at least one “protective” A allele. Furthermore, GA genotypes were 
overrepresented in athletes compared to non-athletes. Although, a COMT rs4680 
genotype-cohort interaction was not observed in Chapter 5, GA genotype runners 
possessed the highest TBMD, LBMD and LSBMD in comparison to GG or AA 
genotypes. Therefore, a larger sample size may increase statistical power and provide 
further evidence for the aforementioned hypothesis.  
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8.2.5 TNFRSF11A rs3018362 
TNFRSF11A rs3018362 was associated with TBMD in males in Chapter 5 as well as 
stress fracture in Chapter 7 before multiple testing correction. In Chapter 5, higher 
TBMD was observed in the GG genotypes compared to GA (as well as compared to 
A allele carriers in dominant analysis model) genotypes in both the total male cohort 
and non-athlete analyses. These findings could suggest that possessing TNFRSF11A 
rs3018362 GG genotype may be important for BMD in non-athlete populations, as 
suggested by GWAS and candidate gene association study (Paternoster et al., 2010; 
Styrkarsdottir et al., 2009). No genotype-dependent differences in TBMD were 
observed in the runner analysis, which could indicate that runners may be able to 
compensate for a potential disadvantageous genetic predisposition through 
completion of large volumes of mechanical loading and subsequently increasing BMD. 
This potential protective mechanism has been observed in children, albeit in different 
variants (Mitchell et al., 2016).  
TNFRSF11A rs3018362 was associated with stress fracture in Chapter 7 before 
multiple testing correction and is therefore in agreement with previous study (Varley et 
al., 2015). Runners who had suffered a stress fracture had over 1.5 times the odds of 
possessing the TNFRSF11A rs3018362 AA genotype in comparison to those who had 
no stress fracture injury history. TNFRSF11A rs3018362, however, was not associated 
with BMD in the runners in Chapter 5. This could indicate that a genotype-dependent 
disruption within a particular phase of the remodelling process following mechanical 
loading, rather than a lower BMD, could aid in aetiology of stress fracture incidence in 
endurance runners. Overall, it is surprising to have not observed more associations 
with TNFRSF11A rs3018362 throughout the thesis, given the functional influence on 
bone and the previous associations with BMD (Paternoster et al., 2010; Styrkarsdottir 
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et al., 2009) although the variant may mediate stress fracture incidence in endurance 
runners.  
8.2.6 BDNF-AS rs6265 
The results from Chapter 5 showed a BDNF-AS rs6265-cohort interaction in the female 
analysis, with runners who were GG (higher BMD-associated) genotype found to 
possess lower LSBMD than non-athletes of the same genotype. It is difficult to 
elucidate why the GG genotype may be disadvantageous for LSBMD in endurance 
runners (due to lack of research on this SNP to date) but it is interesting to note that 
lower LSBMD has been reported in female endurance runners previously, although 
not in this investigation. Overall, BDNF-AS association with BMD has not been 
explored in athletic cohorts and has had relatively little investigation in human 
populations. To the author’s knowledge, this is only the second study to have assessed 
BDNF-AS influence on BMD in humans, and therefore, additional study is still 
warranted in both candidate-gene association and functional studies to provide 
evidence for a potential mechanism and outcome for BMD.  
8.2.7 VDR rs2228570, TNFRSF11B rs4355801 and AXIN1 rs9921222 
VDR rs2228570 has been associated with BMD in a number of populations, as well as 
shown a gene-physical activity interaction and association with stress fracture in 
athletes (Nakamura et al., 2002b; Nakamura et al., 2002a; Varley et al., 2017). 
TNFRSF11B rs4355801 and AXIN1 rs9921222 have also been associated with BMD 
(Estrada et al., 2012) and are involved in bone metabolism pathways. Runners with 
previous stress fracture history had approximately 1.5 times and twice the odds of 
possessing the VDR rs2228570 “risk” T allele and TNFRSF11B rs4355801 “risk” AA 
genotype in comparison to runners with no stress fracture injury history, respectively. 
In addition, the AXIN1 rs9921222 “risk” (lower BMD-associated) T allele and TT 
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genotype were overrepresented in the runners (particularly the more elite) compared 
to the non-athletes before multiple testing correction.  
None of these observations, however reached significance and therefore, are not in 
agreement with the aforementioned previous studies. Differences in the findings could 
be due to the influence of other genes and their associated proteins in their particular 
signalling pathways as discussed in Chapter 5. Additionally, age-associated effects 
could also determine potential genetic associations, for example, in the case of VDR, 
Riggs et al. (1995) proposed that VDR influence on BMD has no effect after the age 
of 70, with differences in BMD only allele-dependent in the pre- and not the post-
menopausal women. Moreover, variability in the sports and the physical attributes of 
the athletes in SFEA cohort, combined with the differences in mechanical loading 
characteristics may also contribute to differences in results. 
8.2.8 LRP5 rs3736228 
No significant findings for LRP5 rs3736228 were observed for any chapter of this 
thesis. It is surprising to observe no associations with LRP5 rs3736228 given the 
functional effect of LRP5 in bone metabolism and findings from previous studies 
(Robinson et al., 2006; Krishnan et al., 2006; Kiel et al., 2007). No association with 
LRP5 rs3736228 and stress fracture in athletes has also been observed previously 
(Varley et al., 2017). Prior studies investigating LRP5 and BMD have primarily been 
conducted in older adults, so it could be hypothesised that LRP5 variants are more 
important for BMD in older people.  
8.2.9 Total genotype score 
Polygenic profiling was conducted to ascertain the combined influence of the 10 
investigated SNPs on athlete status, marathon performance, BMD and stress fracture 
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incidence but no significant findings were observed throughout the thesis. Polygenic 
analysis to examine the potential combined genetic influence on BMD or osteoporotic 
fracture risk has produced exciting outcomes in regards to classifying fracture risk (Lee 
et al., 2014). Only one study so far has completed such analysis in athletic populations 
but initial studies have shown a positive outcome in regards to injury in a small number 
of triathletes (Goodlin et al., 2015). As outlined in Chapter 3, utilising a TGS model 
requires allocating a score based on existing literature and therefore, each SNP 
homozygote associated with higher BMD is given a score of 2, heterozygotes scoring 
1 and the other homozygote given 0, deemed the “risk” genotype. Incorporating this 
approach allows analysis of potential genetic associations in a polygenic, rather than 
singular nature, which can provide a better assessment of a genetic contribution to a 
particular phenotype and is also beneficial given the difficulty of calculating the effect 
size of single or multiple SNPs. Polygenic profiling, however is limited by this method 
of assigning the individual contribution of each SNP as it is extremely likely that the 
contribution of each genotype for each SNP to BMD is variable. Overall, utilising an 
individual SNP approach allows initial assessment of specific associations with a 
phenotype of interest, such as BMD, in comparison to using a TGS method. This will 
provide more convincing evidence regarding the individual variants in question to help 
develop polygenic profiling approaches and allow for more useful estimations of the 
polygenic influence on athlete status, BMD and stress fracture risk in endurance 
runners.  
8.3 Conclusion 
This current thesis investigated 10 BMD-associated genetic variants in a novel 
population (high-level endurance runners) in relation to athlete status, performance, 
BMD and stress fracture incidence. Consequently, this thesis has extended the 
growing body of research suggesting that differences in BMD exist between endurance 
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runners and non-athletes, whilst BMD variability may also influence stress fracture 
incidence. Moreover, there appears to be a genetic influence on BMD and stress 
fracture that may occur via a gene-mechanical loading interaction, whilst BMD-
associated variants may also influence high-level endurance runner status but not 
marathon performance time directly. Athlete status, BMD and stress fracture 
susceptibility, however, are all likely to be highly polygenic as well as determined by 
environmental factors as discussed throughout this thesis.   
8.4 Limitations 
The strength of this thesis was the large homogenous cohort of high-level endurance 
runners that represent one of the largest samples studied to date for genetic 
associations as well as exploration of BMD and stress fracture in such a population. 
Furthermore, it is the first study to investigate the genetic association of BMD-
associated variants with athlete status, performance, BMD and stress fracture 
incidence in a large homogenous high-level endurance runner cohort. Although these 
points represented strengths of the thesis, it is difficult to recruit large numbers of a 
particular population such as high-level endurance runners that meet the criteria 
detailed in Chapter 2. Genetic association studies require large sample sizes to 
ascertain the individual variant effect on a phenotype. However, due to the problems 
associated with measuring physical activity and mechanical loading as discussed in 
Chapter 1, utilising a relatively homogenous population that completes large volumes 
of mechanical loading to examine any potential gene-mechanical loading interaction 
remains a potentially informative approach.  
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8.5 Directions for future research 
Firstly, male runners may possess lower BMD than non-athletes at sites of less loading 
(i.e. lumbar spine), whilst female runners possess higher site-specific BMD (i.e. leg) 
than their non-athlete counterparts. These findings suggest that male runners may be 
at risk for low BMD at the lumbar spine as suggested previously (Hind et al., 2006). 
Despite these associations in Chapter 3, BMD appeared to only influence stress 
fracture incidence in female endurance runners and not males in Chapter 6, 
suggesting that stress fracture is a multi-factorial phenotype influenced by 
biomechanical gait as well as physical and training characteristics. Further research in 
large homogenous cohorts of endurance runners is needed to confirm these findings 
so that preventative strategies can be implemented to avoid potential skeletal health 
issues and stress fracture incidence. Alongside differences in BMD between the 
runners and non-athletes as well as stress fracture groups, a huge variability in BMD 
was observed, highlighting the large genetic component to BMD.  
Genetic analysis revealed the WNT16 rs3801387 and BDNF-AS rs6265 to be 
associated with BMD via a gene-cohort interaction, whilst WNT16 rs3801387 was also 
associated with endurance runner status. Consequently, further research investigating 
WNT16 rs3801387 and BDNF-AS rs6265 in relation to other athletic populations is 
warranted to elucidate the exact contribution of WNT16 rs3801387 to these specific 
phenotypes. P2RX7 rs3751143 and COL1A1 rs1800012 were associated with BMD in 
females and males respectively, providing further evidence for their influence on bone, 
whilst P2RX7 rs3751143 was also associated with athlete status, although this may 
be via another biological mechanism rather than enhanced BMD. It would be 
interesting to continue additional research of these two variants across different 
populations to determine if there are particular time points across the human lifespan 
or specific cohorts where they may be particularly influential on BMD. COMT rs4680 
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was associated with endurance runner status in Chapter 3 and has demonstrated 
potential gene-physical activity interactions previously, and thus, further study in 
athletic populations is suggested. It would be particularly interesting to understand if 
the type of loading that is of greater magnitude (higher peak force/strain 
rate/multidirectional), as seen in sports other than endurance running, may affect 
potential gene-mechanical loading interactions. No SNPs were associated with stress 
fracture, although both VDR rs2228570 and TNFRSF11B rs4355801 demonstrated 
increased odds ratios when investigating genetic association with stress fracture. Both 
these variants have been associated with stress fracture in athletic populations 
previously. Functional studies that can determine the possible genetic pathogenesis 
with stress fracture incidence would, therefore, be a valuable future research focus. 
Although age, running distance volume (and menstrual status) were collected as part 
of this investigation, these were only incorporated to provide descriptive and training 
characteristics of the population. Menstrual status influence on BMD was explored in 
Chapter 1 and no differences were observed between those who were deemed 
eumenorrheic in comparison to those who were termed as amenorrheic. Additionally, 
diluting the groups to smaller sample sizes based on age, running distance volume or 
menstrual status to assess genetic associations would potentially reduce the 
confidence or power of these potential associations. In future, it would be interesting 
to use this type of information (training characteristics, age and menstrual status) to 
explore any potential genetic associations when larger sample sizes have been 
gathered. Such action would allow further exploration into the importance of genetics 
in comparison to menstrual cycle, for example. Additionally, specific research routes 
of interest could include whether certain variants are important during particular 
periods of BMD accrual or loss, or for sports with particular mechanical loading 
patterns.  
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Department of Exercise and Sport Science 
 
Informed Consent Form 
   
(Both the investigator and  
participant should retain a copy of this form) 
 
Name of Participant:     
 
Principal Investigator:  Dr Alun Williams 
 
Project Title: The Genetic Profile of Elite Athletes 
 
Ethics Committee Approval Number: 12.07.11 (i) 
Participant Statement 
I have read the participant information sheet for this study and understand what is 
involved in taking part. Any questions I have about the study, or my participation in 
it, have been answered to my satisfaction. I understand that I do not have to take 
part and that I may decide to withdraw from the study at any point without giving a 
reason. Any concerns I have raised regarding this study have been answered and 
I understand that any further concerns that arise during the time of the study will 
be addressed by the investigator. I therefore agree to participate in the study. 
 
It has been made clear to me that, should I feel that my rights are being infringed 
or that my interests are otherwise being ignored, neglected or denied, I should 
inform the The University Secretary and Clerk to the Board of Governors, 
Manchester Metropolitan University, Ormond Building, Manchester, M15 6BX. 
Tel: 0161 247 3400 who will undertake to investigate my complaint. 
 
 
Signed (Participant)    Date 
 
 
Signed (Investigator)   Date 
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The Genetic Profile of Elite Athletes: Questionnaire 
 
Thank you for your interest in our research study. Please answer the following questions about your 
ethnic origin, athlete status, and your training, diet and injury history.  
 
SECTION A: Questions concerning your ethnic background.  
 
Participant ID code: _________________________ Date of birth: ___________________ 
Gender (please tick): Male  / Female  Height (in metres): _______________ 
Nationality (as on passport, e.g. British): _____________ Body weight (in kg): _____________ 
What is your ethnic group? Please tick the appropriate box. 
A) White: English  Scottish  Welsh  N. Irish  Irish  
 French  South African  New Zealander  Australian  Other  
If other, please state here: ________________________________ 
B) Mixed: White & Black 
British  
White & Black 
Caribbean  
White & Black 
African  
White & 
Asian  
White & Latin 
American  
Other 
 
If other, please state here: ________________________________ 
C) Asian: British  Indian  Pakistani  Chinese  Japanese  Other  
If other, please state here: ________________________________ 
D) Black: British  Caribbean  African  Other  
If other, please state here: _____________________________________________________ 
E) Latin American:  Brazilian  Argentinian  Mexican  Colombian  Other  
If other, please state here: _____________________________________________________ 
F) Pacific Islands:  Samoa  Fiji  Tonga  PNG  Other  
If other, please state here: _____________________________________________________ 
G) Other ethnic background:  Please state here: _________________________________ 
I do not wish to state my ethnic origin   
Using the ethnic groups above as a guide, please tell us the ethnic origin of your:  
Mother: ______________________________________________________ Don’t know:  
Father: ______________________________________________________ Don’t know:  
Mother’s mother: _____________________________________________ Don’t know:   
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Mother’s father: ______________________________________________ Don’t know:   
Father’s mother: ______________________________________________ Don’t know:   
Father’s father: _______________________________________________ Don’t know:   
 
Blood donation 
We would like to take a small (5 mL) blood sample from a vein in your arm. Before doing so, please 
answer the following safety questions.  
1. Have you ever been infected with a blood-borne disease? _______ Yes  No  
2.  Are you anaemic or receiving treatment for anaemia or iron deficiency? __ Yes  No  
 
If you have answered YES to any of these questions and/or you would prefer not to provide a blood 
sample, a saliva sample may be provided instead. 
 
PLEASE TURN OVER 
178 
 
SECTION B: Questions concerning your athlete status.  
 
1. What is/was your main playing sporting discipline/event?  
______________________________________________________________________ 
______________________________________________________________________ 
 
2. 
 
Please state which event(s) you participate(d) in and your preferred event? 
______________________________________________________________________  
______________________________________________________________________ 
______________________________________________________________________ 
 
3.  
 
What is your official PB(s) for these events? 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
   
4. Please state the highest level that you have competed: i.e. international (represented your 
country); national (represented your region/county/club in a national league/competition); 
regional (represented your club/town/university in a local/area league/competition)? 
_____________________________________________________________________________
_____________________________________________________________________________
________________________________________________________ 
 
Please state the name of the highest standard league/competition in which you have competed, 
your placing in that competition and the date(s) you competed at that level: 
_____________________________________________________________________________
_____________________________________________________________________________
________________________________________________________ 
 
5. Have you any other athletic achievements? If so please state highest achievements and include 
relevant details: 
_____________________________________________________________________________
_______________________________________________________________ 
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SECTION C: Questions concerning your training. 
 
 
1.  
 
Typically, how many hours do you train a week?  
 
______________________________________________________________________ 
  
 
2.  
 
Typically, what is your average running distance per week?  
 
______________________________________________________________________ 
  
 
 
PLEASE TURN OVER 
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SECTION D: Questions concerning your injury history. 
 
1. Ignore this, please move to question 2. 
 
2. 
 
Have you ever fractured a bone?  
 
Yes  
 
No  
 
3.  
 
If Yes, please give details of the bone(s) 
you broke and at what age you broke 
them. 
 
Bone 
e.g. upper leg/femur 
 
 
 
 
 
 
 
Age 
e.g. 20 
4.  Have you ever been told that you have 
had a STRESS FRACTURE (or micro-
fracture) injury? 
Yes  No  
 
 
5.  
 
 
If Yes, please give details of the 
bone/bones where the stress fracture 
occurred and at what age the fracture 
occurred. 
 
 
Bone 
e.g. shin/tibia 
 
 
 
 
 
 
 
Age 
e.g. 20 
 
6.  
 
If Yes, was it confirmed by a bone scan, 
e.g. MRI, X-ray, CT scan?  
 
Yes  
 
No  
 
7.  
 
Have you ever suffered from prolonged 
shin pain during exercise that does not 
go away for weeks?  
 
Yes  
 
No  
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8.  Does anyone in your close family suffer 
from OSTEOPOROSIS or FRAGILE bones? 
Yes  No  Don’t know  
 
9.  
 
Has anyone in your close family ever had 
a STRESS FRACTURE?  
 
Yes  
 
No  
 
Don’t know  
 
 
 
 
 
 
 
PLEASE TURN OVER 
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10. Have you ever ruptured your tendon? Yes  If yes, which tendon? 
e.g. Achilles 
No  
  
 
 
 
  
 
11. 
 
If Yes, please give details of how this 
occurred and at what age. 
 
 
 
 
 
Activity 
e.g. sprinting 
 
 
 
 
Age 
e.g. 20 
 
12. 
 
Have you ever suffered from prolonged 
tendon pain during exercise that does 
not go away for weeks? 
 
 
Yes  
 
If yes, which tendon? 
e.g. Achilles 
 
No  
 
 
 
13. 
 
 
 
Have you ever been told that you have 
had tendonitis?  
 
 
 
Yes  
 
 
 
If yes, which tendon? 
e.g. Achilles 
 
 
 
 
No  
 
 
 
14. 
 
 
 
If Yes, was it confirmed by a scan, e.g. 
MRI?  
 
 
 
Yes  
 
 
 
No  
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15. Does anyone in your close family suffer 
from tendonitis? 
Yes  No  Don’t know  
  If yes, which tendon? 
e.g. Achilles 
 
 
 
 
 
 
16. 
 
 
Has anyone in your close family ever 
ruptured a tendon? 
 
 
Yes  
 
 
No  
 
 
Don’t know  
  If yes, which tendon? 
e.g. Achilles 
 
 
 
 
 
 
PLEASE TURN OVER 
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17. 
 
Have you ever fully ruptured a 
ligament? 
 
 
 
 
 
 
 
Yes  
 
If yes, which ligament? 
e.g. ACL 
 
No  
 
18. 
 
If Yes, please give details of how this 
occurred and at what age. 
Contact 
e.g. tackled 
from the side 
 
 
 
 
 
 
Non-contact 
e.g. landing from 
a jump 
 
Age 
e.g. 20 
 
19. 
 
Have you ever been told that you have 
had a ligament sprain/tear?  
 
Yes  
If yes, which 
ligament? 
e.g. ACL 
 
 
 
 
 
 
 
No  
 
20. 
 
If Yes, was it confirmed by a scan, e.g. 
MRI?  
 
 
 
Yes  
 
No  
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21. Has anyone in your close family ever 
ruptured a ligament? 
Yes  No  Don’t know  
  If yes, which ligament? 
e.g. ACL 
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Genetics of Bone Mineral Density and Stress Fracture Incidence 
 
Menstrual History Questionnaire 
To help complete our research in understanding the possible genetic effects on bone 
mineral density, could you please answer the following questions. Please be assured that 
your answers will remain confidential.  
 
1. At what age approximately did you start your menstrual cycle? _________ 
 
2. When approximately was your last period? __________ 
 
3. How often have you had menstrual periods in the last year? (Please circle) 
Once every 20 days or less  
Every 21 – 27 days                            Every 28 – 35 days 
Every 36 – 50 days                            Every 3 – 4 months 
Very irregular (i.e. sometimes monthly, sometimes skip several months) 
Other (Please specify) ________________________________________ 
 
4. Number of menstrual cycles in the last 12 months _______   
 
5. My periods usually last _______ days  
 
6. What is the longest time you have gone without having a menstrual period? _________ 
 
7. Have you ever had irregular menstruation? (i.e. spotting between periods/missed 
periods) YES/NO  
If yes, approximately on how many occasions has this been? 
__________________________ 
 
8. Are you on any form of contraception? (Please delete as appropriate) YES/NO 
If yes, please state what type of contraception, if known: _____________________ 
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9. Have you been through, or are you are going through, the menopause? If yes, what age 
did this occur? ________ 
 
10. Have you ever been pregnant/had children? If yes, how many times/children? 
____________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
189 
 
 
Appendix 2: 
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Department of Exercise and Sport Science 
 
Informed Consent Form 
   
(Both the investigator and  
participant should retain a copy of this form) 
 
Name of Participant:     
 
Principal Investigator:  Dr Alun Williams 
 
Project Title: The Genetic Profile of Elite Athletes 
 
Ethics Committee Approval Number: 12.07.11 (i) 
Participant Statement 
I have read the participant information sheet for this study and understand what is 
involved in taking part. Any questions I have about the study, or my participation in 
it, have been answered to my satisfaction. I understand that I do not have to take 
part and that I may decide to withdraw from the study at any point without giving a 
reason. Any concerns I have raised regarding this study have been answered and 
I understand that any further concerns that arise during the time of the study will 
be addressed by the investigator. I therefore agree to participate in the study. 
 
It has been made clear to me that, should I feel that my rights are being infringed 
or that my interests are otherwise being ignored, neglected or denied, I should 
inform the The University Secretary and Clerk to the Board of Governors, 
Manchester Metropolitan University, Ormond Building, Manchester, M15 6BX. 
Tel: 0161 247 3400 who will undertake to investigate my complaint. 
 
 
Signed (Participant)    Date 
 
 
Signed (Investigator)   Date 
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The Genetic Profile of Elite Athletes Questionnaire: 
Physical Activity & General Health 
 
Thank you for participating in this research study. We would like you to answer a few questions 
concerning your general health and physical activity level. Please answer the following 
questions as honestly as you can. 
 
Participant ID code: _________________________ Date of birth: ___________________ 
Gender (please tick): Male / Female Height: ________________________ 
Nationality (as on passport, e.g. British): _________ Body weight: ___________________  
 
What is your ethnic group? Please tick the appropriate box. 
 
A) White: English Scottish Welsh  N. Irish  Irish 
 French South African New Zealander  Australian Other 
If other, please state here: ________________________________     
B) Mixed: White & Black   White & Black White & Black White & White & Latin     Other 
 British Caribbean African Asian American 
If other, please state here: ________________________________     
C) Asian: British Indian Pakistani Chinese Japanese Other 
If other, please state here: ________________________________     
D) Black: British Caribbean  African  Other 
If other, please state here: _____________________________________________________ 
E) Latin American: Brazilian Argentinian Mexican Colombian Other 
If other, please state here: _____________________________________________________ 
F) Pacific Islands: Samoa Fiji  Tonga  PNG  Other  
If other, please state here: _____________________________________________________ 
 
G) Other ethnic background:  Please state here: _________________________________  
 
I do not wish to state my ethnic origin    
Using the ethnic groups above as a guide, please tell us the ethnic origin of your: 
 
Mother: ______________________________________________________ Do not know: 
Father: ______________________________________________________ Do not know: 
Mother’s mother: _____________________________________________ Do not know: 
Mother’s father: ______________________________________________ Do not know: 
Father’s mother: ______________________________________________ Do not know: 
Father’s father: _______________________________________________ Do not know:  
 
Blood donation 
We would like to take a small (10 mL) blood sample from a vein in your arm. Before doing so, please  
answer the following safety questions.   
1. Have you ever been infected with a blood-borne disease? _____________ Yes No 
2. Are you anaemic or receiving treatment for anaemia or iron deficiency? __ Yes No  
 
If you have answered YES to any of these questions and/or you would prefer not to provide a blood 
sample, a saliva sample may be provided instead. 
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Your general health 
1. At present, do you have any health problem for which you are: 
a) on medication, prescribed (by a doctor) or otherwise ____________ Yes No 
b) attending (visiting) your doctor _____________________________ Yes No 
c) on a hospital waiting list ___________________________________ Yes No  
 
2. Have you ever had any of the following? 
a) Your doctor advised you not to take vigorous exercise ___________ Yes No 
b) Pain in your chest when you undertake physical activity? _________ Yes No  
c) Central Nervous System disease, such as Parkinson, Alzheimer, 
Convulsions/epilepsy _____________________________________   Yes No  
d) Have you any history of chest problems, such as bronchitis, asthma  
 or wheezy chest __________________________________________ Yes No 
e) Major illness, such as viral hepatitis, cancer ___________________ Yes No 
f) Eczema ________________________________________________ Yes No 
g) Diabetes _______________________________________________ Yes No 
h) High blood pressure ______________________________________ Yes No 
i) A limb fracture __________________________________________ Yes No  
j) Blood disorder, such as clotting problems, thrombosis, aneurysm, 
 embolus) _______________________________________________ Yes No 
k) Head injury _____________________________________________ Yes No 
l) Digestive problems _______________________________________ Yes No  
m) Heart problems, such as heart attack, valve disease, palpitations, 
angina _________________________________________________ Yes No 
n)Problems with bones, such as osteoporosis or osteoarthritis _______  Yes No  
o) Problems with joints, such as rheumatoid arthritis, any persistent 
pain, or any surgery on your joints ___________________________ Yes No 
p)Back problems __________________________________________ Yes No  
q) Disturbance of balance/co-ordination, such as dizziness or balance- 
 system dysfunction _______________________________________ Yes No 
r) Numbness in hands or feet _________________________________ Yes No 
s) Disturbance of vision _____________________________________ Yes No 
t) Physical limitations, such as visual, hearing, walking problems ____ Yes No 
u) Thyroid problems, e.g. rapid loss or gain of weight ______________ Yes No 
v) Kidney or liver problems __________________________________ Yes No  
w) A severe allergic reaction, e.g. swelling, breathing difficulties in  
 response to an external stimulus _____________________________ Yes No 
x)Emotional or psychiatric problems ___________________________ Yes No 
y) Any other illness or condition that affects your general health or   
 interferes with your daily activities __________________________ Yes No  
 
4. If you answered YES to any of the questions above, please describe the details briefly 
below or to the investigator if you wish.  
______________________________________________________________________ 
______________________________________________________________________ 
 
5. Are  you  currently involved  in  any other  research  studies  at  the 
University or elsewhere? Yes No 
If YES please provide details of the study:    
______________________________________________________________________ 
______________________________________________________________________ 
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Habitual physical activity 
 
1. What is your main occupation? _____________________________________________ 
 
2. At work I sit Never Seldom Sometimes Often Always 
3. At work I stand Never Seldom Sometimes Often Always 
4. At work I walk Never Seldom Sometimes Often Always  
5. At work I lift heavy 
loads Never Seldom Sometimes Often Always  
6. After work I am 
 tired Never Seldom Sometimes Often Always 
7. At work I sweat Never Seldom Sometimes Often Always  
8. In comparison with others my own age I think my work is:  
 Much heavier Heavier As heavy Lighter Much lighter 
9. Do you play sport or exercise?    Yes No    
 If YES, which sport do you play most frequently? ______________________________ 
 How many hours Less than 1 1 to 2 2 to 3 3 to 4    More than 
 per week?     4 
 Time per session      
 (hours) ½ 1 ½ 2 ½ 3 ½ 4 ½ 
 How many months Less than 1 1 to 3 4 to 6 7 to 9    More than 
 per year?     9 
 What proportion A few hours A few 2 weeks 3 weeks Most of the 
 of the month?     days   month 
 If you do a second sport (or exercise class), which is it? _________________________ 
 How many hours Less than 1 1 to 2 2 to 3 3 to 4    More than 
 per week?     4 
 Time per session      
 (hours) ½ 1 ½ 2 ½ 3 ½ 4 ½ 
 How many months Less than 1 1 to 3 4 to 6 7 to 9    More than 
 per year?     9 
 What proportion A few hours A few 2 weeks 3 weeks Most of the 
 of the month?     days   month  
10. Compared with others of my own age I think my physical activity during leisure time is: 
 Much more More The same Less  Much less 
11. During leisure Very      
 time I sweat Often Often Sometimes  Seldom Never 
12. During leisure       
 time I play sport Never Seldom Sometimes  Often Always 
13. During leisure       
 time I watch TV Never Seldom Sometimes  Often Always 
14. During leisure       
 time I walk Never Seldom Sometimes  Often Always  
15. During leisure 
time I cycle Never Seldom Sometimes Often Always  
16. How many minutes do you walk per day to and from work, school and/or shopping? 
 
Less than 5 5 to 15 16 to 30 31 to 45 More than 45  
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Thank you for completing this questionnaire. All information will be kept strictly 
confidential. 
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Table 5.1: Bone phenotype (TBMD, LBMD, LSBMD, T-score and Z-score) means 
(SD) for each genotype of the 10 investigated variants in males with the associated P- 
values for the additive model genotype-cohort interaction (G*C) and genetic 
association analysis for the main effect of genotype within the total cohort (SNP). N/A 
and (N/A) indicates that no or only one individual possessed the specific genotype for 
that SNP.  
SNP Runners Non-athletes P - Value 
TBMD LBMD LSBMD T-S Z-S TBMD LBMD LSBMD T-S Z-S G*C SNP 
AXIN1 
rs9921222 
CC 
 
CT 
 
TT 
 
 
1.271 
(0.061) 
1.303 
(0.100) 
1.249 
(0.092) 
 
 
1.465 
(0.099) 
1.492 
(0.106) 
1.448 
(0.124) 
 
 
1.039 
(0.104) 
1.104 
(0.152) 
1.081 
(0.180) 
 
 
0.73 
(0.57) 
1.00 
(0.92) 
0.50 
(0.92) 
 
 
0.68 
(0.55) 
0.98 
(0.89) 
0.49 
(0.89) 
 
 
1.335 
(0.114) 
1.316 
(0.127) 
1.292 
(0.089) 
 
 
1.514 
(0.124) 
1.464 
(0.118) 
1.462 
(0.164) 
 
 
1.262 
(0.206) 
1.182 
(0.183) 
1.132 
(0.134) 
 
 
1.30 
(1.00) 
1.21 
(1.20) 
0.90 
(0.87) 
 
 
1.30 
(0.92) 
1.15 
(1.09) 
0.92 
(0.66) 
 
 
0.619 
0.459 
0.189 
0.761 
0.602 
 
 
0.339 
0.633 
0.628 
0.266 
0.297 
BDNF-AS 
rs6265 
GG 
 
GA 
 
AA 
 
 
1.289 
(0.095) 
1.281 
(0.098) 
1.264 
(N/A) 
 
 
1.472 
(0.108) 
1.487 
(0.115) 
1.468 
(N/A) 
 
 
1.095 
(0.144) 
1.077 
(0.169) 
1.066 
(N/A) 
 
 
0.87 
(0.88) 
0.80 
(0.93) 
0.70 
(N/A) 
 
 
0.84 
(0.84) 
0.79 
(0.92) 
0.60 
(N/A) 
 
 
1.319 
(0.901) 
1.301 
(0.156) 
1.400 
(N/A) 
 
 
1.494 
(0.110) 
1.434 
(0.164) 
1.596 
(N/A) 
 
 
1.203 
(0.168) 
1.156 
(0.211) 
1.300 
(N/A) 
 
 
1.24 
(0.87) 
0.94 
(1.50) 
1.90 
(N/A) 
 
 
1.16 
(0.76) 
1.01 
(1.27) 
2.00 
(N/A) 
 
 
0.757 
0.278 
0.792 
0.711 
0.669 
 
 
0.791 
0.572 
0.638 
0.632 
0.772 
COL1A1 
rs1800012 
AA 
 
AC 
 
CC 
 
 
1.301 
(0.085) 
1.259 
(0.109) 
1.226 
(N/A) 
 
 
1.501 
(0.100) 
1.434 
(0.117) 
1.438 
(N/A) 
 
 
1.092 
(0.139) 
1.076 
(0.180) 
1.151 
(N/A) 
 
 
0.99 
(0.79) 
0.59 
(1.03) 
0.30 
(N/A) 
 
 
0.97 
(0.77) 
0.57 
(0.97) 
0.20 
(N/A) 
 
 
1.328 
(0.107) 
1.255 
(0.133) 
1.360 
(0.093) 
 
 
1.496 
(0.118) 
1.406 
(0.165) 
1.485 
(0.126) 
 
 
1.200 
(0.186) 
1.106 
(0.137) 
1.360 
(0.149) 
 
 
1.31 
(0.97) 
0.52 
(1.27) 
1.53 
(0.81) 
 
 
1.24 
(0.89) 
0.65 
(1.11) 
1.50 
(0.70) 
 
 
0.668 
0.178 
0.711 
0.775 
0.630 
 
 
0.067 
0.021* 
0.165 
0.033* 
0.066 
COMT 
rs4680 
GG 
 
 
 
1.300 
(0.093) 
 
 
1.516 
(0.111) 
 
 
1.080 
(0.119) 
 
 
0.98 
(0.87) 
 
 
0.96 
(0.84) 
 
 
1.294 
(0.101) 
 
 
1.461 
(0.130) 
 
 
1.127 
(0.223) 
 
 
0.91 
(0.98) 
 
 
0.97 
(0.85) 
 
 
0.432 
0.581 
 
 
0.687 
0.423 
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GA 
 
AA 
1.304 
(0.091) 
1.257 
(0.096) 
1.489 
(0.104) 
1.444 
(0.108) 
1.087 
(0.116) 
1.092 
(0.200) 
1.02 
(0.82) 
0.58 
(0.93) 
0.99 
(0.79) 
0.55 
(0.89) 
1.318 
(0.101) 
1.323 
(0.150) 
1.488 
(0.108) 
1.463 
(0.178) 
1.201 
(0.161) 
1.211 
(0.193) 
1.25 
(0.95) 
1.14 
(1.36) 
1.15 
(0.86) 
1.20 
(1.21) 
0.735 
0.536 
0.393 
0.596 
0.483 
0.650 
LRP5 
rs3766228 
GG 
 
GA 
 
AA 
 
 
1.294 
(0.097) 
1.274 
(0.093) 
1.245 
(N/A) 
 
 
1.480 
(0.111) 
1.478 
(0.109) 
1.397 
(N/A) 
 
 
1.094 
(0.157) 
1.087 
(0.144) 
0.940 
(N/A) 
 
 
0.91 
(0.88) 
0.74 
(0.91) 
0.50 
(N/A) 
 
 
0.88 
(0.85) 
0.72 
(0.88) 
0.50 
(N/A) 
 
 
1.330 
(0.114) 
1.281 
(0.110) 
N/A 
 
 
1.491 
(0.142) 
1.442 
(0.101) 
N/A 
 
 
1.211 
(0.199) 
1.141 
(0.128) 
N/A 
 
 
1.32 
(1.05) 
0.79 
(1.04) 
N/A 
 
 
1.27 
(0.93) 
0.82 
(0.96) 
N/A 
 
 
0.521 
0.366 
0.391 
0.397 
0.470 
 
 
0.301 
0.493 
0.381 
0.250 
0.281 
P2RX7 
rs3751143 
AA 
 
AC 
 
CC 
 
 
 
1.289 
(0.078) 
1.267 
(0.128) 
1.408 
(N/A) 
 
 
1.479 
(0.104) 
1.462 
(0.122) 
1.621 
(N/A) 
 
 
1.092 
(0.143) 
1.076 
(0.181) 
1.100 
(N/A) 
 
 
0.88 
(0.72) 
0.64 
(1.21) 
2.00 
(N/A) 
 
 
0.86 
(0.71) 
0.61 
(1.14) 
1.90 
(N/A) 
 
 
1.299 
(0.103) 
1.342 
(0.140) 
1.389 
(0.048) 
 
 
1.458 
(0.125) 
1.501 
(0.147) 
1.602 
(0.044) 
 
 
1.174 
(0.189) 
1.199 
(0.163) 
1.383 
(0.086) 
 
 
1.05 
(0.99) 
1.31 
(1.27) 
1.85 
(0.35) 
 
 
1.01 
(0.87) 
1.30 
(1.15) 
1.85 
(0.21) 
 
 
0.390 
0.556 
0.583 
0.499 
0.411 
 
 
0.275 
0.168 
0.592 
0.298 
0.253 
TNFRSF11A 
rs3018362 
GG 
 
GA 
 
 
AA 
 
 
1.297 
(0.107) 
1.272 
(0.076)
1.249 
(0.027) 
 
 
1.477 
(0.128) 
1.480 
(0.077) 
1.464 
(0.041) 
 
 
1.110 
(0.166) 
1.063 
(0.126) 
1.013 
(0.102) 
 
 
0.94 
(0.99) 
0.73 
(0.74) 
0.53 
(0.25) 
 
 
0.90 
(0.93) 
0.73 
(0.77) 
0.47 
(0.21) 
 
 
1.358 
(0.130) 
1.270 
(0.092) 
1.336 
(0.074) 
 
 
1.532 
(0.130) 
1.415 
(0.121) 
1.519 
(0.072) 
 
 
1.222 
(0.195) 
1.156 
(0.126) 
1.204 
(0.102) 
 
 
1.48 
(1.14) 
0.82 
(1.00) 
1.32 
(0.67) 
 
 
1.45 
(0.94) 
0.78 
(0.77) 
1.37 
(0.21) 
 
 
0.286 
0.057 
0.753 
0.468 
0.312 
 
 
0.043* 
0.082 
0.274 
0.128 
0.096 
TNFRSF11B 
rs4355801 
AA 
 
AG 
 
GG 
 
 
1.294 
(0.081) 
1.276 
(0.107) 
1.294 
(0.086) 
 
 
1.487 
(0.116) 
1.471 
(0.114) 
1.479 
(0.123) 
 
 
1.065 
(0.097) 
1.096 
(0.194) 
1.102 
(0.094) 
 
 
0.94 
(0.75) 
0.75 
(1.00) 
0.92 
(0.80) 
 
 
0.89 
(0.78) 
0.73 
(0.95) 
0.92 
(0.76) 
 
 
1.315 
(0.111) 
1.310 
(0.115) 
1.320 
(0.123) 
 
 
1.473 
(0.110) 
1.487 
(0.135) 
1.466 
(0.151) 
 
 
1.199 
(0.183) 
1.162 
(0.185) 
1.213 
(0.182) 
 
 
1.29 
(1.07) 
1.07 
(1.04) 
1.14 
(1.15) 
 
 
1.15 
(0.89) 
1.08 
(1.00) 
1.17 
(0.99) 
 
 
0.966 
0.844 
0.688 
0.965 
0.968 
 
 
0.850 
0.968 
0.797 
0.686 
0.798 
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VDR 
rs2228570 
CC 
 
CT 
 
TT 
 
 
1.296 
(0.088) 
1.269 
(0.104) 
1.299 
(0.090) 
 
 
1.477 
(0.097) 
1.462 
(0.123) 
1.512 
(0.104) 
 
 
1.086 
(0.136) 
1.070 
(0.140) 
1.131 
(0.210) 
 
 
0.94 
(0.79) 
0.68 
(1.00) 
0.99 
(0.84) 
 
 
0.91 
(0.77) 
0.66 
(0.95) 
0.96 
(0.81) 
 
 
1.304 
(0.115) 
1.319 
(0.110) 
1.328 
(0.148) 
 
 
1.462 
(0.148) 
1.483 
(0.120) 
1.494 
(0.144) 
 
 
1.202 
(0.190) 
1.177 
(0.180) 
1.204 
(0.191) 
 
 
1.00 
(1.08) 
1.25 
(1.04) 
1.20 
(1.29) 
 
 
1.01 
(0.94) 
1.20 
(0.94) 
1.17 
(1.19) 
 
 
0.682 
0.771 
0.923 
0.506 
0.538 
 
 
0.843 
0.675 
0.689 
0.909 
0.893 
WNT16 
rs3801387 
AA 
 
AG 
 
GG 
 
 
1.266 
(0.088) 
1.320 
(0.103) 
1.270 
(0.066) 
 
 
1.448 
(0.107) 
1.519 
(0.106) 
1.492 
(0.084) 
 
 
1.043 
(0.128) 
1.166 
(0.172) 
1.053 
(0.037) 
 
 
0.65 
(0.84) 
1.17 
(0.94) 
0.73 
(0.61) 
 
 
0.62 
(0.81) 
1.14 
(0.89) 
0.70 
(0.62) 
 
 
1.342 
(0.123) 
1.287 
(0.101) 
1.277 
(0.979) 
 
 
1.507 
(0.122) 
1.443 
(0.136) 
1.442 
(0.161) 
 
 
1.217 
(0.206) 
1.157 
(0.152) 
1.171 
(0.149) 
 
 
1.34 
(1.09) 
0.85 
(0.97) 
1.48 
(1.30) 
 
 
1.35 
(1.00) 
0.90 
(0.87) 
0.80 
(0.81) 
 
 
0.057 
0.032* 
0.042* 
0.051 
0.045* 
 
 
0.730 
0.952 
0.592 
0.961 
0.731 
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Table 5.2: Bone phenotype (TBMD, LBMD, LSBMD, T-score and Z-score) mean (SD) 
for each genotype of the 10 investigated variants in females with the associated P 
values for the additive model genotype-cohort interaction (G*C) and genetic 
association analysis for the main effect of genotype within the total cohort (SNP). N/A 
and (N/A) indicates that no or only one individual possessed the specific genotype for 
that SNP. 
SNP Runners Non-athletes P - Value 
TBMD LBMD LSBMD T-S Z-S TBMD LBMD LSBMD T-S Z-S G*C SNP 
AXIN1 
rs9921222 
CC 
 
CT 
 
TT 
 
 
1.200 
(0.098) 
1.196 
(0.718) 
1.223 
(0.091) 
 
 
1.286 
(0.103) 
1.290 
(0.100) 
1.273 
(0.095) 
 
 
1.147 
(0.174) 
1.093 
(0.123) 
1.132 
(0.117) 
 
 
1.10 
(1.15) 
1.08 
(0.85) 
1.40 
(1.09) 
 
 
1.05 
(1.03) 
0.99 
(0.66) 
1.15 
(0.96) 
 
 
1.216 
(0.114) 
1.177 
(0.107) 
1.192 
(0.103) 
 
 
1.249 
(0.138) 
1.218 
(0.110) 
1.262 
(0.127) 
 
 
1.169 
(0.146) 
1.186 
(0.199) 
1.153 
(0.176) 
 
 
1.28 
(1.33) 
0.83 
(1.27) 
1.03 
(1.21) 
 
 
1.40 
(1.17) 
0.79 
(1.12) 
1.05 
(1.12) 
 
 
0.586 
0.549 
0.529 
0.577 
0.423 
 
 
0.534 
0.822 
0.859 
0.555 
0.299 
BDNF-AS 
rs6265 
GG 
 
GA 
 
AA 
 
 
1.193 
(0.095) 
1.218 
(0.082) 
1.227 
(0.035) 
 
 
1.276 
(0.101) 
1.305 
(0.103) 
1.282 
(0.057) 
 
 
1.114 
(0.140) 
1.153 
(0.165) 
1.135 
(0.183) 
 
 
1.04 
(1.11) 
1.34 
(0.98) 
1.45 
(0.42) 
 
 
0.97 
(0.99) 
1.18 
(0.77) 
1.30 
(0.29) 
 
 
1.206 
(0.113) 
1.166 
(0.097) 
1.158 
(0.137) 
 
 
1.253 
(0.128) 
1.204 
(0.107) 
1.185 
(0.042) 
 
 
1.210 
(0.180) 
1.124 
(0.160) 
1.031 
(0.205) 
 
 
1.17 
(1.33) 
0.72 
(1.14) 
0.60 
(1.70) 
 
 
1.19 
(1.16) 
0.73 
(1.08) 
0.60 
(1.70) 
 
 
0.219 
0.189 
0.091 
0.212 
0.199 
 
 
0.919 
0.771 
0.480 
0.945 
0.817 
COL1A1 
rs1800012 
AA 
 
AC 
 
CC 
 
 
1.191 
(0.092) 
1.240 
(0.066) 
N/A  
 
 
1.282 
(0.102) 
1.292 
(0.092) 
N/A 
 
 
1.117 
(0.154) 
1.158 
(0.130) 
N/A 
 
 
1.01 
(1.08) 
1.60 
(0.75) 
N/A 
 
 
0.95 
(0.94) 
1.37 
(0.66) 
N/A 
 
 
1.198 
(0.110) 
1.177 
(0.106) 
N/A 
 
 
1.239 
(0.121) 
1.226 
(0.124) 
N/A 
 
 
1.174 
(0.170) 
1.178 
(0.198) 
N/A 
 
 
1.07 
(1.30) 
0.86 
(1.24) 
N/A 
 
 
1.08 
(1.18) 
0.89 
(1.10) 
N/A 
 
 
0.094 
0.620 
0.583 
0.093 
0.154 
 
 
0.488 
0.934 
0.510 
0.437 
0.590 
 
COMT 
rs4680 
GG 
 
 
 
 
1.218 
(0.101) 
 
 
 
1.289 
(0.108) 
 
 
 
1.135 
(0.183) 
 
 
 
1.33 
(1.20) 
 
 
 
1.12 
(1.00) 
 
 
 
1.214 
(0.122) 
 
 
 
1.251 
(0.136) 
 
 
 
1.211 
(0.145) 
 
 
 
1.27 
(1.45) 
 
 
 
1.33 
(1.23) 
 
 
 
0.936 
0.871 
 
 
 
0.427 
0.716 
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GA 
 
AA 
1.196 
(0.093) 
1.198 
(0.069) 
1.281 
(0.104) 
1.285 
(0.089) 
1.130 
(0.155) 
1.115 
(0.109) 
1.07 
(1.11) 
1.11 
(0.80) 
1.03 
(0.98) 
1.03 
(0.72) 
1.178 
(0.106) 
1.192 
(0.102) 
1.220 
(0.111) 
1.246 
(0.128) 
1.168 
(0.184) 
1.556 
(0.201) 
0.84 
(1.24) 
1.03 
(1.19) 
0.88 
(1.13) 
0.98 
(1.11) 
0.867 
0.942 
0.745 
0.659 
0.429 
0.508 
LRP5 
rs3766228 
GG 
 
GA 
 
AA 
 
 
1.217 
(0.089) 
1.167 
(0.079) 
1.235 
(0.091) 
 
 
1.300 
(0.092) 
1.240 
(0.105) 
1.359 
(0.066) 
 
 
1.148 
(0.147) 
1.087 
(0.152) 
1.047 
(0.112) 
 
 
1.32 
(1.05) 
0.74 
(0.94) 
1.55 
(1.06) 
 
 
1.21 
(0.87) 
0.67 
(0.89) 
1.30 
(0.71) 
 
 
1.196 
(0.111) 
1.178 
(0.105) 
1.155 
(N/A) 
 
 
1.230 
(0.121) 
1.253 
(0.124) 
1.149 
(N/A) 
 
 
1.182 
(0.173) 
1.161 
(0.202) 
1.123 
(N/A) 
 
 
1.06 
(1.31) 
0.86 
(1.23) 
0.60 
(N/A) 
 
 
1.06 
(1.17) 
0.94 
(1.15) 
0.50 
(N/A) 
 
 
0.634 
0.097 
0.836 
0.625 
0.510 
 
 
0.242 
0.709 
0.390 
0.273 
0.310 
P2RX7 
rs3751143 
AA 
 
AC 
 
CC 
 
 
1.220 
(0.085) 
1.159 
(0.072) 
1.271 
(0.127) 
 
 
1.306 
(0.106) 
1.243 
(0.080) 
1.294 
(0.042) 
 
 
1.137 
(0.151) 
1.098 
(0.145) 
1.187 
(0.157) 
 
 
1.36 
(1.00) 
0.64 
(0.88) 
1.90 
(1.47) 
 
 
1.27 
(0.82) 
0.57 
(0.82) 
1.50 
(1.30) 
 
 
1.207 
(0.106) 
1.164 
(0.116) 
1.129 
(0.379) 
 
 
1.251 
(0.119) 
1.208 
(0.126) 
1.163 
(0.088) 
 
 
1.200 
(0.171) 
1.146 
(0.187) 
0.999 
(0.154) 
 
 
1.19 
(1.24) 
0.68(1.
37) 
0.30 
(0.46) 
 
 
1.78 
(1.15) 
0.72 
(1.18) 
0.53 
(0.55) 
 
 
0.232 
0.601 
0.194 
0.262 
0.447 
 
 
0.030* 
0.048* 
0.251 
0.030* 
0.022* 
TNFRSF11A 
rs3018362 
GG 
 
GA 
 
AA 
 
 
1.216 
(0.076) 
1.200 
(0.101) 
1.158 
(0.095) 
 
 
1.296 
(0.094) 
1.278 
(0.112) 
1.256 
(0.088) 
 
 
1.128 
(0.137) 
1.152 
(0.178) 
1.063 
(0.106) 
 
 
1.32 
(0.89) 
1.11 
(1.18) 
0.61 
(1.13) 
 
 
1.22 
(0.67) 
0.96 
(1.09) 
0.63 
(1.09) 
 
 
1.180 
(0.123) 
1.197 
(0.090) 
1.213 
(0.161) 
 
 
1.224 
(0.130) 
1.237 
(0.109) 
1.286 
(0.170) 
 
 
1.165 
(0.194) 
1.188 
(0.172) 
1.143 
(0.153) 
 
 
0.86 
(1.46) 
1.08 
(1.04) 
1.23 
(1.90) 
 
 
0.93 
(1.24) 
1.06 
(1.00) 
1.18 
(1.90) 
 
 
0.350 
0.374 
0.921 
0.332 
0.389 
 
 
0.922 
0.936 
0.463 
0.897 
0.862 
TNFRSF11B 
rs4355801 
AA 
 
AG 
 
GG 
 
 
1.201 
(0.083) 
1.209 
(0.084) 
1.191 
(0.110) 
 
 
1.303 
(0.110) 
1.289 
(0.096) 
1.247 
(0.122) 
 
 
1.131 
(0.155) 
1.123 
(0.153) 
1.128 
(0.140) 
 
 
1.13 
(0.97) 
1.23 
(1.00) 
1.00 
(1.28) 
 
 
1.01 
(0.92) 
1.14 
(0.82) 
0.93 
(1.08) 
 
 
1.238 
(0.093) 
1.170 
(0.096) 
1.196 
(0.132) 
 
 
1.295 
(0.108) 
1.220 
(0.109) 
1.219 
(0.142) 
 
 
1.187 
(0.144) 
1.144 
(0.171) 
1.224 
(0.209) 
 
 
1.58 
(1.06) 
0.75 
(1.13) 
1.04 
(1.56) 
 
 
1.65 
(0.92) 
0.75 
(1.06) 
1.05 
(1.31) 
 
 
0.213 
0.432 
0.616 
0.200 
0.087 
 
 
0.391 
0.070 
0.509 
0.360 
0.237 
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VDR 
rs2228570 
CC 
 
 
CT 
 
TT 
 
 
1.196 
(0.074) 
1.210 
(0.098) 
1.201 
(0.101) 
 
 
1.276 
(0.090) 
1.299 
(0.105) 
1.271 
(0.109) 
 
 
1.107 
(0.107) 
1.147 
(0.183) 
1.125 
(0.152) 
 
 
1.09 
(0.87) 
1.23 
(1.15) 
1.12 
(1.20) 
 
 
1.01 
(0.81) 
1.07 
(0.97) 
1.12 
(0.98) 
 
 
1.173 
(0.094) 
1.219 
(0.114) 
1.134 
(0.098) 
 
 
1.223 
(0.106) 
1.249 
(0.133) 
1.210 
(0.113) 
 
 
1.156 
(0.186) 
1.211 
(0.171) 
1.096 
(0.174) 
 
 
0.79 
(1.11) 
1.34 
(1.32) 
0.31 
(1.16) 
 
 
0.89 
(1.04) 
1.30 
(1.17) 
0.32 
(1.04) 
 
 
0.330 
0.984 
0.563 
0.313 
0.164 
 
 
0.134 
0.405 
0.190 
0.124 
0.200 
WNT16 
rs3801387 
AA 
 
AG 
 
GG 
 
 
1.211 
(0.086) 
1.184 
(0.101) 
1.204 
(0.059) 
 
 
1.299 
(0.091) 
1.245 
(0.120) 
1.304 
(0.066) 
 
 
1.147 
(0.136) 
1.101 
(0.185) 
1.071 
(0.109) 
 
 
1.25 
(1.01) 
0.92 
(1.21) 
1.18 
(0.71) 
 
 
1.14 
(0.90) 
0.84 
(1.00) 
1.13 
(0.54) 
 
 
1.184 
(0.102) 
1.195 
(0.116) 
1.195 
(0.110) 
 
 
1.234 
(0.115) 
1.229 
(0.130) 
1.255 
(0.117) 
 
 
1.183 
(0.216) 
1.179 
(0.157) 
1.145 
(0.158) 
 
 
0.93 
(1.19) 
1.04 
(1.36) 
1.06 
(1.28) 
 
 
0.86 
(1.03) 
1.08 
(1.24) 
1.19 
(1.20) 
 
 
0.658 
0.555 
0.814 
0.659 
0.472 
 
 
0.914 
0.326 
0.463 
0.876 
0.818 
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